The CEO-Only Forum is for qualified attendance only. Registrants for the CEO-Only Forum must be registered for The MedTech Conference (https://themedtechconference.com/register/). Participation is complimentary; however, registrations are subject to review and approval.The CEO-Only Forum is for qualified attendance only. Registrants for the CEO-Only Forum must be registered for The MedTech Conference (https://themedtechconference.com/register/). Participation is complimentary; however, registrations are subject to review and approval. Attendance is limited to the first 100 approved registrants. Please complete this form (https://advamed.formstack.com/forms/2026_medtechcon) to sign up and contact bperkins@advamed.org to register specifically for the MedTech CEO-Only Forum.
The inaugural MedTech CEO Only Forum at The MedTech Conference, curated by Lifeblood in partnership with Goodwin and AdvaMed Accel, is an exclusive gathering for 100 current MedTech CEOs from venture backed medical device startup companies. It brings together first time founders and seasoned serial entrepreneurs in a setting where everyone participates, asks questions, and learns from one another.
The CEO Only Forum is guided by experienced CEOs who serve as “point guards,” a format designed by Lifeblood and Goodwin to encourage candid, peer driven conversation. These leaders help shape an open discussion around the real challenges of building and scaling a MedTech company. Topics commonly include raising capital, building teams, board management, choosing strategic partners, navigating regulatory agencies, protecting intellectual property, and the psychology and sacrifice required to lead.
There are no investors, corporate strategics, service providers, or regulators in the room. This creates a protected environment where CEOs can speak freely, compare experiences, and get the insight and support needed to endure the demands of leadership and thrive.
Agenda:
9:00 AM - 10:00 AM | Networking Breakfast
10:00 AM - 10:30 AM | Fireside Chat with Maria Bennett
10:30 AM - 12:30 PM | MedTech CEO-Only Forum
12:30 PM - 1:00 PM | Closing and Networking
Also tagged: Emerging Companies
Program: AdvaMed in Actionread more · Original Link ↗
13th Annual Symposium on Pediatric Device Innovation
● Pediatric Devices
Special Program
📍 Meeting Level 1, Room 157AB
Note: This is a ticketed event and is now sold out. Add this to your registration today to join the Wait List and AdvaMed will notify you if space becomes available.Note: This is a ticketed event and is now sold out. Add this to your registration today to join the Wait List and AdvaMed will notify you if space becomes available.
Built for Children: Evidence Strategies for Pediatric Device Labeling
Children remain significantly underrepresented in medical device and AI labeling, despite widespread use of these technologies in pediatric care. This program will explore innovative approaches to generating pediatric evidence - including Bayesian methods, adaptive trial designs, real-world evidence, computational modeling, in silico trials, and synthetic controls - and examine how emerging regulatory pathways can accelerate appropriate pediatric labeling. The discussion will focus on moving from defining the challenge to implementing practical solutions that expand access to safe, effective, and evidence-based technologies for children.
Networking Breakfast
10:30 am - 10:55 am
Welcome Remarks
10:55 am - 11:00 am
Opening Keynote | The Pediatric Evidence Imperative
11:00 am - 11:30 am
Speaker: Suzanne Schwartz, Director - Office of Strategic Partnerships & Technology Innovation, U.S. Food and Drug Administration
Make Your Medical Device Pitch for Kids!™
11:30 am - 1:10 pm
Lunch Presentation: Impact1 Pediatric Landscape with Ignacio Perez, MD
1:10 pm - 1:55 pm
Panel 1: The Pediatric Labeling Gap: Why It Persists
1:55 pm - 2:30 pm
Why, in 2026, are children still treated with devices that were not designed, studied, or labeled for them?
Moderator: Juan Espinoza, Chief Research Informatics Officer/Associate Director, Ann & Robert H. Lurie Children's Hospital of Chicago/Center for Biomedical Informatics and Data Science, Northwestern University
Speakers:
- Dr. Bala Haridas, Deputy Executive Director, Southwest Pediatric Devices Innovation Consortium (SWPDC), Professor of Practice, Biomedical Engineering, Texas A&M University
- David Hoganson, Assistant in Cardiac Surgery, Boston Children's Hospital
- Julia Finkel, Founder, AlgometRx
Jill Gambon, Patient
Panel 2: The Modern Evidence Toolkit Beyond the RCT
2:30 pm - 3:05 pm
When the traditional pivotal trial cannot scale to pediatric populations, what methods produce evidence the FDA will accept?
Moderator: Cory Criss, Founder and Director of the Innovation Center, Nationwide Children’s Hospital
Speakers:
- Steven Kreuzer, Senior Managing Engineer, Exponent
- Aaron Tenhusian, Chief Operating Officer, Project Medtech
- Corinne Maegely, Vice President, Partnerships Management, MDIC
BREAK
3:05 pm - 3:15 pm
Panel 3: Operationalizing the Toolkit: Case Studies in Pediatric Labeling
3:15 pm - 3:50 pm
How have specific products moved from off-label pediatric use to labeled pediatric indication, and what is replicable?
Moderator: Hanmin Lee, Professor of Surgery, and Director of the Fetal Treatment Center, UCSF
Speakers:
- Angela Lorts, MD, MBA, Co-Founder and Co-Director, ACTION (Advanced Cardiac Therapies Improving Outcomes Network); Director of Ventricular Assist Device, Cincinnati Children's Hospital Medical Center
- Jon McElwee, Director, Regulatory Affairs, Atricure, Inc.
- Simon Mason, President, NEST
- Nada Hanafi, Founder & Manager, MedTech Strategy Advisors, llc
Panel 4: Funding and Coverage for Pediatric Devices
3:50 pm - 4:25 pm
Authorization is a milestone, not a finish line. What coordinated capital and coverage levers move labeled pediatric devices from indication to bedside use, and how is federal funding structured to accelerate evidence generation in the first place?
Moderator: Chester Koh, Pediatric Urologist and Tenured Professor of Urology, Pediatrics, and OB/GYN, Baylor College of Medicine (BCM)
Speaker(s):
- Mary Larkin, PhD, Program Manager, BARDA Accelerator Network, Biomedical Advanced Research and Development Authority (BARDA)
- Perry Bridger, Executive Vice President of Public Affairs, Mussallem CHD Alliance
- John Konsin, Principal Founder, Prapela, Inc.
- Chris Mathia, Venture Partner, Springhood Impact Ventures
Closing Keynote | Fireside Chat: The Coordinated Path Forward
4:25 pm - 4:55 pm
What does coordinated FDA, CMS, and ecosystem action look like to close the pediatric evidence and access gap within five years?
Moderator: Jim Hammerand, Managing Editor, Medical Design & Outsourcing/MassDevice (Arrowfly)
Speaker: April Marrone, Associate Director for TAP, U.S. Food and Drug Administration (FDA)
Announcement of Pitch Competition Winners and Closing Remarks
4:55 pm - 5:00 pmread more · Original Link ↗
Doing Business Globally: U.S. Market Access Seminar
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
Lunch will be available between 11:00 - 11:30 am ahead of the program
The U.S. Market Access Seminar will provide an overview of key considerations for non-U.S. medtech companies looking to enter and establish a presence in the U.S. market.Lunch will be available between 11:00 - 11:30 am ahead of the program
The U.S. Market Access Seminar will provide an overview of key considerations for non-U.S. medtech companies looking to enter and establish a presence in the U.S. market. The seminar will explore important market access, regulatory, business, and operational considerations, along with insights and lessons learned from companies with experience navigating the U.S. market.
Agenda:
11:30 am - 12:10 pm | FDA Pathways for Companies Entering the U.S. Market
Speaker: Georgia Ravitz, Orrick
12:10 pm - 12:45 pm | Reimbursement in the U.S. Healthcare System
Speaker: Parashar Patel, Market Access Strategy
12:45 pm - 1:15 pm | Making Location Decisions in the U.S.
Moderator: Angus McQuilken, Orrick
Speakers:
- Bob Cormier, Rhode Island Life Sciences Hub
- Kylle Jordan, Destination Medical Center
- Jeanne LeClair, Massachusetts Life Sciences Center
1:15 pm - 1:30 pm | US Entity Formation
Speakers:
- Angus McQuilken, Orrickread more · Original Link ↗
Angus McQuilkenOrrick (Moderator)
Bob CormierRhode Island Life Sciences Hub (RILSH)
Kylle JordanDestination Medical Center Economic Development Agency
Jeanne LeClairMassachusetts Life Sciences Center
Parashar PatelMarket Access Strategy, LLC
Georgia RavitzOrrick
☆
Sun Oct 18 · 11:30 AM - 1:10 PM
13th Annual Symposium on Pediatric Device Innovation: Make Your Medical Device Pitch for Kids!™
● Pediatric Devices
Special Program
📍 Meeting Level 1, Room 157AB
Note: This is a ticketed event and is now sold out. Add this to your registration today to join the Wait List and AdvaMed will notify you if space becomes available.Note: This is a ticketed event and is now sold out. Add this to your registration today to join the Wait List and AdvaMed will notify you if space becomes available.
Make Your Medical Device Pitch for Kids!™ is part of the 13th Annual Symposium on Pediatric Device Innovation.
Presenters:
- Dean Koch, CEO & Co-Founder, smallTalk
- Iman Salafian, President & CEO, Imagine Devices, Inc.
- Alan Groves, Chief Medical Officer, Imagine Devices, Inc.
- Edward Buijs, CEO & Co-Founder, Ventora Medical
- Joanna Xylas, CEO, Materialize Bio
- Dori Jones, CEO, Acqumen Medical
- Kunj Sheth, CEO, Maguro Surgical
- Robert Canfield, Chief Product Officer, Altra Infusion Systems
- Tim Hopper, CEO, Cerulean Scientific
- Annamarie Saarinen, Co-Founder, Bloom Standard
- Andrew Cothrel, CEO, Kilele Health, Inc.
Judges:
- Kevin Jackson, CEO, AlgometRx, Inc.
- Stephanie Sturm, Quality & Safety Data Specialist, Administrative Assistant, USA Health
- Raj Ratwani, VP of Scientific Affairs, MedStar Health
- Jeff Collins, VP, Business Innovation, MedStar Health
- Jana Mike, Partner, Fractal Pediatric Capital
- James Love, Partner, Oblon Intellectual Property Lawyersread more · Original Link ↗
Medtech Frontier AI Day: From Innovation to Impact - How AI is Transforming the Frontier MedTech Enterprise
● Special Program
Special Program
📍 Meeting Level 1, Room 162AB
Lunch will be available at 11:30 am ahead of the program
This half-day program brings together MedTech and technology leaders to explore how AI is moving from innovation to real-world impact across the frontier MedTech enterprise.Lunch will be available at 11:30 am ahead of the program
This half-day program brings together MedTech and technology leaders to explore how AI is moving from innovation to real-world impact across the frontier MedTech enterprise. Through executive discussions and practical examples, attendees will learn how leading organizations are scaling AI responsibly to strengthen governance and compliance, create intelligent connected care experiences, transform commercial effectiveness, accelerate product innovation.
Intro: Frontier MedTech Firms: Leading in the AI Era
Opening executive discussion exploring how leading MedTech organizations are transforming into AI-powered frontier firms. The conversation will focus on leadership, innovation, operational transformation, and what it takes to compete in an increasingly intelligent healthcare ecosystem.
Speaker: Todd Mersch, Microsoft
#1 Accelerating Innovation: Connecting Data, AI & Market Access
From product development through commercialization, AI and connected data are helping MedTech organizations accelerate innovation, improve evidence generation, streamline development processes, and expand patient access to life-changing technologies. This session will explore how leading organizations are connecting research, product innovation, real-world evidence, and reimbursement strategies to bring innovation to patients faster.
Moderator: Dean Cimini, Microsoft
Speakers:
- Dr. David Rhew, Microsoft
- Sandeep Naik, Accenture
- Wendel Smith, Edwards Lifesciences
- Kirsten Tullia, AdvaMed
#2 Embedding AI into Devices for Intelligent, Connected Care
Real-world examples of AI-enabled medical devices and digital health solutions that improve patient outcomes, clinician experiences, and connected care delivery while addressing security and trust requirements.
Moderator: Jeff Garnai, Microsoft
Speakers:
- Robert Cohen, Stryker
- Shaun Braun, Zimmer Biomet
- Dana Kau, Microsoft AI
- Syed Naveed, Olympus
#3 Transforming Commercial Execution with AI-Powered Field Engagement
How MedTech organizations are leveraging AI to modernize commercial operations, improve field productivity, deliver personalized engagement, and drive sales effectiveness.
Moderator: Taylor Vakulskas, Microsoft
Speakers:
- Oliver Richards, Accenture
- Todd Mersch, Microsoftread more · Original Link ↗
Doing Business Globally: From Ontario to the World: Scaling MedTech Companies Globally
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
How an Ontario-built medtech company scales into international markets, growth capital, market entry, and what kept them anchored in Ontario along the way. · Original Link ↗
Garrett ToneInvest Ontario (Moderator)
Tyler AllsoppGovernment of Ontario, Canada
Frank BaylisBaylis Medical Technologies
Jason WeshlerSiemens Healthineers
Built for you by(617)-PATRICK, Champion AI speaker
Leading Across Generations: Advancing Women, Strengthening MedTech
● Special Program
Special Program
📍 Meeting Level 2, Room 260
Today's medtech workforce spans five generations - each bringing different perspectives on leadership, career growth, communication, and work.Today's medtech workforce spans five generations - each bringing different perspectives on leadership, career growth, communication, and work. This dynamic conversation brings together leaders from Gen Z, Millennials, Gen X, and Baby Boomers to explore how their experiences have shaped their leadership journeys and what they expect from the next generation of women leaders. Through candid discussion, panelists will challenge stereotypes, share lessons learned, and identify practical ways to bridge generational differences to build stronger teams, accelerate innovation, and expand opportunities for women across the industry.
AdvaMed Advance® is an industry convener dedicated to unlocking the potential of all talent and driving innovation in medical technology through leading inclusion and belonging practices. By uniting our efforts under the AdvaMed Advance Initiative, we ensure that support, resources, and opportunities are accessible to everyone and fostering a more unified, inclusive community. Join us on Sunday, October 18 for thought-provoking content that will bring together diverse voices from across the medtech industry.
Program: AdvaMed in Actionread more · Original Link ↗
Delphine Zurkiya PhDMcKinsey & Company (Moderator)
Colby HoltshouseMay Health
Emily ManVenova Technologies, Inc.
Martha ShadanBrilliantStrings Therapeutics
Amogha TadimetyNanopath
☆
Sun Oct 18 · 2:10 PM - 2:30 PM
Doing Business Globally: Ireland: A Proven Location for Medical Technologies
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
Session will focus on why Ireland is a global center of excellence for medical technology (MedTech), boasting a 50-year track record of attracting international investment.Session will focus on why Ireland is a global center of excellence for medical technology (MedTech), boasting a 50-year track record of attracting international investment. The sector is one of the country's primary economic pillars, driven by a deeply collaborative ecosystem between global corporations, state agencies, and academic institutions.read more · Original Link ↗
Doing Business Globally: UK: At the Forefront of Global Innovation in MedTech
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
The UK’s Life Sciences sector is one of our greatest national assets.The UK’s Life Sciences sector is one of our greatest national assets. By supporting innovation from lab bench to bedside, across sectors, across government, and across industry, we are building the engine needed to supercharge both the MedTech sector and economic growth.read more · Original Link ↗
Steve Bates OBEUK Office for Life Sciences (Moderator)
Pitch & Pour: Start-up Pitch Competition and Happy Hour
● Start-up Pitch Competition
Start-up Pitch Competition
📍 Meeting Level 1, Room 160ABC
Pitch & Pour: Medtech Pitch Competition and Happy Hour
Sunday, October 18, 2026
12 standout startups innovating in military health will deliver 5-minute pitches to a panel of expert judges, followed by a 3-minute Q&A session.Pitch & Pour: Medtech Pitch Competition and Happy Hour
Sunday, October 18, 2026
12 standout startups innovating in military health will deliver 5-minute pitches to a panel of expert judges, followed by a 3-minute Q&A session. The winner will receive a $7,500 cash prize, courtesy of sponsors Medmarc and MTEC, a complimentary all-access registration for The MedTech Conference 2027, and a complimentary Company Presentation slot at #MTC27.
Pitch Schedule:
3:00 - 3:05 | Welcome and Introductions
3:05 - 3:13 | Noxsano (https://www.noxsanohealth.com/)
3:13 - 3:21 | GenAssist (http://www.genassist.co)
3:21 - 3:29 | Plas-Free (http://www.plas-free.com)
3:29 - 3:37 | SafeBVM (https://safebvm.com/)
3:37 - 3:45 | CranioSense (http://www.CranioSense.com)
3:45 - 3:53 | MedCu Technologies (http://www.medcu.com)
3:53 - 4:03 | Sponsor Remarks
4:03 - 4:11 | Surgicure Technologies (https://www.surgicuretech.com/)
4:11 - 4:19 | BLASTID (https://www.blastid.ai/)
4:19 - 4:27 | Halite Medical (http://www.halitemedical.com)
4:27 - 4:35 | Omedus - Triage360 (https://www.triage360.com)
4:35 - 4:43 | ARMR Systems (http://www.armrsystems.com)
4:43 - 4:51 | RBT Resources, Inc.
4:51 - 5:21 | Networking Break and Happy Hour
5:21 - 5:30 | Winner Announcement and Closing Remarks
Program: Investor Forumread more · Original Link ↗
Jessica Queen APRNOmedus - Triage360
Joe BeggsGenAssist, Inc.
Ze'ev DvashiPlas-Free LTD
Chibueze IhenachoARMR Systems Inc
Danny LustigerMedCu Technologies Ltd
Anthony Capuano MBARBT RESOURCES
Ryan MyersCranioSense
Irena King PhDSurgicure Technologies, Inc.
Paulo Garcia PhDBLASTID
Prathamesh PrabhudesaiSafeBVM
Alan WilleyNoxsano Inc.
Rachel WongHalite Medical
☆
Sun Oct 18 · 3:10 PM - 3:30 PM
Doing Business Globally: Leveraging Australia to Speed Your USA/International Path to Market
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
Australia is a strong and reliable partner in speeding your path to market. Australia's medtech product development offers end-to-end design, engineering, and manufacturing expertise to propel your innovations forward.Australia is a strong and reliable partner in speeding your path to market. Australia's medtech product development offers end-to-end design, engineering, and manufacturing expertise to propel your innovations forward. We also have the clinical trial ecosystem and experience to speed your path to approval and market. With our lower cost base and R&D Tax incentives, Australia offers huge savings while maintaining or increasing speed. Learn how you can tap into Australia's strengths and get your product to market faster and cheaper than doing it in the USA or Europe alone.read more · Original Link ↗
To participate in Build with Gemini, you must be registered for The MedTech Conference and select Build with Gemini as an add-on during registration. Participation is complimentary. Attendance is limited to the first 100 registrants.To participate in Build with Gemini, you must be registered for The MedTech Conference and select Build with Gemini as an add-on during registration. Participation is complimentary. Attendance is limited to the first 100 registrants.
Build with Gemini is a complimentary, hands-on workshop designed to help you learn to build, implement, and scale autonomous AI agents across your organization to help you transform your day-to-day work.
Why Attend?
- Executive Insights: Hear directly from Google Cloud experts on how leading organizations are scaling agentic AI.
- Hands-on Learning: No hype, just get straight into live hands-on labs with assistance from Google Cloud experts.
- Not technical? No problem. This workshop is purpose-built for business leaders who have minimal experience coding.
- Networking: Connect with fellow industry innovators in the medtech community.
What You Will Build and Explore:
- Learn to leverage the foundational power of Gemini Enterprise to build agents that eliminate repetitive tasks, help unlock insights from your data, and enable new ways of working for your team.
- Learn how to effortlessly automate recurring reporting, triage emails, summarize complex meetings, and generate impactful content to make your days more productive.
- Discover how Agent Designer can stitch individual agents together into secure, multi-step, cross-departmental workflows that interact seamlessly with both Google Workspace and Microsoft 365.read more · Original Link ↗
Pete ClardyGoogle for Health
Mrina SawhneyGoogle Cloud
Kyle SwartoutGoogle Cloud
☆
Sun Oct 18 · 3:40 PM - 4:00 PM
Doing Business Globally: Why Japan Matters for the Future of Global MedTech Innovation
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
Japan is one of the first countries in the world to experience a super-aged society, making it a unique testbed for healthcare innovations that address the needs of aging populations worldwide.Japan is one of the first countries in the world to experience a super-aged society, making it a unique testbed for healthcare innovations that address the needs of aging populations worldwide. At the same time, Japan offers access to one of the world's largest and most sophisticated medical device markets, supported by a universal healthcare system and strong clinical infrastructure. Japan has also significantly reduced barriers to market entry through regulatory reforms, including streamlined approval pathways, greater acceptance of English-language documentation, and new frameworks for innovative digital health technologies such as SaMD and AI-enabled devices. These advantages make Japan an increasingly attractive destination for global MedTech companies seeking to accelerate innovation, clinical validation, and commercialization across Asia and beyond.read more · Original Link ↗
Shoya TAKIMinistry of Health, Labour and Welfare (MHLW) (Moderator)
Built for you by(617)-PATRICK, Champion AI speaker
Doing Business Globally: So How Exactly Does Your Business Need Singapore?
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
As the global environment grows increasing complex, decisions on where to innovate, manufacture and scale have become increasingly strategic.As the global environment grows increasing complex, decisions on where to innovate, manufacture and scale have become increasingly strategic. This session invites an upfront discussion on how Asia is becoming central to global MedTech business models, both as a growth market and a platform for innovation and manufacturing resilience.
Asia is driving a growing share of global healthcare demand, supported by expanding healthcare systems, rising incomes and accelerating digitalisation. Many MedTech firms are re-examining their global footprints to capture these opportunities while maintaining resilience across supply chains and operations. This includes evaluating where to locate R&D, advanced manufacturing and regional headquarters to effectively serve diverse Asian markets and support global growth.
Within this broader context, Singapore has emerged as a key gateway and operating base for companies expanding in Asia. The country hosts more than 400 MedTech companies spanning devices, diagnostics and digital health, supported by over 25 R&D centres and advanced manufacturing capabilities that produce more than US$12 billion in MedTech products annually. Its strong regulatory environment, connectivity and integration with global supply chains position it as a platform for coordinating regional and global activities.
This session will move beyond broad narratives to a candid discussion with industry leaders on how companies are structuring their Asia strategies and operating models. Attendees will gain practical insights on where Asia fits into global growth plans, what capabilities are needed on the ground, and how locations such as Singapore can support innovation, manufacturing and market access across the region.read more · Original Link ↗
John EngSingapore Economic Development Board (EDB) (Moderator)
Doing Business Globally: Why Global MedTech Leaders Are Choosing the Dominican Republic
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
Discover why global MedTech leaders are choosing the Dominican Republic as their strategic manufacturing platform.Discover why global MedTech leaders are choosing the Dominican Republic as their strategic manufacturing platform. From world-class Free Zone infrastructure to rapid time-to-market advantages, learn how operating in the Caribbean’s premier MedTech hub can accelerate growth, protect supply chains, and drive innovation.
Program: LatAmread more · Original Link ↗
María Isabel CastilloDominican Republic (Moderator)
Johannes KelnerNational Free Zones Council of the Dominican Republic
Doing Business Globally: Costa Rica: The Strategic and Trusted Choice for MedTech
● Doing Business Globally
Doing Business Globally
📍 Meeting Level 1, Room 157C
Costa Rica has established itself as a strategic destination for MedTech investment, supported by a robust life sciences ecosystem, institutional stability, and a strong track record of quality and reliability.Costa Rica has established itself as a strategic destination for MedTech investment, supported by a robust life sciences ecosystem, institutional stability, and a strong track record of quality and reliability. As a like-minded partner of the United States, Costa Rica plays an increasingly important role in resilient and secure supply chains, with companies operating across multiple segments of the value chain and producing highly complex medical technologies that contribute to better health outcomes for patients around the world.
Program: LatAmread more · Original Link ↗
Indiana TrejosMinistry of Foreign Trade, Costa Rica (COMEX) (Moderator)
Kick off the conference by connecting with peers, partners, and new contacts from across the medtech ecosystem. Enjoy a relaxed social setting designed to spark conversations, build relationships, and get your networking started. · Original Link ↗
The 9th Annual MedTech Color Networking Breakfast is MTC’s signature event, bringing together executives, clinicians, innovators, entrepreneurs, investors, advocates, industry professionals, and emerging leaders committed to strengthening the medtech ecosystem and improving health outcomes for all patients.The 9th Annual MedTech Color Networking Breakfast is MTC’s signature event, bringing together executives, clinicians, innovators, entrepreneurs, investors, advocates, industry professionals, and emerging leaders committed to strengthening the medtech ecosystem and improving health outcomes for all patients.
Guided by the 2026 theme, 'Where Inclusive Collaboration Meets Health Impact', and our campaign message, 'Collaboration Saves Lives', this year’s program will explore how diverse perspectives, inclusive leadership, and cross-sector partnerships accelerate innovation and improve patient outcomes. Through engaging conversations and meaningful networking, the Breakfast reinforces a central belief: inclusive collaboration is not simply aspirational - it is operational.
Program: Investor Forumread more · Original Link ↗
Presenting startups:
- WovenX Health - Integrated platform accelerating specialty care access with AI, virtual APPs, and MD oversight - woven into existing system.Presenting startups:
- WovenX Health - Integrated platform accelerating specialty care access with AI, virtual APPs, and MD oversight - woven into existing system.
- XEOS - We close the loop in surgical oncology by providing the surgeon with a detailed 3D view of what they resected to help assess if surgery was successful.
- Wicked Technologies - Wicked Smart Pad: Washable, sensorized bedding for smart incontinence care.
- Dermagnostix - Dermagnostix developed a portable point-of-care diagnostic system delivering objective data on patients' molecular profiles.
Program: Investor Forumread more · Original Link ↗
What does it take to attract growth-stage capital in today’s medtech market? This session brings together leading late-stage venture investors and strategic partners to discuss the characteristics that separate companies that successfully scale from those that struggle to gain momentum.What does it take to attract growth-stage capital in today’s medtech market? This session brings together leading late-stage venture investors and strategic partners to discuss the characteristics that separate companies that successfully scale from those that struggle to gain momentum. The panel will discuss reimbursement readiness, commercialization strategies, and strategic partnerships that drive growth and effectively position companies for M&A or the public markets. Attendees will gain practical insight into how investors assess risk, growth potential, and long-term value creation in an increasingly competitive funding environment.
Program: Investor Forumread more · Original Link ↗
Pain: Less than 60% of 10 million patients with essential tremor in the USA find adequate treatment for their debilitating condition. Most
prescribed medications were developed for other conditions and carry unpleasant side effects.Pain: Less than 60% of 10 million patients with essential tremor in the USA find adequate treatment for their debilitating condition. Most
prescribed medications were developed for other conditions and carry unpleasant side effects. Invasive protocols like brain implants carry significant risk and cost. Patients need a low-cost, effective solution without risky side effects to help perform “routine” daily activities.
Solution: Initially developed as a research project to help the father of one of our founders, Regain BioMedicals has developed GRACE, a
wearable, novel, non-invasive, personalized, adaptable, non-neuronal-based and patented device to stimulate the muscles involved in
essential tremor of the arms, resulting in elimination or reduction of the tremor without side effects. GRACE has also reduced Parkinson’s
patients tremors and is a novel platform that can potentially be used to treat additional movement disorders (restless leg syndrome / others).
Company Sector: Neurology
Program: Investor Forumread more · Original Link ↗
Harbinger Health is leading a transformation in multi-cancer detection, introducing fundamentally new approaches to resolving cancer-related uncertainty across multiple clinical contexts.Harbinger Health is leading a transformation in multi-cancer detection, introducing fundamentally new approaches to resolving cancer-related uncertainty across multiple clinical contexts. The company combines advances in artificial intelligence with proprietary insights into the biology of the origins of cancer to enable fit-for-purpose strategies grounded in shared biology and a common platform - all through a low-cost blood test. Harbinger is advancing multiple tests in its RESOLVE™ portfolio designed to help bring clarity more efficiently to clinicians when cancer is suspected.
Company Sector: Blood, Digital Health, In Vitro Diagnostics
Program: Investor Forumread more · Original Link ↗
Tony ShuberHarbinger Health
Built for you by(617)-PATRICK, Champion AI speaker
AI in MedTech: Where Will Real Value (Actually) Be Created?
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 162AB
AI is rapidly reshaping MedTech, but many companies are still grappling with where real value will be created.AI is rapidly reshaping MedTech, but many companies are still grappling with where real value will be created. Beyond pilots and proofs of concept, executives face pressing questions: where should AI capabilities be built, how can solutions be validated in real clinical environments, and which markets will drive meaningful adoption and returns?
This session will examine how global MedTech firms are approaching these decisions across R&D, product development, regulatory strategy and commercialisation. The greatest AI opportunities lie in tailoring solutions to clinical needs and healthcare systems, which differ substantially across markets. This requires close integration between technology development, providers and regulators. Forging the right partnerships is therefore critical in accelerating validation, enabling real-world deployment and ensuring solutions can scale effectively across diverse markets.
Globally, innovation ecosystems are emerging to support this partnership-driven approach, offering access to clinical collaborators, research institutions and regulatory pathways that enable faster iteration and deployment. Understanding how to navigate and leverage these ecosystems will be central to capturing AI’s full potential in MedTech.
Rather than presenting a single model, this session will bring together industry and ecosystem perspectives to examine where AI initiatives are succeeding, where challenges remain, and what capabilities companies need to build. Attendees will gain a clearer understanding of how strategic partnerships across technology, clinical and market ecosystems can accelerate the development, validation and scaling of AI-enabled MedTech solutions globally.read more · Original Link ↗
John EngSingapore Economic Development Board (EDB) (Moderator)
Raymond ChuaHealth Sciences Authority
Goh Su-YenSingHealth
☆
Mon Oct 19 · 9:30 AM - 10:30 AM
The Future of Prior Authorization: Balancing Oversight and Access
● Health Access
Panel Session
📍 Meeting Level 1, Room 160ABC
This session will explore the growing role of prior authorization in Medicare and its implications for beneficiary access.This session will explore the growing role of prior authorization in Medicare and its implications for beneficiary access. The speakers will examine how prior authorization - while intended to promote appropriate utilization and safeguard program integrity - can also create delays, administrative burden, and barriers to medically necessary care for Medicare beneficiaries. Speakers will review the current Medicare prior authorization programs, policies, and recent reforms under Traditional Medicare and Medicare Advantage. A central theme of the session will be balancing program oversight with beneficiary access. Speakers will discuss policy and operational strategies to improve the prior authorization process while maintaining safeguards against inappropriate utilization. The session will conclude with a forward‑looking discussion on policy opportunities to modernize prior authorization in Medicare, focusing on reforms that prioritize patient access, support clinicians, and promote high‑value care without unnecessary delay.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Christine Jackson JDMedtronic (Moderator)
Heather McComasAmerican Medical Association (AMA)
Robert McDonaldPHAZE 4 Medical, LLC
Victoria WallaceHogan Lovells Cadwalader
Stephanie WimmerPhilips
☆
Mon Oct 19 · 9:30 AM - 10:30 AM
Standards: A Collaborative Path Forward
● International
Panel Session
📍 Meeting Level 1, Room 157AB
In a globalized MedTech marketplace, companies develop, manufacture, and deploy technologies across borders - yet face differing expectations, interpretations, and documentation demands from market to market.In a globalized MedTech marketplace, companies develop, manufacture, and deploy technologies across borders - yet face differing expectations, interpretations, and documentation demands from market to market. Standards can serve as the common language that helps reduce friction, build confidence, and support safe, scalable innovation worldwide.
This moderated panel will examine the value of standards from an international perspective and discuss how globally active MedTech companies use consensus standards to support multi-market strategies. Speakers from industry, regulators, and the standards community will explore how standards can strengthen trust, streamline compliance efforts across jurisdictions, and improve consistency in areas where fragmentation slows adoption.
The discussion will address how standards function within regulatory and policy ecosystems across major markets, where harmonization is succeeding (and where it still falls short), and how companies can think about standards as both a risk-management tool and a growth enabler. Panelists will also share practical insights on what makes standards useful and usable globally - clarity, relevance, and timeliness - and what stakeholders can do to strengthen alignment going forward.
The session will conclude with audience Q&A focused on real-world challenges attendees face when bringing products to multiple markets and how standards can help.
Also tagged: Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Lena Cordie-BancroftMedtronic (Moderator)
Scott ColburnU.S. Food and Drug Administration (FDA)
Nick DeckerRoche
Andrew Kuhls-GilcristCanon Medical Systems USA
Vishal ThakkerBSI Group
☆
Mon Oct 19 · 9:30 AM - 10:30 AM
Accessing the Japanese Market: Market Overview, Trials, Regulation, and Reimbursement
● International
Panel Session
📍 Meeting Level 1, Room 159
Japan remains one of the world’s leading medical device markets, with strong clinical demand and a mature regulatory and reimbursement environment.Japan remains one of the world’s leading medical device markets, with strong clinical demand and a mature regulatory and reimbursement environment. As Japan accelerates efforts to reduce device loss and enhance regulatory predictability, understanding the pathway from clinical development to reimbursement is important. This session provides a practical overview for companies considering expansion into Japan, connecting clinical development, regulatory review, reimbursement, and market adoption.
The session will open with Japan’s position as the world’s fourth-largest medical device market and the “device loss” situation from a patient access perspective. We will highlight therapeutic areas where adoption is anticipated and market-entry opportunities exist, reflecting Japan’s interest in innovative devices. We will then address conducting clinical trials in Japan, including strengths such as high-quality data generation and efficient patient enrollment.
Next, PMDA’s Washington, D.C. Office will present its role as an overseas hub, established in November 2024, supporting companies seeking to understand Japanese regulatory procedures and facilitating connections with PMDA review teams in Japan. PMDA will share progress since launch and introduce key initiatives to enhance predictability, expand consultation opportunities, ensure review quality, and promote international collaboration.
The session will close with the Ministry of Health, Labour and Welfare outlining the FY2026 medical fee schedule revision and reimbursement considerations for medical devices, followed by a panel discussion and audience Q&A, enabling direct dialogue with regulatory and reimbursement authorities.
PMDA aims to support efforts to reduce device loss and advance adoption of innovation in Japan, and looks forward to your participation.
Also tagged: Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Kenichi IshibashiPharmaceuticals and Medical Devices Agency (PMDA) (Moderator)
Hirokazu HorioOlympus Corporation
Manabu InouePharmaceuticals and Medical Devices Agency (PMDA)
Akihiro IshiguroPharmaceuticals and Medical Devices Agency (PMDA)
Shoya TAKIMinistry of Health, Labour and Welfare (MHLW)
Taku ToyoshimaOsaka International Medical & Science Center, Osaka Keisatsu Hospital
☆
Mon Oct 19 · 9:30 AM - 10:30 AM
From Promise to Practice: Building Trust in Real-World Evidence for Medical Devices
● Legal and Health Care Compliance Best Practices
Panel Session
📍 Meeting Level 1, Room 157C
Real-world evidence (RWE) is rapidly transforming how medtech companies generate clinical evidence and how medical devices are evaluated by regulators, particularly for label expansions, new indications, and areas where traditional clinical trials may be slow, costly, or impractical, such as...Real-world evidence (RWE) is rapidly transforming how medtech companies generate clinical evidence and how medical devices are evaluated by regulators, particularly for label expansions, new indications, and areas where traditional clinical trials may be slow, costly, or impractical, such as pediatrics. As regulators increasingly recognize the value of real-world data (RWD) to support medical device regulatory decision-making, the focus is shifting from whether RWE can be used to what constitutes credible, relevant, and reliable evidence, and how medtech companies can apply it successfully in practice.
This panel brings together regulators, manufacturers, data leaders, and policy experts to examine the evolving role of RWE across the medical device lifecycle. Panelists will explore emerging expectations for “what good looks like” in RWE generation and discuss practical approaches for building trust in RWE through transparency, data quality, governance, and study design. The discussion will also address practical considerations for designing, conducting, and communicating RWE in ways that support confidence, credibility, and more consistent regulatory use.
The session will feature real-world case studies demonstrating how RWE has successfully supported device marketing authorizations, expanded indications, and modernization of labeling in both the United States and international markets. Discussion will also explore the growing role of initiatives such as NEST and the NEST Mark™ framework in improving predictability, consistency, and confidence in RWD sources used for regulatory submissions.
Also tagged: Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Donielle JohnsonBaxter International (Moderator)
Juan EspinozaNorthwestern University
Daniel Caños PhD, MPHU.S. Food and Drug Administration (FDA)
Heather Colvin MPPJohnson & Johnson Medtech
Simon MasonMDIC (NEST)
☆
Mon Oct 19 · 9:30 AM - 10:30 AM
If We Build It, Will They Come? Patient Advocates Are Ready, Are We?
● Patient Engagement
Panel Session
📍 Meeting Level 1, Room 161
Patient advocates consistently express readiness to partner across the medical device lifecycle. The operational question facing the industry is whether companies are structured to engage them meaningfully.Patient advocates consistently express readiness to partner across the medical device lifecycle. The operational question facing the industry is whether companies are structured to engage them meaningfully. This session is designed to empower medical device companies with a model to convene a Patient Advisory Board as a strategic asset. Experts will share their experience, insights, and strategies after convening a product-agnostic Patient Advisory Board to define what a strong industry - patient partnership looks like and to better understand lived-experiences to improve clinical trial design and product usability. Advisors emphasized structured collaboration, clear project scope, measurable milestones, and visibility into how their input drives action, while rejecting symbolic engagement models.
This session presents a scalable governance framework for integrating patient advisory input across Clinical, Regulatory, Product Development, and Commercial functions. The model aligns with FDA expectations for Patient-Focused Development. Attendees will leave with a practical blueprint for enhancing patient engagement beyond narrative storytelling and into structured, measurable impacts that support product lifecycle development.
Also tagged: Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Noël TheodosiouLuminous (Moderator)
Erin CallahanDiabetes Patient Advocacy Coalition
Scott GoatesAbbott Cardiovascular
Paul Coplan ScD, MBA, MSJohnson & Johnson MedTech
Cynthia (Cyndi) Grossman PhDU.S. Food and Drug Administration (FDA)
Reyo Medtech (formerly Beam Medical) is a clinical-need-first product development and commercialization team specializing in chronic low back pain diagnostic and treatment.Reyo Medtech (formerly Beam Medical) is a clinical-need-first product development and commercialization team specializing in chronic low back pain diagnostic and treatment. Committed to innovation and excellence, we design cutting-edge interventional spine solutions for clinicians to better address pathologies for individuals suffering from chronic lower back pain.
Our first product is a simplified basivertebral nerve ablation (BVNA) system, where the same pain relief outcome is achieved more easily, 4x faster.
Company Sector: Orthopaedic, Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Aethl Bio is a Pittsburgh biomaterials company developing products on its proprietary Hydro-Activated Supersaturation (HAS) platform.Aethl Bio is a Pittsburgh biomaterials company developing products on its proprietary Hydro-Activated Supersaturation (HAS) platform. CEO Carmelo Montalvo will share the company's path from platform science to its lead medical product candidate, Nuvoxen, which is being developed for the FDA 510(k) pathway, and how Aethl is building its clinical bench in Pittsburgh. Nuvoxen is not cleared by the FDA.
Company Sector: Wound Management
Program: Investor Forumread more · Original Link ↗
Presenting startups:
- AcQumen Medical - UltraTrac combines ultrasound and impedance for safer, smarter hemodynamic insights in critically ill pediatric patients.Presenting startups:
- AcQumen Medical - UltraTrac combines ultrasound and impedance for safer, smarter hemodynamic insights in critically ill pediatric patients.
- AION Biosystems - AION Biosystems is redefining continuous body temperature as a real-time biomarker, using its wearable patch to generate EMR-linked longitudinal data that enables earlier infection detection, proactive care, and improved patient outcomes.
- BioSens8 - Pushing the possibilities of human performance with a Continuous Cortisol Monitor (CCM).
- Galenband - 90-day Continuous ECG.
Program: Investor Forumread more · Original Link ↗
Mark JuravicDexcom (Moderator)
Samara BarendAION Biosystems
Dori JonesAcQumen Medical
Uroš KuzmanovicBioSens8
Eddie McDaidGalenband
☆
Mon Oct 19 · 9:50 AM - 10:05 AM
Solutions Showcase: How MedTech Commercial Teams Are Putting AI to Work
AI has changed what MedTech commercial teams can accomplish with market data and insights.AI has changed what MedTech commercial teams can accomplish with market data and insights. The right AI partner should understand your business and how you sell, adapt to your motion instead of forcing you into a rigid ecosystem, and deliver outcomes rather than just access.
MedScout CEO Skylar Talley will walk through real examples of how the right combination of intelligence, AI, and MedTech-specific tools can lead to smarter territory design, clear market share and white space analysis, and more reliable field team execution. He’ll also make the case that the companies that put these capabilities to work first will pull away fast.read more · Original Link ↗
MedCu Technologies is a medical device company pioneering copper-based wound care.MedCu Technologies is a medical device company pioneering copper-based wound care. MedCu is the first company to develop FDA- and CE-cleared copper wound dressings and bandages, transforming traditional dressings from passive wound coverings into active antimicrobial, anti-biofilm, and regenerative wound-healing solutions.
MedCu is an alumni of MedTech Innovator Accelerator program (MTI). Revived a recognition reward under the mid-stage companies in 2025.
The company’s core wound-management platform is designed to treat a broad range of wounds, including chronic wounds, diabetic foot ulcers, venous leg ulcers, pressure injuries, post-surgical wounds, burns, and traumatic wounds. MedCu’s technology is based on the controlled local delivery of copper ions to the wound bed, leveraging copper’s unique biological properties: powerful broad-spectrum antimicrobial activity, anti-biofilm effect, and support of key regenerative processes such as angiogenesis, collagen formation, and tissue repair.
In parallel to its commercial wound-management business, MedCu has a dedicated focus on military and defense wound applications. The company’s copper technology is already being applied to personal emergency bandages selected by the IDF as the new antimicrobial personal bandage, and MedCu is developing next-generation copper hemostatic dressings designed to combine hemorrhage control, infection prevention, and active healing in one field-ready solution. MedCu also has a CRADA international development collaboration with the U.S. military focused on advancing copper-based military bandages.
MedCu’s vision is to establish copper as a new standard of care in both civilian wound management and military trauma care by providing simple, effective, and scalable wound-care solutions that protect wounds from infection, disrupt biofilm, and support faster healing.
Company Sector: Wound Management
Program: Investor Forumread more · Original Link ↗
Danny LustigerMedCu Technologies Ltd
Built for you by(617)-PATRICK, Champion AI speaker
ANEUVO is developing revolutionary bioelectronic medicine to help restore functional independence, improve quality of life, and create a healthier and more equitable world for people living with disabling diseases and conditions.ANEUVO is developing revolutionary bioelectronic medicine to help restore functional independence, improve quality of life, and create a healthier and more equitable world for people living with disabling diseases and conditions. Leveraging the company’s advanced biotechnology platform and deep expertise, ANEUVO is tackling critical healthcare challenges to deliver meaningful solutions to underserved patients in need.
Company Sector: Digital Health, Neurology, Physical Medicine and Rehabilitation
Program: Investor Forumread more · Original Link ↗
Yi-Kai LoANEUVO
☆
Mon Oct 19 · 10:10 AM - 10:25 AM
Solutions Showcase: How Patient & Provider Experience Powers the Medtech Innovation Flywheel
This talk argues that the surgical care system's real bottleneck isn't capacity but experience - broken, manual, fragmented workflows for both patients and providers are choking throughput even as demand for procedures grows.This talk argues that the surgical care system's real bottleneck isn't capacity but experience - broken, manual, fragmented workflows for both patients and providers are choking throughput even as demand for procedures grows. DocSpera addresses this through "Innovation Flywheel": improving patient and provider experience drives adoption, which generates rich surgical data, which fuels device and technique innovation, which improves outcomes - reinforcing experience in turn. DocSpera's platform already powers 1,100+ surgical sites and 40K+ surgeries per month, with a customer case study showing 90% patient engagement and 10K+ patients contributing real-world outcome data as proof the flywheel works in practice.read more · Original Link ↗
Samuel EthiopiaDocSpera
☆
Mon Oct 19 · 10:10 AM - 10:40 AM
Resilient by Design: Navigating Uncertainty in MedTech Supply Chains
Geopolitical uncertainty is reshaping the foundations of global supply chains. For medtech companies, rising tariffs, regionalization pressures, natural disasters, climate change, and volatility in critical inputs are forcing a shift from cost-optimized networks to resilience-driven strategies.Geopolitical uncertainty is reshaping the foundations of global supply chains. For medtech companies, rising tariffs, regionalization pressures, natural disasters, climate change, and volatility in critical inputs are forcing a shift from cost-optimized networks to resilience-driven strategies. Supply chain decisions are no longer purely operational - they are increasingly central to enterprise risk management and long-term growth.
This session will examine how medtech CEOs are embedding uncertainty drivers into strategic planning and redesigning their supply chains to operate in an era of persistent disruption. Discussion topics will include managing single-source risk, balancing global efficiency with regional proximity, and identifying “no-regret” moves across a range of future scenarios. Panelists will also share how advanced analytics and AI are enhancing visibility and enabling faster, more informed decision-making in complex and rapidly changing environments.read more · Original Link ↗
Assistive Technology Development, Inc. (ATDev) builds intelligent robotic solutions that transform how people with mobility challenges live and recover.Assistive Technology Development, Inc. (ATDev) builds intelligent robotic solutions that transform how people with mobility challenges live and recover. Our flagship device, Reflex, is an FDA-registered, telehealth-enabled smart knee brace that delivers passive range of motion, active resistance training, and daily strength measurement for at-home post-surgical rehabilitation. We also co-lead the $41M ARPA-H RAMMP consortium, developing the first open-source robotic wheelchair platform. Founded in 2020 by UC Berkeley roommates Owen Kent and Todd Roberts, ATDev combines hardware innovation, real-time biometric data, and lived disability experience to make advanced assistive technology accessible and affordable.
Company Sector: Digital Health, Orthopaedic, Physical Medicine and Rehabilitation
Program: Investor Forumread more · Original Link ↗
Todd RobertsATDev
☆
Mon Oct 19 · 10:20 AM - 10:50 AM
MedTech Innovator Showcase: Innovative Procedural Tech in Urology, GI, and Oncology
Presenting startups:
- Cymantic Medical - An automated, AI-powered device for real-time tissue analysis during oncology procedures. - Drive Medical - Our robotic endoscopic platform, Pollywog(TM), provides full small bowel coverage- the current blind spot in GI tract.Presenting startups:
- Cymantic Medical - An automated, AI-powered device for real-time tissue analysis during oncology procedures.
- Drive Medical - Our robotic endoscopic platform, Pollywog(TM), provides full small bowel coverage- the current blind spot in GI tract. By capturing previously inaccessible multimodal data, our foundational AI enables intelligent navigation and diagnostic insights, creating a proprietary data moat for clinical and pharma applications.
- Optheras A/S - ATLAS is an assistive endoscopic laser platform that moves bladder cancer treatment from the operating room to the procedure room - with precision, with simplicity, without surgery, without general anesthesia, reducing disease burden on patients and healthcare system.
- Urologic - Full urodynamics without catheters- accurate, comfortable, and scalable through natural filling and voiding.
Program: Investor Forumread more · Original Link ↗
ClearPath Cardio, an early-stage cardiovascular medical device company currently collaborating with Mayo Clinic to develop a patent-pending next-generation solution in cardiac lead extraction.ClearPath Cardio, an early-stage cardiovascular medical device company currently collaborating with Mayo Clinic to develop a patent-pending next-generation solution in cardiac lead extraction. They are led by a highly seasoned management team with extensive operational experience in developing and commercializing cardiovascular products at Medtronic, Shockwave, Zimmer Biomet, Smith & Nephew, Hologic, Endologix, and Trivascular.
Program: Investor Forumread more · Original Link ↗
Howard HechlerClearPath Cardio
☆
Mon Oct 19 · 10:25 AM - 10:40 AM
Patient Story: Resmed
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
From Exhausted to Empowered: Brittany’s Journey to Better Sleep
Better sleep can change more than your nights - it can change how you experience your life.From Exhausted to Empowered: Brittany’s Journey to Better Sleep
Better sleep can change more than your nights - it can change how you experience your life.
For years, Brittany lived with constant exhaustion, struggling to stay awake at work, behind the wheel, and during moments with the people she loved. When she was finally diagnosed with severe sleep apnea, she had an answer - but starting CPAP therapy came with fears and uncertainty of its own.
In this candid conversation, Dr. Carlos Nunez sits down with Brittany, who shares how overcoming those initial concerns opened the door to a transformation she could feel almost immediately. Today, therapy has given her more than better sleep - it has helped her regain her energy, confidence, independence, and ability to be fully present in her life.
Brittany’s story is a powerful reminder of what medical technology ultimately makes possible: helping people move beyond their condition and get back to living the lives they want to lead.read more · Original Link ↗
Carlos NunezResmed (Moderator)
Brittany B.
Built for you by(617)-PATRICK, Champion AI speaker
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Kristine MullenPhilips
☆
Mon Oct 19 · 10:30 AM - 10:45 AM
Solutions Showcase: The AI-Powered Commercial Team: Real-World Lessons from MedTech Companies Using AI
For decades, MedTech sales has been built on relationships. While that hasn't changed, the way commercial teams build and strengthen those relationships has.For decades, MedTech sales has been built on relationships. While that hasn't changed, the way commercial teams build and strengthen those relationships has.
AI is now transforming how MedTech organizations identify opportunities, prioritize accounts, understand healthcare providers, prepare for customer conversations, and uncover insights hidden across vast amounts of commercial and market data. And not all AI delivers the same value. The greatest impact comes when AI is grounded in the rich, interconnected MedTech data and market context that commercial teams can rely on to make informed decisions. With this AI, commercial teams are having the right conversations at the right time with the right targets. The result? MedTech solutions get to patients faster, improving outcomes.
Drawing on insights from hundreds of MedTech organizations adopting AI, Mike Monovoukas, CEO and Co-Founder of AcuityMD along with a MedTech commercial leader, will explore how teams are using AI in the field today as well as the results they’re achieving.read more · Original Link ↗
RevBio, Inc., is a clinical stage medical device company developing and commercializing TETRANITE®, a novel biomaterial poised to end medicines 50-year search for a regenerative bone glue.RevBio, Inc., is a clinical stage medical device company developing and commercializing TETRANITE®, a novel biomaterial poised to end medicines 50-year search for a regenerative bone glue. The game changing properties enable the adhesive biomaterial to fills gaps, rapidly fixate bone, and stabilize metal hardware. As a therapeutic device, TETRANITE stimulates new bone formation to accelerate healing and improve patient outcomes. We have demonstrated product safety and efficacy in early clinical studies and are uniquely positioned with multiple approved clinical trials - next up being our pivotal clinical trial for cranial flap fixation which aims to redefine the standard of care for cranial restoration procedures. Bioengineered for a body of applications, the TETRANITE platform will address a total addressable market of over $10 billion in neurosurgical, orthopaedic and dental use cases. FDA approved studies are under way for several indications targeting commercial access in sequence over the coming few years.
Company Sector: Dental, Drug Delivery, Neurology, Orthopaedic
Program: Investor Forumread more · Original Link ↗
Brian HessRevBio
☆
Mon Oct 19 · 10:45 AM - 11:45 AM
The Role of Emerging Markets Within a Global Strategy
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 157C
This panel session aims to give a voice to international markets by engaging in a candid, dynamic discussion on their vital role within a global MedTech strategy.This panel session aims to give a voice to international markets by engaging in a candid, dynamic discussion on their vital role within a global MedTech strategy. Panelists will define the scope of international markets and evaluate their growing importance, particularly analyzing the shifts seen in 2025 - 2026 and forecasting the outlook for the next five to ten years. The conversation will explore the specific countries and regions expected to drive future growth, the main catalysts for these changes, and the anticipated sources of global innovation. Guided by three main axes, the discussion will highlight the major opportunities found in international markets, navigate the main challenges companies face, and share key learnings essential for successfully navigating the evolving global MedTech landscape.
Also tagged: International
Program: LatAmread more · Original Link ↗
Mariana Romero RoyGlobal Health Intelligence (Moderator)
Rafael BraileBraile Biomédica
Eric HonrothGetinge
Sam TalyaPhilips
☆
Mon Oct 19 · 10:45 AM - 11:45 AM
How a Sex-Specific Lens Can Improve Care and Expand Market Opportunities: A Cardiovascular Case Study
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 159
Cardiovascular disease is the leading cause of death in women worldwide, yet much of our clinical evidence, diagnostic paradigms, and device development strategies have historically centered on male disease patterns.Cardiovascular disease is the leading cause of death in women worldwide, yet much of our clinical evidence, diagnostic paradigms, and device development strategies have historically centered on male disease patterns. The result is not just a care gap, but a commercial blind spot.
This panel will translate emerging science on sex-specific cardiovascular biology into actionable strategy for medtech leaders. In recent years, our understanding of how cardiovascular disease manifests differently in women has advanced significantly. At the same time, novel approaches - including a AI-enabled and other diagnostics, remote monitoring, and innovative device platforms - are creating new pathways to detect, stratify, and treat women more effectively.
The implications are clear: women represent one of the largest under-optimized segments in cardiovascular care. Companies that incorporate sex-specific data into trial design, product development, regulatory strategy, and commercialization will be better positioned to differentiate and expand indications to meet the needs of this important market segment.
This discussion will bring together clinical experts and industry leaders to explore how emerging evidence translates into product strategy, investment priorities, and competitive advantage. Attendees will leave with a clearer view of where the science is heading and how to position their organizations to lead in the next era of cardiovascular innovation.
Also tagged: Health Accessread more · Original Link ↗
Colby HoltshouseMay Health (Moderator)
Sarah HuohEdwards Lifesciences
Kathleen Jordan MDMidi Health
Laura MauriMedtronic
Alicia Chong RodriguezBloomer Tech
☆
Mon Oct 19 · 10:45 AM - 11:45 AM
The Future of MedTech Innovation: Inside the Build-to-Buy Model
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 160ABC
This session explores how the Build-to-Buy model is redefining innovation and value creation in MedTech.This session explores how the Build-to-Buy model is redefining innovation and value creation in MedTech. Rather than scaling companies in isolation and hoping for downstream acquisition, Build-to-Buy aligns product development, clinical strategy, and commercialization from day one with the priorities of future strategic buyers. The result is a new venture framework designed for integration, not independence.
Program: Investor Forumread more · Original Link ↗
OrisDX is a precision diagnostics startup. Its first product is a salivary diagnostic aid that utilizes noninvasive, molecular-based genetic techniques to detect oral cancer with high accuracy (sensitivity 93% / specificity >99%).OrisDX is a precision diagnostics startup. Its first product is a salivary diagnostic aid that utilizes noninvasive, molecular-based genetic techniques to detect oral cancer with high accuracy (sensitivity 93% / specificity >99%). The oral rinse test can catalyze changes in the standard of care, leading to earlier detection. It is the only solution that leverages a 7-gene panel using next-generation sequencing (NGS), is pain-free, and can be sampled in either a clinical setting or at home. HPV cancer biomarkers are being optimized for addition in 2027.
Company Sector: Dental, Ear, Nose & Throat (ENT), In Vitro Diagnostics
Program: Investor Forumread more · Original Link ↗
Harald SteltzerOrisDX
☆
Mon Oct 19 · 10:45 AM - 11:00 AM
Corporate Reverse Pitch Presentation: W.L. Gore & Associates, Inc.
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Jason WolfeW. L. Gore & Associates, Inc.
☆
Mon Oct 19 · 10:45 AM - 11:45 AM
From Data to Decisions: How Longitudinal Insights Enable Smarter Patient Care
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 162AB
Healthcare unfolds across a lifetime, yet most digital systems still operate in isolated episodes - fragmenting data across devices, departments, and care settings, and limiting predictive, value-based care.Healthcare unfolds across a lifetime, yet most digital systems still operate in isolated episodes - fragmenting data across devices, departments, and care settings, and limiting predictive, value-based care. As health systems accelerate investment in digital health and AI, a critical truth is emerging: artificial intelligence cannot safely or effectively scale without longitudinal, interoperable, and contextual data at its core.
At the heart of connected care is the ability to connect health data longitudinally - from hospital to home and everywhere in between. What began as individual bedside devices has evolved into real-time care intelligence, where continuous data can be transformed into actionable insights that enable earlier intervention, reduce clinician burden, and improve patient outcomes.
This panel will explore how connected digital health platforms enable context-aware AI across both clinical and consumer environments. Panelists will discuss how longitudinal infrastructure strengthens continuity of care, reduces preventable harm, supports commercialization and adoption of digital health innovations, and creates the foundation for scalable AI and reliable outcomes across health systems.
Also tagged: Legal and Health Care Compliance Best Practicesread more · Original Link ↗
Julia StrandbergPhilips (Moderator)
Emily CapodilupoWHOOP
Nader MherabiNYU Langone
Jacob ShiffCMS Innovation Center
☆
Mon Oct 19 · 10:45 AM - 11:45 AM
Big and Small MedTech Companies in the Enforcement Crosshairs: Are You Ready?
● Emerging Companies
Panel Session
📍 Meeting Level 1, Room 161
Medical device enforcement is entering a more aggressive and coordinated phase - placing companies of every size squarely in regulators’ crosshairs.Medical device enforcement is entering a more aggressive and coordinated phase - placing companies of every size squarely in regulators’ crosshairs. Recent DOJ and FDA actions, coupled with the launch of the DOJ - HHS False Claims Act Working Group, signal heightened scrutiny of medical device manufacturers, including priorities such as defective devices, kickbacks, reimbursement practices, and compliance failures.
This new enforcement environment affects not only global manufacturers but also emerging and mid-size companies, which may face heightened risk due to rapid growth, limited compliance infrastructure, and increasing operational complexity. Regulators expect companies of all sizes to maintain robust compliance programs, executive oversight, and proactive risk management.
This panel will provide senior executives with practical insights into current enforcement priorities, lessons from recent civil and criminal cases, and what enforcement trends reveal about regulators’ expectations. Panelists will address the enforcement threats that are keeping executives up at night - including individual accountability, False Claims Act exposure, quality and reporting risks, and commercial practices.
Most importantly, the session will equip attendees with actionable compliance and governance strategies to reduce enforcement risk, strengthen internal controls, and demonstrate good-faith compliance. Attendees will leave with a clearer understanding of how to navigate this evolving enforcement landscape and protect their organizations, their patients, and themselves.
Also tagged: Legal and Health Care Compliance Best Practicesread more · Original Link ↗
Ralph CacciaWiley Rein (Moderator)
Kate GodfreyKarl Storz
Perri PomperStryker Corporation
Augustine RipaWhistleblower Law Collaborative LLC
Tara ShewchukMedtronic
☆
Mon Oct 19 · 10:45 AM - 11:45 AM
Lessons from Year 1 of QMSR Implementation: What’s Next for Aligning Quality Systems, ISO 13485, Inspection Readiness, and Compliance
● Regulatory, Quality and Good Manufacturing Practices
Panel Session
📍 Meeting Level 1, Room 157AB
FDA's Quality Management System Regulation (QMSR) went into full effect on February 2, 2026.FDA's Quality Management System Regulation (QMSR) went into full effect on February 2, 2026. While industry and FDA had prepared for the transition for years, this milestone date ushered in the implementation of a significant evolution in medical device quality and regulatory compliance, harmonizing U.S. requirements with ISO 13485:2016: FDA investigators were in the field utilizing the new inspection model on day one of the transition. Now months into the transition, understanding quality systems, regulatory strategy, and inspection readiness is essential.
This panel will bring together key FDA officials, industry quality/regulatory leaders, and standards experts, to discuss lessons learned, ongoing and emerging implementation challenges, and best practices for achieving compliance under the still-relatively-new framework. Panelists will explore the intersection of QMSR and ISO 13485 requirements, strategies for managing quality system updates, and approaches to maintaining global harmonization across markets.
The discussion will address how FDA inspections have evolved under QMSR, what companies can expect during inspection based on implementation to date, common areas of 483 observations, teachings from the first batch of warning letters and how organizations can strengthen their inspection preparedness programs. Attendees will gain practical insights into risk-based quality management, documentation expectations, supplier controls, corrective action, effectiveness, and internal audit strategies that support both compliance and operational excellence. Attendees will also learn about potential issues posed by standards maintenance and regulatory convergence activities that could support the QMSR implementation.
Key discussion topics include:
- Understanding the FDA's QMSR transition and alignment with ISO 13485:2016 since the implementation date
- Preparing for FDA inspections under the QMSR framework, leveraging lessons learned from implementation efforts, inspection experiences, and first batch of warning letters
- Appreciating how standards maintenance and other regulatory convergence activities, for instance IMDRF, could impact the continuing implementation
- Developing and maintaining a sustainable culture of quality in an increasingly global regulatory environment
This session is designed for quality, regulatory, compliance, and executive leaders seeking practical guidance for successfully implementing QMSR while maintaining inspection readiness and supporting business objectives.
#AdvaMedinAction
Program: AdvaMed in Actionread more · Original Link ↗
Jamie WolszonAdvaMed (Moderator)
Karen Masley-JosephU.S. Food and Drug Administration (FDA)
Douglas ReimerJohnson & Johnson Vision
Scott SardesonSt. Cloud State University - Twin Cities
Keisha ThomasU.S. Food and Drug Administration (FDA)
☆
Mon Oct 19 · 10:50 AM - 11:20 AM
The Big Tech Question: Partner, Build, or Compete?
Technology companies are moving rapidly into healthcare, reshaping how innovation is developed, scaled, and delivered. As these worlds converge, both MedTech and Big Tech leaders face critical choices around where to partner, where to build, and where to compete.Technology companies are moving rapidly into healthcare, reshaping how innovation is developed, scaled, and delivered. As these worlds converge, both MedTech and Big Tech leaders face critical choices around where to partner, where to build, and where to compete.
This discussion brings together leaders from across the ecosystem to examine how these relationships are taking shape, the risks and opportunities they create, and how each side is defining its role in an increasingly AI-enabled healthcare landscape.
Also tagged: Digital Health Technologiesread more · Original Link ↗
Monish RajpalL.E.K. Consulting (Moderator)
Quentin BlackfordiRhythm Technologies
Prerna DograNVIDIA
Mick Farrell SM, MBAResmed
☆
Mon Oct 19 · 10:50 AM - 11:05 AM
Patient Story: Insulet
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
From Diabetes Stress to Diabetes Confidence: One patient's experience with automated insulin delivery An Omnipod® 5 user shares their journey from multiple daily insulin injections to automated insulin delivery and discusses how a simpler approach to diabetes management provided greater...From Diabetes Stress to Diabetes Confidence: One patient's experience with automated insulin delivery
An Omnipod® 5 user shares their journey from multiple daily insulin injections to automated insulin delivery and discusses how a simpler approach to diabetes management provided greater freedom, flexibility, and peace of mind.read more · Original Link ↗
Eric BenjaminInsulet (Moderator)
Erick Rivera
☆
Mon Oct 19 · 10:50 AM - 11:05 AM
Solutions Showcase: Can Agents Be Compliant? Governing AI Across the Product Lifecycle
Large, AI-forward medtech organizations have an agent problem. They want agents working across the product lifecycle, but many lack a clear path to compliant deployment.Large, AI-forward medtech organizations have an agent problem. They want agents working across the product lifecycle, but many lack a clear path to compliant deployment. Teams are improvising against standards originally written for human-run lifecycles, and the cost of getting it wrong is a recall, a failed audit, or worst of all, an unsafe product that should not have shipped.
Erez Kaminski, Founder and CEO of Ketryx, will present a working governance model for AI agents across the total product lifecycle: how to scope an agent’s work, to qualify and approve it, and stay audit-ready throughout deployment. The model accelerates development while improving quality and has been successfully deployed at four of the world’s top five medical device manufacturers. It has cleared audits with notifying bodies and has been integrated into the work of over 100,000 professionals building regulated products worldwide.read more · Original Link ↗
Erez KaminskiKetryx
☆
Mon Oct 19 · 10:55 AM - 11:05 AM
Company Presentation: OtoNexus Medical Technologies
OtoNexus Medical Technologies has developed the Novoscope, a handheld ultrasound-based otoscope that delivers objective, real-time data at the point of care.OtoNexus Medical Technologies has developed the Novoscope, a handheld ultrasound-based otoscope that delivers objective, real-time data at the point of care. In less than 2 seconds, the device helps clinicians assess for middle ear effusion and determine whether the findings are consistent with a bacterial or non-bacterial infection.
Middle ear infections remain a leading reason children receive antibiotics, even though many cases are not bacterial. Our goal is to improve diagnostic confidence, support antimicrobial stewardship, reduce unnecessary antibiotic use, and lower care costs.
Company Sector: Diagnostic Imaging, Ear, Nose & Throat (ENT)
Program: Investor Forumread more · Original Link ↗
Caitlin CameronOtoNexus Medical Technologies
☆
Mon Oct 19 · 10:55 AM - 11:25 AM
MedTech Innovator Showcase: Innovative Urology & GI Patient Care
Presenting startups:
- BeCapio - Non-invasive wearable for fecal incontinence: immediate symptom control with long-term pelvic floor rehabilitation. - Class Medical - TUC Safety Valve prevents the inflation of an anchoring balloon of a foley catheter in the urethra.Presenting startups:
- BeCapio - Non-invasive wearable for fecal incontinence: immediate symptom control with long-term pelvic floor rehabilitation.
- Class Medical - TUC Safety Valve prevents the inflation of an anchoring balloon of a foley catheter in the urethra.
- Imagine Devices Inc. - Pediatric feeding tube integrating airway pressure, ECG, and temp monitoring to improve safety & reduce wires in the NICU.
- VIVIFI MEDICAL INC - Vivifi Medical is developing the first and only treatment that addresses BPH at the source, without the side-effects.
Program: Investor Forumread more · Original Link ↗
Skander LimemBecton Dickinson (Moderator)
Daniel FordeClass Medical
Iman SalafianImagine Devices Inc.
Tushar SharmaVIVIFI MEDICAL INC
Conrad SmitsBeCapio
Built for you by(617)-PATRICK, Champion AI speaker
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Kathryn BeckerLicensing, Acquistions and Ventures Abbott
☆
Mon Oct 19 · 11:05 AM - 11:15 AM
Company Presentation: Pretika MedTech Corporation - OptixDX
Pretika MedTech’s OptixDX is a breakthrough predictive imaging platform embedded in a wound dressing, designed to detect post-surgical complications within hours of formation.Pretika MedTech’s OptixDX is a breakthrough predictive imaging platform embedded in a wound dressing, designed to detect post-surgical complications within hours of formation. By combining non-invasive optical imaging with AI-driven analytics, OptixDX enables earlier intervention, reduces costly readmissions, and brings continuous, actionable intelligence to surgical wound care.
Company Sector: Diagnostic Imaging, Digital Health, Patient Monitoring, Wound Management
Program: Investor Forumread more · Original Link ↗
Thomas NicholsPretika MedTech Corporation
☆
Mon Oct 19 · 11:10 AM - 11:25 AM
Solutions Showcase: Unlock the Full Potential of Enterprise AI with Process Intelligence
Enterprise AI can only deliver business outcomes when it understands how work actually happens.Enterprise AI can only deliver business outcomes when it understands how work actually happens. Discover how Celonis provides the execution context AI needs to uncover execution constraints, predict risks, and orchestrate actions across product development, manufacturing, supply chain, commercial operations, and field service, turning enterprise data into measurable business outcomes.read more · Original Link ↗
Akeyna is a medical device company developing a smart injection platform designed to bring real-time intelligence to injection-based procedures.Akeyna is a medical device company developing a smart injection platform designed to bring real-time intelligence to injection-based procedures. The company’s proprietary technology uses light-based sensing at the tip of the a needle or cannula to detect blood or vessel entry in real time. When blood is detected, the system provides an immediate visual and/or audio indicator to the clinician, helping inform placement decisions at the point of care.
Akeyna’s first application is in dermal filler injections, a high-volume, cash-pay aesthetic market where inadvertent vascular entry can lead to serious complications including permanent blindness. This market offers an attractive initial commercialization pathway because the device can be adopted without reimbursement, integrates into existing injector workflows, and addresses a clear safety concern for both clinicians and patients.
Beyond aesthetics, Akeyna’s platform has potential to expand into broader clinical applications, including smart cannulas and smart IVs for therapeutic injections, IV placement, chemotherapy administration, pediatrics, emergency care, and military field medicine. In each setting, the goal is to provide affordable, real-time procedural feedback where accurate placement, vessel awareness, and avoidance of unintended drug delivery are clinically important.
Akeyna is led by experienced, medical device serial entrepreneurs, with deep expertise in clinical development, product design, regulatory strategy, operations, and commercialization. The company’s technology was developed by leading physician-scientists at Massachusetts General Hospital, a Harvard-affiliated institution, and is supported by an exclusive, worldwide license from MGH.
Akeyna’s vision is to establish a new standard of care with affordable and simple, intelligent injection devices that improve patient safety, enhance clinician confidence, and reduce preventable complications across high-volume medical procedures.
Company Sector: General Hospital & Healthcare Supply, Patient Monitoring
Program: Investor Forumread more · Original Link ↗
Karen CronholmAkeyna
☆
Mon Oct 19 · 11:15 AM - 11:30 AM
Corporate Reverse Pitch Presentation: GE Healthcare
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Ivan MartinezGE HealthCare
☆
Mon Oct 19 · 11:15 AM - 11:30 AM
Patient Story: Stryker
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
Aneurysm discovery, treatment and peace of mind: Janelle’s story
For years, Janelle navigated the challenges of a rare vascular condition while raising her family and maintaining an active lifestyle.Aneurysm discovery, treatment and peace of mind: Janelle’s story
For years, Janelle navigated the challenges of a rare vascular condition while raising her family and maintaining an active lifestyle. When routine imaging revealed an unruptured aneurysm and pseudoaneurysm, she faced a difficult choice: continue monitoring the condition or pursue treatment. Together with her neurovascular care team, Janelle chose a path that would allow her to move forward with confidence. Janelle’s story is one of resilience, informed decision-making and the profound impact that early diagnosis and advanced treatment can have on a patient’s quality of life.read more · Original Link ↗
Actuated Medical’s patented NeuralGlider is positioned at the forefront of the growing neurotech market as the access tool of choice.Actuated Medical’s patented NeuralGlider is positioned at the forefront of the growing neurotech market as the access tool of choice. An estimated 100M patients worldwide suffer treatment resistant neurological conditions that are candidates for neurotech treatments; a 10% addressable share implies a TAM > $30B. NeuralGlider inserts neurotech with gentle, electronically controlled motion for greater precision and less trauma, improving outcomes. Developed with ~$18M in non dilutive NIH and DARPA funding, NeuralGlider has generated $500k in research sales, been adopted by 41+ research labs, and is cited in 44+ publications, demonstrating technology validation and traction. With growing awareness among clinical neurotech stakeholders, Actuated Medical is raising a $10M Series A to commercialize a clinical single use NeuralGlider tool to improve 1) deep brain probe placement to reduce revisions (e.g., deep brain stimulation (DBS) probes, Next-gen flexible implants, and brain computer interfaces (BCI)); and 2) chronic biologic delivery to deep brain structures (e.g., brain cancer, gene therapy, and addiction treatments). Our commercial model projects device sales and licensing revenue, supported by defensible IP, clinical pathways, and scalable manufacturing. We will divest two non core FDA cleared assets where profits are reinvested to fuel growth minimizing future round dilution. We have a dedicated team of 13 with plans to hire an experienced neurotech Chief Commercialization Officer (previously on a neurotech leadership team that sold to Stryker). With a five year exit plan, projected investor returns are 8 - 10x. Term sheet and diligence report available from Keiretsu Forum-MST.
Company Sector: Endoscopy, Gastroenterology, Neurology, Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Maureen Mulvihill PhDActuated Medical, Inc.
Built for you by(617)-PATRICK, Champion AI speaker
Policy and regulatory changes have added an additional financial strain on healthcare providers.Policy and regulatory changes have added an additional financial strain on healthcare providers. Capital budgets have tightened, operating costs remain elevated and reimbursement headwinds have forced leadership teams to make difficult, real‑time trade‑offs that directly affect patient outcomes, workforce capacity and quality of care.
This CEOs Unplugged panel will bring provider and MedTech executives together for a candid discussion on how budget pressure has played out over the course of 2026 and what those realities mean heading into 2027. Drawing on recent provider research, the session will explore how financial constraints are reshaping investment decisions across specialties, staffing, AI adoption and care delivery models, as well as the downstream impact on patient access and outcomes.
The conversation will focus on decisions already made, lessons learned and how expectations for MedTech partners have evolved as providers demand clearer ROI, faster value realization and demonstrable impact on both efficiency and quality of care.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Ajay DhankharSmith+Nephew
☆
Mon Oct 19 · 11:30 AM - 12:00 PM
MedTech Innovator Showcase: Innovative Procedural Care Tech
Presenting startups:
- Cannulight Technology - A small, sterile, single-use device that fits standard IV catheters and lights up instantly to confirm successful vein entry. - Lenneuro - The SnapCath(TM) covers and anchors tubes with a clear, snap-on lid.Presenting startups:
- Cannulight Technology - A small, sterile, single-use device that fits standard IV catheters and lights up instantly to confirm successful vein entry.
- Lenneuro - The SnapCath(TM) covers and anchors tubes with a clear, snap-on lid. Just pop the top for easy catheter care at all skill levels.
- Ring Rescue Inc. - Ring Rescue saves fingers, and sets a global Standard of Care for a common medical problem. Stuck rings, solved!
- VIS, Inc. - Opti-K is a groundbreaking, patented eyecare technology designed to address prevalent vision impairments through a noninvasive, painless, repeatable, and rapid procedure. Leveraging a unique thulium laser system, Opti-K offers immediate improvements in low vision conditions including hyperopia, presbyopia, and age-related macular degeneration (AMD) while providing true multifocality.
Program: Investor Forumread more · Original Link ↗
Continuous software innovation presents new challenges for product development teams seeking to deliver improvements quickly while maintaining safety, effectiveness, and regulatory readiness. This session examines how manufacturers can move beyond traditional change control toward a more adaptive lifecycle management approach.Continuous software innovation presents new challenges for product development teams seeking to deliver improvements quickly while maintaining safety, effectiveness, and regulatory readiness. This session examines how manufacturers can move beyond traditional change control toward a more adaptive lifecycle management approach. Participants will explore practical principles for anticipating software evolution, planning evidence proportionate to risk, and improving collaboration across engineering, quality, clinical, and regulatory functions throughout the product lifecycle.read more · Original Link ↗
Fziomed is a recognized global leader in postsurgical adhesion prevention focused on addressing an unmet clinical need in spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures.Fziomed is a recognized global leader in postsurgical adhesion prevention focused on addressing an unmet clinical need in spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures. Fziomed develops, manufactures, and commercializes best-in-class surgical biomaterials used by clinicians to Preserve Surgical Excellence and improve patient outcomes. Fziomed’s portfolio of adhesion barrier products are marketed in more than 50 countries under various brand names and have been used clinically since 2002 in more than 1 million procedures worldwide.
Company Sector: Endoscopy, Neurology, Orthopaedic, Surgical Device, Instruments and Accessories, Women’s Health
Program: Investor Forumread more · Original Link ↗
Contour Medical is a medical device company developing an industry-first platform of soft robotic catheters designed to diagnose and treat cardiac arrhythmias such as Atrial Fibrillation (AFib) and Ventricular Tachycardia (VTach).Contour Medical is a medical device company developing an industry-first platform of soft robotic catheters designed to diagnose and treat cardiac arrhythmias such as Atrial Fibrillation (AFib) and Ventricular Tachycardia (VTach). By replacing traditional, rigid nitinol metal splines with inflatable polymer actuators and stretchable flex-PCBs, Contour's catheters are 1000x less rigid than legacy devices and achieve ~90% tissue contact across complex cardiac anatomy.
HIGH-DEFINITION CARDIAC MAPPING (ATLAS 360) The company’s initial entry, the Atlas 360 (Class II diagnostic catheter), leverages 80 sensing electrodes to deliver whole-chamber high-density mapping in record time, completing atrial maps in ~30 seconds (a 94%-time reduction versus market leaders) and ventricular maps in ~70 - 90 seconds. Featuring a dynamic ""one-size-fits-all"" inflatable design that resizes from 6.5 mm to 65 mm, a single device can map large chambers as well as narrow pulmonary veins without requiring catheter exchanges. PULSED FIELD ABLATION (PFA COMBINATION PLATFORM) Contour Medical's flagship Class III device combines its whole-chamber high-definition mapping capabilities with non-thermal Pulsed Field Ablation (PFA) on a single catheter. PFA uses short-duration DC electrical pulses to cause irreversible electroporation, selectively disabling tissue responsible for erratic electrical signals without causing thermal collateral damage to surrounding structures. The platform features single-sided electrodes with dielectric backing, ensuring the electric field targets the endocardial tissue rather than the blood pool to enhance lesion depth while preventing hemolysis and thrombus formation.
Company Sector: Cardiology
Program: Investor Forumread more · Original Link ↗
Vidur SahneyContour Medical
☆
Mon Oct 19 · 11:45 AM - 12:00 PM
Corporate Reverse Pitch Presentation: Johnson & Johnson MedTech
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Sonal PatelJohnson & Johnson
Built for you by(617)-PATRICK, Champion AI speaker
Pulse on Medtech: The Best Opportunities in Medtech for 2026 - 2027
● Keynote
Keynote
📍 Exhibit Level, Medtech Campus, Keynote Theater
This CEO panel will bring together leading CEOs to discuss where value creation is most likely to emerge over the next two years. The session will focus on accelerating role of innovation and AI-enabled technology as a competitive differentiator.This CEO panel will bring together leading CEOs to discuss where value creation is most likely to emerge over the next two years.
The session will focus on accelerating role of innovation and AI-enabled technology as a competitive differentiator. Panelists will discuss and emphasize that AI is moving beyond experimentation into scaled, workflow-embedded applications that improve clinical decision-making, automate manual processes, and enhance patient engagement. The discussion will also highlight how data, software, and connected devices are becoming inseparable from core Medtech platforms, with winners defined by their ability to deliver clear clinical and economic value.
The conversation will also underscore the growing importance of ambulatory surgical centers (ASCs) as a structural shift in care delivery. Discussion will focus on procedure migration out of acute settings as a durable trend, creating opportunities for device companies that can design solutions optimized for efficiency, ease of use, and total cost of care. Focus will be on discussing ASCs as not just as a site-of-care change, but as a catalyst for rethinking product design, service models, and commercial strategy.
Finally, MA&D continues to play a key role in long term Medtech strategy. Panelists will discuss how a disciplined MA&D environment - with increased focus on strategic fit, technology differentiation, and the ability to scale innovation post-acquisition - are tied to thoughtful portfolio shaping and partnerships that accelerate access to new technologies and care settings.
Keynote session to feature the following special content from Operation Smille - Many Hands, One Purpose: Medtech’s Collective Impact
Medtech’s greatest impact occurs when companies and clinicians work together to turn innovation into life-changing care. By joining with expert global community partners, medtech companies can increase their reach and help even more patients. Illustrated by experiences throughout his career, Operation Smile’s Chief Medical Officer Dr. William Magee III shows how medtech-clinician partnerships expand access, strengthen communities, and improve patient outcomes around the world.
Brought to you by Johnson & Johnson MedTech
Keynote and Lunch open to All-Access passholders only
Program: Investor Forumread more · Original Link ↗
Bank of America: Shareholder Activism: Scourge or Savior?
● Business Strategies and Finance
Panel Session
📍 Exhibit Level, Room 050
Opening Remarks: 1:45 pm - 2:00 pm
Panel Session: 2:00 pm - 3:00 pm
Shareholder activism is playing an increasingly visible role in MedTech, prompting companies and boards to confront questions about strategy, performance, portfolio composition, and shareholder value creation.Opening Remarks: 1:45 pm - 2:00 pm
Panel Session: 2:00 pm - 3:00 pm
Shareholder activism is playing an increasingly visible role in MedTech, prompting companies and boards to confront questions about strategy, performance, portfolio composition, and shareholder value creation. This panel will explore how activists develop investment theses, engage with research analysts and other investors, and identify companies where alternative strategic or financial actions may unlock value. The discussion will examine how MedTech activism has evolved, which campaign themes are resonating with shareholders, and why the sector continues to attract prominent activist investors. Panelists will also discuss how companies can prepare for activist approaches, communicate effectively with shareholders, and determine when private engagement or settlement is preferable to a public campaign. Bringing together perspectives from strategic communications, equity research, and corporate law, the panel will consider what companies do well, where they falter, and what ultimately determines whether activism serves as a catalyst for value creation or a source of disruption.
#BankofAmerica
Program: Investor Forumread more · Original Link ↗
Medtech CEOs are navigating a moment of compounding pressure unlike any in recent memory. Regulatory environments are in flux. Macro and geopolitical factors are constantly in flux. Health system consolidation and reimbursement dynamics are reshaping the customer landscape.Medtech CEOs are navigating a moment of compounding pressure unlike any in recent memory. Regulatory environments are in flux. Macro and geopolitical factors are constantly in flux. Health system consolidation and reimbursement dynamics are reshaping the customer landscape. At the same time, artificial intelligence is creating new opportunities to accelerate innovation, strengthen connectivity and improve patient outcomes, while raising questions about use at the same time. Meanwhile, organizations that have been through years of restructuring, post-pandemic recovery, and portfolio rationalization are being asked to transform again, faster - with workforces that are stretched thin. This session brings together CEOs of leading medtech companies for a candid, unscripted conversation about what it actually takes to drive change in this environment - what separates the companies coming out stronger from those falling behind - and what excites them about the future of Med Tech.read more · Original Link ↗
WearableDose is developing an AI-powered, real-time radiation monitoring platform that provides personalized dosimetry insights for patients and clinicians.WearableDose is developing an AI-powered, real-time radiation monitoring platform that provides personalized dosimetry insights for patients and clinicians. Our wearable technology enables continuous radiation exposure monitoring to improve patient safety, optimize treatment delivery, and support data-driven decision-making across healthcare, government, and defense applications.
Company Sector: Radiation Therapy (RT)
Program: Investor Forumread more · Original Link ↗
John Sanwo MBAWearableDose, Inc
☆
Mon Oct 19 · 1:45 PM - 2:00 PM
Corporate Reverse Pitch Presentation: Medtronic
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Presenting startups:
- BrainMatterZ - BrainMatterZ is Unlocking Sleep as the 6th Vital Sign with simple, comprehensive home testing. - OmniBuds, Inc. - OmniBuds clinically accurate earbud wearables delivering effortless, everyday monitoring of blood pressure & vital signs.Presenting startups:
- BrainMatterZ - BrainMatterZ is Unlocking Sleep as the 6th Vital Sign with simple, comprehensive home testing.
- OmniBuds, Inc. - OmniBuds clinically accurate earbud wearables delivering effortless, everyday monitoring of blood pressure & vital signs.
- Quantanosis.ai - A non-invasive, AI-powered histotripsy system enabling rapid, operator-free discovery & treatment of large vessel occlusion strokes.
- Theta Neurotech - 24/7-wearable EEG patches that predict/alert patients with epilepsy of their impending seizures, enabling preventative action.
Program: Investor Forumread more · Original Link ↗
This session brings together three leading medtech organizations to explore how and why the industry is increasingly turning to direct-to-patient (DTP) campaigns.This session brings together three leading medtech organizations to explore how and why the industry is increasingly turning to direct-to-patient (DTP) campaigns. Each panelist represents a distinct strategic rationale for going direct to patients - from disease awareness and public health screening to product marketing and advocacy for legislative change. Together, they offer attendees a panoramic view of the DTP landscape across orthopedics, diabetes technology, women’s health and cardiovascular care. The session will be structured as a moderated panel discussion with brief case study introductions from each panelist, followed by cross-cutting discussion on themes including regulatory compliance, measuring ROI, creative strategy, health equity, and the future of patient engagement in medtech.
#AdvaMedinAction
Program: AdvaMed in Actionread more · Original Link ↗
Medical device complaint handling demands speed, accuracy, and compliance.Medical device complaint handling demands speed, accuracy, and compliance. Join Honeywell Technologies | Life Sciences for a 15-minute Solution Showcase to see how its Processing Agent, powered by Salesforce agentic AI and embedded in TrackWise Digital QMS, helps classify complaints, detect duplicates, assess reportability, recommend coding, and generate summaries with clear rationale for review.
Learn how AI can improve efficiency and consistency while preserving the human oversight and traceability essential for regulated quality operations.read more · Original Link ↗
Healionics is developing safer, more reliable vascular access solutions to enhance the health and longevity of kidney failure patients while reducing the high cost of dialysis care.
Company Sector: Surgical Device, Instruments and Accessories
Program: Investor Forum · Original Link ↗
Mike Connolly MS, MBAHealionics
Built for you by(617)-PATRICK, Champion AI speaker
A New Era in MedTech Go-To-Market: How Commercial Challenges are Driving Dealmaking
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 157C
Market dynamics are rapidly changing for medtech companies, and the strategic deal activity is reflecting those go-to-market pressures.Market dynamics are rapidly changing for medtech companies, and the strategic deal activity is reflecting those go-to-market pressures. Trends in reimbursement, pricing, contracting, rep access, competition and technology are all impacting what’s hot and what’s not in medtech M&A, partnerships, and growth strategies.
As commercialization becomes more complex and costly, investors and strategic acquirers are placing greater emphasis on how companies execute in the field and perform within health systems. Go-to-market readiness, sales efficiency, and the ability to scale under margin pressure are now critical factors influencing valuation, deal structure, and portfolio decisions.
Hear perspectives from leading industry executives, investors and emerging company CEOs as they seek to align their strategies to find success in this transforming landscape. Panelists will explore which go-to-market signals matter most to buyers and investors, where companies can struggle to prove scalability, and how commercial execution is increasingly separating technologies from investable and acquirable businesses.
Also tagged: Emerging Companies
Program: Investor Forumread more · Original Link ↗
Amy SiegelS2N Health (Moderator)
Lana CaronSolas BioVentures
Lori ChmuraNyra Medical
Anil KeniEdwards Lifesciences
Drew LoganMedtronic
☆
Mon Oct 19 · 2:00 PM - 3:00 PM
Beyond the Device: Rethinking MedTech Through Ecosystems, Economics, and Enterprise Value
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 162AB
For decades, MedTech growth has been anchored in the device.For decades, MedTech growth has been anchored in the device. But as AI and digital health reshape care delivery, and as health systems face workforce shortages, value-based pressures, rising chronic disease burden, and growing expectations to improve outcomes - the next phase of MedTech success will require innovative models that align technology, evidence, workflow, economics, and the partners needed to deliver care at scale.
Join this timely conversation with leaders at the forefront of what comes beyond the device: ecosystem-driven approaches that combine evidence-backed MedTech with digital health services, data and AI, health system workflow integration, and scalable care pathways.
Hear how these models can support more proactive care while creating durable enterprise value and advancing the quintuple aim: better outcomes, improved patient and clinician experiences, lower costs, and greater access and health equity.
Also tagged: Digital Health Technologies
Program: Investor Forumread more · Original Link ↗
Justin KleinVensana Capital (Moderator)
Quentin BlackfordiRhythm Technologies
Sean CassidyLucem Health
Xiaoyan Huang MD, MHCM, FACC, FACPCenterWell
Jeffrey Wessler MDHeartbeat Health
☆
Mon Oct 19 · 2:00 PM - 2:15 PM
Corporate Reverse Pitch Presentation: Boston Scientific
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Michael RyanBoston Scientific
☆
Mon Oct 19 · 2:00 PM - 3:00 PM
AI Agents in MedTech: Promise, Risk, and Governance
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 159
AI agents - systems that can autonomously plan, act, and interact with other software or users - are quickly moving from experimental tools to operational components within MedTech organizations.AI agents - systems that can autonomously plan, act, and interact with other software or users - are quickly moving from experimental tools to operational components within MedTech organizations. Unlike traditional AI models that generate outputs in response to prompts, AI agents can execute multi‑step tasks, integrate with enterprise systems, and make decisions with limited human intervention. These capabilities create significant opportunities across R&D, quality, regulatory, supply chain, and commercial functions - but they also raise novel legal, compliance, and governance questions.
This session will examine how AI agents are being deployed, or actively considered, in MedTech environments and what distinguishes them from more familiar AI applications. Panelists will explore emerging use cases such as automated regulatory intelligence, continuous quality monitoring, clinical trial operations support, and enterprise workflow optimization. The discussion will focus on the unique risk profile of AI agents, including issues related to accountability, validation, data access, cybersecurity, auditability, and regulatory oversight.
Speakers will also address how existing legal and regulatory frameworks apply to AI agents, where gaps remain, and how companies can design governance structures that align innovation with compliance. Topics will include appropriate human‑in‑the‑loop controls, documentation and recordkeeping expectations, vendor management, and internal policies to manage autonomy and escalation. The session will conclude with practical guidance for MedTech leaders evaluating whether, when, and how to responsibly deploy AI agents within their organizations.
Also tagged: Legal and Health Care Compliance Best Practicesread more · Original Link ↗
Mark BrennanHogan Lovells Cadwalader (Moderator)
Joseph CvelbarCurai Health
Lesley Anne DurantPrivia Health
Matthew McDonellZimmer Biomet
☆
Mon Oct 19 · 2:00 PM - 3:00 PM
Rethinking Care Delivery: Scalable Access Through Point-of-Care Innovation
● Health Access
Panel Session
📍 Meeting Level 1, Room 160ABC
Expanding healthcare access requires more than new technology. It requires rethinking where care is delivered, how clinicians work, and how reimbursement supports new models of care.Expanding healthcare access requires more than new technology. It requires rethinking where care is delivered, how clinicians work, and how reimbursement supports new models of care.
This session explores how point-of-care ultrasound, AI-enabled workflows, telemedicine, and connected care are expanding access beyond traditional hospital settings, particularly in rural and underserved communities. Through real-world examples, panelists will examine how health systems, industry, and payers can work together to implement scalable care models that bring diagnostics closer to patients while improving workflow efficiency, reducing unnecessary hospitalizations, and supporting value-based care.
The discussion will address the practical challenges of adoption, including clinician training, workflow integration, reimbursement pathways, and cross-sector collaboration. Panelists will also consider how remote screening, virtual specialist oversight, and connected diagnostic platforms can help detect high-cost conditions earlier, improve patient access and experience, and create more sustainable models for providers and payers alike.
Attendees will leave with practical insights into how technology, operations, and reimbursement must evolve together to make decentralized care both clinically effective and economically sustainable.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Ritu ThammanUniversity of Pittsburgh School of Medicine (Moderator)
Karl DauphinaisSenior Community Care for Optum Connecticut
Joseph DeVivoButterfly Network, Inc.
Elazer EdelmanHarvard Medical School; MIT
☆
Mon Oct 19 · 2:00 PM - 3:00 PM
Recent Trends and Policy Outlook for Medicare Coverage and Payment of Molecular Diagnostics
● In Vitro Diagnostic Tests and Technologies
Panel Session
📍 Meeting Level 1, Room 157AB
This session will convene leading reimbursement experts on diagnostics to discuss recent trends in Medicare coverage and payment for molecular diagnostics.This session will convene leading reimbursement experts on diagnostics to discuss recent trends in Medicare coverage and payment for molecular diagnostics. The panel will draw on the experience and expertise of the panel members at CMS, Medicare Administrative Contractors and companies to discuss the evolving landscape for coverage of diagnostics. The panel will discuss the use of the National Coverage Determination (NCD) process to cover new cancer diagnostics, including modernization of current NCD 90.2 for Next Generation Sequencing and updates by the Trump Administration to the TCET/MCIT pathway for novel devices. Additionally, the panel will look at the evolving role of MACs and the potential for national expansion of the MolDX program. The panel will look at coverage for new emerging technologies like multi-cancer early detection tests and the role of Medicare benefit categories for screening tests, along with the growing role of Medicare Advantage plans in the coverage process, including the use of prior authorization for covered services. The panel will also talk about state biomarker law coverage requirements. Finally, the panel will discuss developments in market-based pricing and rate-setting under the Medicare Clinical Laboratory Fee Schedule with the second reporting cycle under the Protecting Access to Medicare Act in 2026.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Brian CareyHogan Lovells Cadwalader (Moderator)
Tara BurkeCaris Life Sciences
Tamara Syrek Jensen JDRubrum Advising
Bruce Quinn, MD, PhD MD, PhD, MBABruce Quinn Associates LLC
☆
Mon Oct 19 · 2:00 PM - 3:00 PM
MDR/IVDR Implementation: A Changed Landscape
● International
Panel Session
📍 Meeting Level 1, Room 161
This session will cover the Commission's ambitious legislative proposals to modernize MDR/IVDR, industry response and suggested amendments, and the process for adoption of these real reforms in the near future to ensure substantial, long-term improvements in MDR/IVDR.This session will cover the Commission's ambitious legislative proposals to modernize MDR/IVDR, industry response and suggested amendments, and the process for adoption of these real reforms in the near future to ensure substantial, long-term improvements in MDR/IVDR. This session will examine the Commission’s proposal and its potential to strengthen the EU regulatory framework, assess the implications of these proposed reforms, and discuss what additional measures are needed to ensure the system is future-proof, innovation-friendly, and globally competitive, while maintaining the highest levels of safety.
#AdvaMedinAction
Also tagged: Regulatory, Quality and Good Manufacturing Practices
Program: AdvaMed in Actionread more · Original Link ↗
Joseph GatewoodAdvaMed (Moderator)
Michel Marboeuf Master Business AdministrationStryker Corporation
Our mission is to improve the cancer treatment quality, patient quality of life and reduce healthcare costs.Our mission is to improve the cancer treatment quality, patient quality of life and reduce healthcare costs. We have developed a patented cold plasma technology that can reduce local cancer recurrence and/or radiation therapy dosage by treating residual disease at the surgical margin after a solid tumor is removed. Our platform technology can treat any solid tumor cancer. In the short term, we will target breast cancer, non-melanoma and melanoma skin cancers. In the mid-term, we will target non-small cell lung cancer and in the long-term, ovarian, glioblastoma, sarcoma, pancreatic cancers. Our technology addresses a huge unmet need: Breast and skin cancers have the higher incidence rates. High-risk breast cancer recurrence rate is about 40% after 3-5 years, for high-risk non-melanoma is it about 80% after 3 years and 70% for high-risk melanoma after 5 years. Current standard of care to reduce recurrence rate, such as intraoperative radiotherapy is likely to not be used since ASTRO does not recommend it since 2024, radiation therapy and chemotherapy have important sides effects and toxicity, brachytherapy is a complex and long treatment, and cavity shaving has poor cosmetic outcomes. Therefore, there is a need for a novel easy-to-use, fast treatment that is not toxic with no side effects to reduce cancer local recurrence.
Company Sector: Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Valerie LeveilleNexPlasmaGen Inc.
☆
Mon Oct 19 · 2:05 PM - 2:20 PM
Solutions Showcase: From Blind Spot to Signal: Tracking Real-World Product Utilization in Medtech
Product usage has always been a blind spot for the Medical Device industry. After a brand is sold into a facility, the transparency of usage erodes. We are seeing rising off-label usage as physicians become more creative in improving outcomes.Product usage has always been a blind spot for the Medical Device industry. After a brand is sold into a facility, the transparency of usage erodes. We are seeing rising off-label usage as physicians become more creative in improving outcomes. We are also seeing the importance of product compatibility in the world of M&A and multi-device procedures.
In this session, attendees will be introduced to how Product Procedure Analytics (PPA) provides visibility into these dynamics - bringing clarity to how devices are actually used in real-world settings.
Product Procedure Analytics (PPA) provides the Medtech Industry with an insider perspective on brand utilization, both against competitors and across all procedures. We can isolate brand usage on a case-by-case basis, sharing insights into top product combinations - i.e. what is the correlation of product pairing by brand and product attribute.
Crucially, PPA also enables the tracking of indication expansion and monitors how product penetration evolves over time - highlighting where usage is growing, diversifying, or shifting across procedures and specialties.
This mapping acts as a leading indicator of where the market is heading, and which product attributes are becoming favoured across physician specialties and procedure types.read more · Original Link ↗
InnoCare Urologics developed the Egress Safety Foley Catheter, designed to improve care, reduce risk, and avoid costs of traumatic Foley pullouts.
Company Sector: Urology
Program: Investor Forum · Original Link ↗
Presenting startups:
- Axoft - A neural interface ""as soft as the brain"" to diagnose disorders of consciousness and establish communication with patients.Presenting startups:
- Axoft - A neural interface ""as soft as the brain"" to diagnose disorders of consciousness and establish communication with patients.
- Magnetic Tides - Magnetic Tides is a clinical-stage, NIH-backed UC Berkeley spinout developing a non-invasive neuromodulation platform to help chronic stroke survivors recover motor function after plateauing, using a highly tolerable technology that directly targets the brain without the need for surgery.
- Panaxium Research Inc - Implanted neurostimulation therapy that adapts in real time to rewire the brain and restore function after stroke.
- Panda Surgical Limited - Handheld robotic platform offering enhanced dexterity, control and decision-support for safer and more effective neurosurgery.
Program: Investor Forumread more · Original Link ↗
Mirren MandaliaLivaNova (Moderator)
Oliver ArmitageAxoft
Manios DimitrakakisPanda Surgical Limited
Ludovica LabrunaMagnetic Tides
Brad SchmidtPanaxium
☆
Mon Oct 19 · 2:25 PM - 2:55 PM
Who's Running Your Workforce? The CEO's Dilemma in the Age of Agentic AI
Speed or safety? Automation or accountability? Efficiency or empathy? Agentic AI is compressing these tradeoffs into decisions MedTech CEOs can no longer defer.Speed or safety? Automation or accountability? Efficiency or empathy? Agentic AI is compressing these tradeoffs into decisions MedTech CEOs can no longer defer.
AI systems capable of reasoning, planning, and acting autonomously are moving from pilot to infrastructure faster than most organizations are prepared to govern them. Organizations taking a human-centric approach to AI are significantly more
likely to exceed their return on investment expectations - yet most MedTech companies are still designing for people and machines separately, leaving enormous value and patient risk on
the table.
This panel focus on what matters most: As a CEO, how do you maintain clinical accountability when autonomous systems make thousands of micro-decisions daily? How do you build a culture where people feel empowered by AI rather than displaced by it? And how do you govern all of this without sacrificing the speed that makes agentic AI valuable?
The leaders who will define the next decade are making bold, intentional choices now - before the relationship between human
judgment and machine autonomy defines itself.
Also tagged: Digital Health Technologiesread more · Original Link ↗
HeartPoint Global is a cardiovascular medical device company whose patented IntelliStent® is a minimally invasive, adjustable multi-lumen stent designed to precisely control blood flow and pressure in the pulmonary artery.HeartPoint Global is a cardiovascular medical device company whose patented IntelliStent® is a minimally invasive, adjustable multi-lumen stent designed to precisely control blood flow and pressure in the pulmonary artery. Initially focused on children with congenital heart disease, IntelliStent® has the potential to address many additional cardiac and non-cardiac indications.
Company Sector: Cardiology
Program: Investor Forumread more · Original Link ↗
Elena Amin MDHeartPoint Global Inc
☆
Mon Oct 19 · 2:25 PM - 2:40 PM
Solutions Showcase: Managing Commercial Complexity: Getting the Right Price to the Right Customer
Commercial complexity exists across buying centers, channels, contracts, GPOs, IDNs, tiers, and customer relationships.Commercial complexity exists across buying centers, channels, contracts, GPOs, IDNs, tiers, and customer relationships. Determining who is entitled to what price can quickly become a fragmented process, creating pricing errors, margin leakage, compliance risk, and friction across commercial and contracting teams.
This 15-minute session examines how MedTech companies can better manage pricing and entitlement complexity to improve pricing precision, compliance, and revenue control. We’ll explore how connecting customer, contract, membership, and pricing data can help teams validate eligibility earlier, apply the right price with greater confidence, and protect contract value as customer relationships and commercial structures change.read more · Original Link ↗
Kyle KinnellServiceNow
Laura SchliemServiceNow
Built for you by(617)-PATRICK, Champion AI speaker
Corporate Reverse Pitch Presentation: Olympus Corporation of the Americas
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Organos, Inc. is a biotechnology company advancing transformative cardiomyopathy therapies through an AI enabled, high throughput human cardiac muscle platform to rapidly identify and develop novel, clinically meaningful cardiac drug candidates.
Company Sector: Cardiology
Program: Investor Forum · Original Link ↗
Samuel WallOrganos, Inc.
☆
Mon Oct 19 · 2:35 PM - 2:50 PM
Patient Story: Edwards Lifesciences
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
How Innovation Leads to Longevity in Structural Heart Disease
Heart patient Denise shares her story of how innovation stopped the family cycle of heart disease leading to an early death.How Innovation Leads to Longevity in Structural Heart Disease
Heart patient Denise shares her story of how innovation stopped the family cycle of heart disease leading to an early death. Denise has undergone numerous cardiac procedures including open-heart surgery and received 2 aortic valve replacements. She will share how this journey has shaped her passion as a patient advocate for WomenHeart.read more · Original Link ↗
PolyVascular is developing minimally invasive, polymer-based transcatheter heart valves. Their core technology allows catheter-based replacement of degrading biological tissue valves with biocompatible, balloon-expandable polymer valves designed to accompany the growth of children born with congenital heart defects.PolyVascular is developing minimally invasive, polymer-based transcatheter heart valves. Their core technology allows catheter-based replacement of degrading biological tissue valves with biocompatible, balloon-expandable polymer valves designed to accompany the growth of children born with congenital heart defects.
Company Sector: Cardiology
Program: Investor Forumread more · Original Link ↗
Henri Justino MDPolyVascular
☆
Mon Oct 19 · 2:45 PM - 3:00 PM
Corporate Reverse Pitch Presentation: Terumo
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
John MadiganTerumo
☆
Mon Oct 19 · 2:45 PM - 3:00 PM
Solutions Showcase: From Point Solutions to Agentic Platform - How Medical Device Companies are Rethinking AI-Driven Document Authoring and Strategy
The first wave of AI in life sciences took a document-by-document approach - one solution for 510(k)s and regulatory submissions, another for the CSR, another for the IB.The first wave of AI in life sciences took a document-by-document approach - one solution for 510(k)s and regulatory submissions, another for the CSR, another for the IB. The result: fragmented tools, duplicated validation efforts, and AI that can't learn across your document ecosystem. There is a better architecture. A single AI platform that understands your internal data - clinical, quality, CMC, safety - and combines it with external regulatory intelligence to author any document type on demand. No bespoke point solutions or re-implementation for every new document class. This session draws on how top-20 medical device and pharma companies are deploying this platform approach today - compressing timelines that once took months, reducing the burden on already-stretched medical writing and regulatory affairs teams, and building institutional AI that compounds in value over time. Attendees will leave with a framework for evaluating their current AI document strategy, a clear-eyed view of where point solutions fall short at enterprise scale, and a model for what a mature, platform-native AI approach looks like in practice.read more · Original Link ↗
CytexOrtho is a clinical-stage medtech company focused on restoring joints rather than replacing them. Its first clinical asset, ReNew™ Hip, addresses a critical gap in hip preservation, one of the fastest-growing segments in orthopedic sports medicine.CytexOrtho is a clinical-stage medtech company focused on restoring joints rather than replacing them. Its first clinical asset, ReNew™ Hip, addresses a critical gap in hip preservation, one of the fastest-growing segments in orthopedic sports medicine. The population of young, active patients with hip joint damage is increasing approximately 7% annually, yet these patients have few durable treatment options. They are often caught in a “missing middle”: arthroscopic procedures may correct bone shape and soft-tissue pathology but cannot restore lost cartilage, while total hip replacement is often premature given their age and activity level. Building on ReNew Hip, CytexOrtho is expanding its technology across multiple joints to establish a new category of orthopedic care for patients in this missing middle.
Company Sector: Orthopaedic
Program: Investor Forumread more · Original Link ↗
Brad Estes Ph.D.CytexOrtho
☆
Mon Oct 19 · 2:55 PM - 3:25 PM
MedTech Innovator Showcase: Innovative Orthopedic Surgery & Sensing Tech
Presenting startups:
- ABANZA TECNOMED, S.L. - WasherCap technology secures soft tissue and suture/tape fixation, mitigates low bone density risks in sports medicine surgery, aiding vulnerable groups: women, children and elderly.Presenting startups:
- ABANZA TECNOMED, S.L. - WasherCap technology secures soft tissue and suture/tape fixation, mitigates low bone density risks in sports medicine surgery, aiding vulnerable groups: women, children and elderly.
- ForCast Orthopedics - Our targeted antibiotic therapy can dramatically improve outcomes and survival rates for PJI patients, an underserved market with a nearly $2B TAM.
- OrthoSens - Transforming implants into connected devices improving patient outcomes.
- PathKeeper Surgical - AI driven, optical navigation system for spine and orthopedics.
Program: Investor Forumread more · Original Link ↗
Tarun MahajanZimmer Biomet (Moderator)
Hugo DomínguezABANZA TECNOMED, S.L.
Gwenael HannemaOrthoSens
Ryan LeBlancPathKeeper Surgical
Peter NoymerForCast Orthopedics
Built for you by(617)-PATRICK, Champion AI speaker
Bank of America: The Resurgence of Private Equity: The Next Wave of MedTech Deals
● Business Strategies and Finance
Panel Session
📍 Exhibit Level, Room 050
Private equity is re-emerging as an important player in MedTech deal-making, expanding the buyer universe and creating opportunities for portfolio transformation.Private equity is re-emerging as an important player in MedTech deal-making, expanding the buyer universe and creating opportunities for portfolio transformation. This panel will explore how leading PE firms evaluate opportunities across the sector, including public-to-private transactions, corporate carve-outs, founder-owned companies, and scaled platforms. The discussion will examine what makes a MedTech business attractive to private equity, how PE underwrites growth and execution risk, and where private ownership can unlock value. Panelists will also discuss the role of operational improvement and add-on M&A, the role of AI to drive efficiencies, the evolving relationship between PE and strategic buyers, and where the next wave of private equity activity may emerge across MedTech.
#BankofAmerica
Program: Investor Forumread more · Original Link ↗
Milton HsuBank of America Securities (Moderator)
Chris GordonBain Capital
Ravi SachdevCD&R
Bobby SchmidtCarlyle
☆
Mon Oct 19 · 3:00 PM - 3:15 PM
Corporate Reverse Pitch Presentation: ZOLL
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Jennifer LandisZOLL Medical Corp., An Asahi Kasei Group Company
☆
Mon Oct 19 · 3:00 PM - 3:15 PM
Patient Story: Smith+Nephew
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
Life Unlimited: How Getting Back to Life Changed Everything Smith+Nephew CEO Deepak Nath sits down with Chris Fox, a healthcare marketing executive, husband, father of two young daughters, and avid outdoor enthusiast, to discuss his journey with knee pain and...Life Unlimited: How Getting Back to Life Changed Everything
Smith+Nephew CEO Deepak Nath sits down with Chris Fox, a healthcare marketing executive, husband, father of two young daughters, and avid outdoor enthusiast, to discuss his journey with knee pain and recovery following treatment with Cartiheal's Agili-C implant. Like many active adults, Chris spent years adapting his life around increasing pain before seeking treatment. He describes his outcome as ""game-changing,"" allowing him to move through daily life without thinking about his knee. In this conversation, Chris shares how chronic pain affected his mobility, family life, and overall wellbeing, what drove his treatment decision, and how restoring knee function has allowed him to focus on what matters most. Together, Deepak and Chris explore the importance of innovation that addresses unmet patient needs and the real-world impact these technologies have on people's lives.read more · Original Link ↗
Deepak NathSmith+Nephew (Moderator)
Chris Fox
☆
Mon Oct 19 · 3:05 PM - 3:35 PM
Redefining Women's Health: Opportunities for Investment and Innovation in Medtech
Women's health is gaining momentum as a targeted investment opportunity in medtech. Half of the world's patients are female, yet products, pipelines, and clinical strategies have not consistently reflected that reality.Women's health is gaining momentum as a targeted investment opportunity in medtech. Half of the world's patients are female, yet products, pipelines, and clinical strategies have not consistently reflected that reality. As innovation and capital begin to shift, the question is where and how medtech can create real, scalable value.
This CEO panel will focus on execution. Leaders from large strategics, scaled innovators, and private equity will share where they are placing bets across areas such as minimally invasive gynecologic procedures, breast and oncology diagnostics, pelvic health, and emerging segments like menopause and cardiovascular conditions in women. The discussion will explore how device innovation is evolving-from anatomy-specific design to AI-enabled diagnostics and at-home testing-and what it takes
to move beyond point solutions into platforms that drive adoption,
reimbursement, and sustained growth.
Attendees will gain insight into:
- Where medtech is creating value in women's health today and
where the opportunities are
- How leading companies are prioritizing women's health within
broader portfolio and R&D strategies
- The types of device and diagnostic innovations gaining traction
with providers, payers, and patients
- How private equity is shaping investment, M&A, and scale in the
category
Also tagged: Health Access
Program: Investor Forumread more · Original Link ↗
Active Life Scientific, Inc. (ALSI) is an FDA registered manufacturer device manufacturer. They produce the OsteoProbe® device, which is used to perform the BoneScore® procedure.Active Life Scientific, Inc. (ALSI) is an FDA registered manufacturer device manufacturer. They produce the OsteoProbe® device, which is used to perform the BoneScore® procedure. OsteoProbe® is FDA cleared device to measure bone material strength, which correlates with whole bone strength and fracture toughness.
NIH funded research (R44AG071034) found that OsteoProbe has a direct Whole-Bone Strength Correlation:
- - Phase II SBIR research demonstrated that BMSi measurements taken by the OsteoProbe exhibit strong statistical correlations with ex vivo whole-bone strength testing across critical fracture sites, including hip and spine models.
- - Fracture Toughness Validation: The studies proved that the device closely aligns with established physical metrics of bone durability, such as post-yield deformation and true fracture toughness (the bone’s intrinsic tissue ability to resist micro-cracking).
Synergy with DXA Scans: The research highlighted that while standard Dual-energy X-ray Absorptiometry (DXA) scans measure bone quantity (density), the OsteoProbe successfully measures bone quality (tissue strength), offering a powerful diagnostic adjunct for identifying weak bones in patients misclassified by density alone.
Since the most recent FDA clearance (K250216), reimbursement for the procedure (CPT III 0547T) is being paid by private insurance for high-need patients. ALSI is seeking growth capital to expand utilization and commercialize nationally.
Company Sector: Orthopaedic, Patient Monitoring, Surgical Device, Instruments and Accessories, Women's Health
Program: Investor Forumread more · Original Link ↗
Alexander ProctorActive Life Scientific, Inc.
☆
Mon Oct 19 · 3:05 PM - 3:20 PM
Solutions Showcase: Core vs Deploy: The case for strategic R&D partnerships in healthcare robotics innovation
This session introduces a new framework for building R&D teams: Core vs Deploy.This session introduces a new framework for building R&D teams: Core vs Deploy. Those device companies that clearly identify their true differentiators - and strategically deploy trusted external engineering partners for everything else - can move faster, stay focused, and build better products. It's not outsourcing. It's a smarter architecture for how great teams get built.read more · Original Link ↗
Corey SmigelskiCambridge Design Partnership
☆
Mon Oct 19 · 3:15 PM - 4:15 PM
Designing for Launch: Embedding Commercialization Early in MedTech Innovation
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 162AB
In today’s MedTech landscape, even the most intuitively designed products and strongest clinical trial results can struggle to gain traction if market realities aren’t addressed early.In today’s MedTech landscape, even the most intuitively designed products and strongest clinical trial results can struggle to gain traction if market realities aren’t addressed early. To maximize adoption and impact, leading organizations are rethinking when and how commercialization should shape their innovation journey. True market success depends on weaving commercial strategy, including demand planning, customer segmentation, and go-to-market modeling. into the very fabric of physical and digital product solution development from day one. Additionally, successfully navigating the development lifecycle requires managing the complex (and sometimes competing) influences of investors and strategic partners on early product design. This forward-thinking panel will explore why early integration of commercial perspectives is crucial for MedTech companies aiming to accelerate growth, differentiate offerings, and deliver meaningful value to patients, clinicians, and business stakeholders.
Learning objectives:
Industry experts will share real-world examples and actionable approaches for:
<ul
- Segmenting and understanding customer needs, including clinicians, patients, payers, and channel partners, well before launch.
- Building demand planning and forecasting capabilities into the R&D process to inform decisions on features, resource allocation, and scalability.
- Aligning product design, regulatory strategy, and commercial objectives for smoother, more rapid market entry and adoption.
- Balancing investor expectations and strategic partner influence throughout the development lifecycle to align early innovation with long-term commercial milestones.
Bridging traditional gaps between product, marketing, and sales teams through cross-functional collaboration and early stakeholder engagement.
Attendees will leave with practical frameworks to deploy a model where product-market fit, scalability, and commercial success are actively engineered, reducing time-to-market risks and fueling sustainable growth in MedTech.read more · Original Link ↗
Ksana Health is a behavioral health technology company that helps clinicians, health systems, and researchers improve mental health outcomes through AI-powered measurement and decision support.Ksana Health is a behavioral health technology company that helps clinicians, health systems, and researchers improve mental health outcomes through AI-powered measurement and decision support. Its flagship platform, Vira, combines patient-reported information, continuous behavioral data, and clinical workflows to provide more objective assessment, personalized care, and timely interventions. Founded on more than a decade of NIH-funded research, Ksana Health is working to transform behavioral health care through continuous measurement, evidence-based practice, and responsible AI.
Company Sector: Digital Health, Patient Monitoring
Program: Investor Forumread more · Original Link ↗
Nick Allen PhDKsana Health
☆
Mon Oct 19 · 3:15 PM - 3:30 PM
Corporate Reverse Pitch Presentation: Solventum
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Dennis CrowleySolventum
☆
Mon Oct 19 · 3:15 PM - 4:15 PM
Investor Working Session: Navigating the Early-Stage Medtech Financing Landscape
● Emerging Companies
Panel Session
📍 Meeting Level 1, Room 157AB
Early-stage medtech fundraising remains a competitive and challenging environment more than ever, with a surplus of companies raising and scarce pools of dedicated Medtech capital.Early-stage medtech fundraising remains a competitive and challenging environment more than ever, with a surplus of companies raising and scarce pools of dedicated Medtech capital. Investors who have stayed committed can afford to be highly selective, suggesting the companies that do get funded will be exceptionally high quality - yet second and third institutional rounds are no easier to secure, meaning financing risk and the strength and support of a company's initial syndicate matter significantly. This working session convenes early-stage venture investors for an interactive, peer-driven discussion of these shared challenges and creative solutions - from deal selectivity to syndicate-building and next-stage financing risk mitigation. Rather than a traditional panel, the format is designed to surface candid perspectives and practical takeaways that benefit both the investor community and the startups seeking their capital.
Program: Investor Forumread more · Original Link ↗
Jenny BarbaFeatures Capital (Moderator)
Maria BerkmanVensana Capital
Amy SalzhauerGood Growth Capital
Kwame UlmerWavemaker Three-Sixty Health
Darshana ZaveriCatalyst Health Ventures
☆
Mon Oct 19 · 3:15 PM - 4:15 PM
Catalyzing Rural Innovation: Increasing Access to Healthcare through the Rural Health Transformation Program
● Health Access
Panel Session
📍 Meeting Level 1, Room 159
The Rural Health Transformation Program is driving major investments to expand healthcare access in rural America through innovative technology and care models.The Rural Health Transformation Program is driving major investments to expand healthcare access in rural America through innovative technology and care models. This panel highlights how partnerships and funding are addressing critical gaps in rural health infrastructure and cancer care access.
#AdvaMedinAction
Also tagged: Market Access, Payment and Health Care Delivery
Program: AdvaMed in Actionread more · Original Link ↗
Bobby PatrickAdvaMed (Moderator)
Kate EllisonThe Guthrie Clinic
Zachary GaumerBipartisan Quality Center
Ali MurphySiemens Healthineers
☆
Mon Oct 19 · 3:15 PM - 4:15 PM
Decentralized Testing at the Point of Care: Regulatory Readiness, Reimbursement, and Real-World Clinical Impact
● In Vitro Diagnostic Tests and Technologies
Panel Session
📍 Meeting Level 1, Room 161
The rapid expansion of point-of-care testing - including molecular tests, immunoassays, rapid antigen tests, and emerging biosensor platforms - is reshaping how care is delivered in urgent care centers, retail clinics, pharmacies, and community health settings.The rapid expansion of point-of-care testing - including molecular tests, immunoassays, rapid antigen tests, and emerging biosensor platforms - is reshaping how care is delivered in urgent care centers, retail clinics, pharmacies, and community health settings. This session will examine the regulatory and reimbursement trends driving decentralized testing forward, including the evolving role of FDA oversight in ensuring analytical and clinical validity for CLIA-waived technologies. Panelists will also highlight the measurable "proof points" organizations are tracking to demonstrate value: turnaround time, diagnostic yield, antibiotic stewardship, patient outcomes, and accurate communication of results as testing programs scale.
Also tagged: Market Access, Payment and Health Care Delivery, Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Mike RyanMcDermott Will & Schulte (Moderator)
Shivang DoshiCepheid
Nicholas HalzackRoche Diagnostics Corporation
Marianela Perez-TorresU.S. Food and Drug Administration (FDA)
Hongwei ZhangAbbott
☆
Mon Oct 19 · 3:15 PM - 4:15 PM
Priorities and Updates from the Medical Device Single Audit Program (MDSAP) Regulatory Authority Council
● International
Panel Session
📍 Meeting Level 1, Room 160ABC
The 2026-2027 MDSAP Chair, CAPT Kimberly Lewandowski-Walker, of the U.S. Food and Drug Administration and other Regulatory Authority Council members will provide programmatic updates and priorities for the program.The 2026-2027 MDSAP Chair, CAPT Kimberly Lewandowski-Walker, of the U.S. Food and Drug Administration and other Regulatory Authority Council members will provide programmatic updates and priorities for the program. MedTech participants will hear first-hand from MDSAP leadership on recent developments, achievements and strategic priorities for the program.
This panel session will be moderated by AdvaMed, the inaugural chair of the MDSAP Industry Group. MDSAP Auditing Organizations will also participate in the panel session and will provide their perspective on conducting audits for MDSAP and other medical device regulatory frameworks.
#AdvaMedinAction
Also tagged: Regulatory, Quality and Good Manufacturing Practices
Program: AdvaMed in Actionread more · Original Link ↗
Carolyn HullAdvaMed (Moderator)
Thiago Rezende P. CunhaANVISA
Kenichi IshibashiPharmaceuticals and Medical Devices Agency (PMDA)
Kimberly Lewandowski-WalkerU.S. Food and Drug Administration
Sebastiano PaneTÜV Rheinland
Sally PrawdzikHealth Canada
☆
Mon Oct 19 · 3:15 PM - 4:15 PM
China Regulatory: Latest Updates and Hot Topics
● International
Panel Session
📍 Meeting Level 1, Room 157C
This session unpacks China's most consequential regulatory updates of 2026, spanning both pre-market and post-market requirements.This session unpacks China's most consequential regulatory updates of 2026, spanning both pre-market and post-market requirements. Panelists will share practical strategies for shortening time to market, including how to leverage real-world or other clinical evidence to replace in-China trials and fast-track approvals through "green-channel" pathways. The discussion will also spotlight alternative market entry routes through the Greater Bay Area, exploring how Hong Kong and Macau approvals can accelerate access. On the post-market side, the discussion will focus on how closely China's revised GMP aligns with ISO 13485 and increasing vigilance requirements, as the regulator accelerates its lifecycle scrutiny including overseas inspections.
Also tagged: Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Hamish KingCisema (Moderator)
Scott SardesonSt. Cloud State University - Twin Cities
Q-rounds is a digital rounding tool that answers the question, "When will the doctor be here?" by providing real-time updates to nurses, patients, and their families of when to expect the doctors for hospital rounds, and gives families who can't...Q-rounds is a digital rounding tool that answers the question, "When will the doctor be here?" by providing real-time updates to nurses, patients, and their families of when to expect the doctors for hospital rounds, and gives families who can't be there the opportunity to RSVP to join rounds remotely. Q-rounds orchestrates getting all the right people in the room, in person or virtually, for the most important discussion of the day.
Company Sector: Digital Health, General Hospital & Healthcare Supply
Program: Investor Forumread more · Original Link ↗
Mike Pitt MDQ-rounds
☆
Mon Oct 19 · 3:25 PM - 3:40 PM
Patient Story: Siemens Healthineers
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
From Innovation to Hope: Changing the Cancer Story for This Generation and the Next Yolanda (Yoli) Origel will share a deeply personal story spanning two generations of cancer care, from her mother's diagnosis in 1983 to her own diagnosis 18...From Innovation to Hope: Changing the Cancer Story for This Generation and the Next
Yolanda (Yoli) Origel will share a deeply personal story spanning two generations of cancer care, from her mother's diagnosis in 1983 to her own diagnosis 18 years ago. As Founder and CEO of Cancer Kinship, she will offer a unique perspective on how the patient experience has evolved and what patients and families need most today.
Stacy and Yoli will discuss the powerful combination of patients and Siemens Healthineers as partners in human-centered innovation from cancer screening to treatment to surveillance and how building trust and knowledge will fundamentally change the story and legacy for future generations.
The audience will walk away with a deeper understanding of the cancer community and a clear vision of cancer patients not just as recipients of innovation, but as partners in how it is understood, communicated, and delivered.read more · Original Link ↗
Stacy StordahlSiemens Healthineers (Moderator)
Yolanda Origel
☆
Mon Oct 19 · 3:25 PM - 3:40 PM
Solutions Showcase: AI Is Here. Is It Working for You? How to Evaluate AI Across the Medtech Product Lifecycle.
AI can now create drafts of your risk analysis, trace your requirements, and move your CAPA investigations forward.AI can now create drafts of your risk analysis, trace your requirements, and move your CAPA investigations forward. Getting AI to do that work reliably every day, on your real data, and in a way that holds up in an audit is much harder. That's why only one in ten medtech companies say generative AI has created real value in their organizations.
Harry Blumsack, Founder and CEO of Infera and former neurodiagnostics VP of Engineering, will break down how to separate AI hype from reality. You'll leave with a scorecard for evaluating any AI tool across five core dimensions, from accuracy to audit-readiness, so you can choose solutions that actually move the needle for your team.read more · Original Link ↗
Harry BlumsackInfera
Built for you by(617)-PATRICK, Champion AI speaker
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Presenting startups:
- HY2Care - A joint-mimicking hydrogel implant that is a natural scaffold for cartilage repair, enabling the body to heal itself. - Lenoss Medical, Inc.Presenting startups:
- HY2Care - A joint-mimicking hydrogel implant that is a natural scaffold for cartilage repair, enabling the body to heal itself.
- Lenoss Medical, Inc. - The first and only natural bone tissue solution to treat debilitating osteoporotic spinal fractures.
- OrthoPreserve, Inc. - OrthoPreserve is developing a synthetic meniscus replacement that restores knee cushioning and function for patients with meniscus damage, providing a minimally invasive, joint-preserving solution for those with persistent pain and limited treatment options.
- OsteoCure Therapeutics, Inc - OsteoCure is developing an injectable combination device that accelerates bone repair while simultaneously reducing pain and preventing infection.
Program: Investor Forumread more · Original Link ↗
iSono Health is a seed-stage, revenue-generating medical technology company applying robotics, 3D quantitative ultrasound, and AI to point-of-care breast imaging.iSono Health is a seed-stage, revenue-generating medical technology company applying robotics, 3D quantitative ultrasound, and AI to point-of-care breast imaging. Our FDA-cleared, body-worn ATUSA™ whole breast imaging system scans the whole breast in about two minutes, with no sonographer required, at a lower cost and smaller footprint than traditional imaging systems. We're commercial today across a $14.5B U.S. breast imaging market, addressing needs spanning breast implant surveillance (10M+ women), dense-breast imaging (39M women), and early cancer detection, serving the 84 million American women eligible for regular breast imaging. Our mission: make breast health monitoring as routine and accessible as a blood pressure check.
Company Sector: Diagnostic Imaging, Digital Health, Imaging, Patient Monitoring, Women's Health
Program: Investor Forumread more · Original Link ↗
Neda Razavi neda@isonohealth.comiSono Health
☆
Mon Oct 19 · 3:45 PM - 4:15 PM
Lessons from Building, Scaling and Exiting MedTech Companies
Building a MedTech company that reaches patients at scale demands a different high-stakes decision at nearly every stage - when to raise, when to expand globally, when to go public, and when to merge or sell.Building a MedTech company that reaches patients at scale demands a different high-stakes decision at nearly every stage - when to raise, when to expand globally, when to go public, and when to merge or sell. This panel brings together CEOs who have built transformative MedTech businesses, plus a banker who has managed the sector's transactions, IPOs and strategic financings. Moderated by a dealmaker behind many of healthcare's most notable deals over 30 years, the conversation examines how these leaders made their toughest calls - and what those decisions meant for growth, valuation and patient impact.read more · Original Link ↗
Keith PagnaniSullivan & Cromwell LLP (Moderator)
Ramin MousaviNovoMed PARTNERS
Yassaman SalasGoldman Sachs
Katie SzymanMasimo - Acquired by Danaher June 2026
Sonavex is a venture-backed medtech company spun out from Johns Hopkins with a portfolio of products to improve outcomes and costs for dialysis patients.Sonavex is a venture-backed medtech company spun out from Johns Hopkins with a portfolio of products to improve outcomes and costs for dialysis patients. EchoMap is an AI-enabled 3D ultrasound solution to improve needle cannulation in the dialysis clinic to reduce failed cannulations, infiltrations and missed treatments. These complications cost large dialysis organizations ~$350M/year or ~$125,000/clinic/year. Sonavex’s pipeline includes EchoMark (implantable bioresorbable fiducial marker) & EchoSure (automated AI-enabled 3D ultrasound), which allow dialysis technicians to assess AV fistula maturation in the clinic, which reduces dangerous and expensive catheter contact time.
Company Sector: Diagnostic Imaging, Dialysis, Imaging
Program: Investor Forumread more · Original Link ↗
David NarrowSonavex, Inc.
☆
Mon Oct 19 · 3:45 PM - 4:00 PM
Corporate Reverse Pitch Presentation: LivaNova
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Mirren MandaliaLivaNova
☆
Mon Oct 19 · 3:45 PM - 4:00 PM
Solutions Showcase: TCS Bidirectional Haptic Feedback System - Transforming Robotic Surgery with Real-Time Tactile Intelligence
For decades, robotic-assisted surgery has advanced visualization, precision, and control, enabling increasingly complex procedures with remarkable accuracy. Yet one critical element has remained largely absent: the sense of touch.For decades, robotic-assisted surgery has advanced visualization, precision, and control, enabling increasingly complex procedures with remarkable accuracy. Yet one critical element has remained largely absent: the sense of touch. This sensory feedback is essential for delicate tissue handling, force modulation, and minimizing unintended trauma.
The TCS Bidirectional Haptic Feedback System bridges this gap through advanced force sensing, real-time signal processing, and high-fidelity haptic rendering, creating a closed-loop connection between the surgeon and the operative field. As surgical robotics evolves toward greater autonomy and intelligence, restoring touch unites machine precision with human instinct to enable safer, smarter, and more effective patient care.read more · Original Link ↗
Pathik AguanTATA Consultancy Services
Pere VenturaTATA Consultancy Services
☆
Mon Oct 19 · 3:50 PM - 4:05 PM
Patient Story: Solventum
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
Finding renewed purpose through the power of healing
Behind every medical technology innovation is a patient story.Finding renewed purpose through the power of healing
Behind every medical technology innovation is a patient story. In this intimate conversation, Heather Knight, Chief Commercial Officer of Solventum, sits down with Solventum quality engineer Arend Schuurman to discuss his personal journey after being diagnosed with a rare genetic heart condition, how VAC Therapy helped support the healing of his wound after major surgery, and how this experience has transformed his perspective on healthcare innovation.
Together, they will explore the powerful connection between lived patient experience, medical technology innovation and quality assurance. The conversation will highlight how personal health challenges can inspire greater empathy, urgency, and commitment in the development of healthcare solutions. Attendees will gain insight into the human impact behind healthcare advances and hear a firsthand account of resilience, recovery, and renewed purpose.read more · Original Link ↗
Patients with hydrocephalus often face repeated emergency visits, imaging, and invasive procedures because clinicians lack a simple, reliable way to determine whether a shunt is functioning.Patients with hydrocephalus often face repeated emergency visits, imaging, and invasive procedures because clinicians lack a simple, reliable way to determine whether a shunt is functioning. Rhaeos is a venture-backed medical technology company developing noninvasive, wireless wearable sensors, led by FlowSense®, designed to rapidly assess cerebrospinal fluid flow through a shunt and provide actionable information at the point of care. With more than $25 million in financing and support to date, including significant funding from the NIH and NSF, Rhaeos is advancing FlowSense toward commercialization and preparing for a Series B financing in 2027 to support commercial launch and expansion of its wearable sensing platform.
Company Sector: Neurology
Program: Investor Forumread more · Original Link ↗
Anna Somera MS, MBA, MPHRhaeos, Inc
Built for you by(617)-PATRICK, Champion AI speaker
Bank of America: Investor Perspectives: Headwinds and Tailwinds…Where is the MedTech Sector Heading?
● Business Strategies and Finance
Panel Session
📍 Exhibit Level, Room 050
MedTech investors are navigating a shifting landscape shaped by changing growth expectations, valuation compression, and continued innovation across the sector.MedTech investors are navigating a shifting landscape shaped by changing growth expectations, valuation compression, and continued innovation across the sector. This panel will explore how leading public and crossover investors are weighing the headwinds and tailwinds impacting MedTech performance, including procedure trends, pricing and utilization, hospital capital spending, reimbursement, and the pace of new product launches. The discussion will examine what distinguishes the sector’s most compelling investment opportunities, how investors are assessing growth durability and execution risk, and whether current market is the new norm or a near term blip.
#BankofAmerica
Program: Investor Forumread more · Original Link ↗
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Founded in 2017, RestorEAR Devices is pioneering the use of mild therapeutic hypothermia ("cold therapy") for issues related to the ear and inner ear.Founded in 2017, RestorEAR Devices is pioneering the use of mild therapeutic hypothermia ("cold therapy") for issues related to the ear and inner ear. We focus specifically on hearing loss prevention, tinnitus, pain management, and improved outcomes in cochlear implant surgery. RestorEAR medical products are undergoing human clinical trials in the US and our consumer grade products are actively building market presence worldwide.
Company Sector: Ear, Nose & Throat (ENT), Neurology, Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Curtis KingRestorEAR Devices
☆
Mon Oct 19 · 4:05 PM - 4:35 PM
MedTech Innovator Showcase: Innovative Materials and Formulation Processing Tech
Presenting startups:
- GeniPhys - Proprietary restorative biopolymer platform that forms a tissue supporting collagen scaffold without an inflammatory response.Presenting startups:
- GeniPhys - Proprietary restorative biopolymer platform that forms a tissue supporting collagen scaffold without an inflammatory response.
- Portal Instruments - Portal Instruments is developing PRIME NEXUS, a reusable, computer-controlled auto-injector platform designed to deliver next-generation biologics that are too high-volume or viscous for conventional injection devices.
- TissueForm - Allovia is the first off-the-shelf, flowable human extracellular matrix (ECM) implant designed to provide immediate structural cartilage repair and support long-term joint regeneration in a single-stage procedure.
- Zonova - Zonova makes infection-resistant medical devices the new standard of care.
Program: Investor Forumread more · Original Link ↗
Eclipse Regenesis, Inc. is developing the first restorative therapy to address pediatric and adult Short Bowel Syndrome (SBS), a malabsorption disorder caused by a loss of functional small intestine.Eclipse Regenesis, Inc. is developing the first restorative therapy to address pediatric and adult Short Bowel Syndrome (SBS), a malabsorption disorder caused by a loss of functional small intestine. Current chronic therapies for SBS include parenteral nutrition, daily medications and intestinal surgery, which come at a staggering average 5-year cost of $1.6M per patient. Via distraction enterogenesis, the Eclipse XL1 System is able to harness the body’s own tissue regenerative capabilities to produce new, fully functional intestine in vivo. Together with the world’s leading clinical thought leaders in SBS, our team is passionate about pioneering our restorative therapy to a disease state that today has no cure.
Company Sector: Gastroenterology, Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Andre BessetteEclipse Regenesis Inc
☆
Mon Oct 19 · 4:15 PM - 4:30 PM
Patient Story: Medtronic
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
One Patient’s Journey from Surgery to Life in Motion
What does successful medical technology look like to a patient?One Patient’s Journey from Surgery to Life in Motion
What does successful medical technology look like to a patient? For Noah Brauner, it looks like playing ultimate frisbee, riding 100 miles on a bike and going through college without constantly thinking about his back. Medtronic Chairman and CEO Geoff Martha sits down with Noah to explore his scoliosis journey, recovery and what medtech innovation can make possible long after a patient leaves the operating room.read more · Original Link ↗
Geoff MarthaMedtronic (Moderator)
Noah Brauner
☆
Mon Oct 19 · 4:25 PM - 4:35 PM
Company Presentation: Syntr Health Technologies, Inc.
Syntr Health is a medical technology company commercializing an automated autologous tissue processing platform for chronic wound healing, breast reconstruction, and soft tissue restoration.Syntr Health is a medical technology company commercializing an automated autologous tissue processing platform for chronic wound healing, breast reconstruction, and soft tissue restoration. Backed by over $4 million in NIH funding and encouraging early clinical results, Syntr is executing a VA-first commercialization strategy to reduce amputations and healthcare costs for veterans with diabetic foot ulcers while expanding into breast reconstruction to address the growing needs of veterans affected by breast cancer, creating a scalable, high-margin platform with significant market potential.
Company Sector: Diabetic Care, General Hospital & Healthcare Supply, Surgical Device, Instruments and Accessories, Women's Health, Wound Management
Program: Investor Forumread more · Original Link ↗
Ahmed Zobi EMBASyntr Health Technologies, Inc.
Built for you by(617)-PATRICK, Champion AI speaker
Following the Leading Across Generations: Advancing Women, Strengthening MedTech session, join us for an informal networking meet-up designed to continue the dialogue beyond the stage.Following the Leading Across Generations: Advancing Women, Strengthening MedTech session, join us for an informal networking meet-up designed to continue the dialogue beyond the stage. Connect with professionals across generations and career levels, share perspectives, build new relationships, and discuss practical ways to strengthen leadership pipelines, foster collaboration, and create opportunities. Whether you attended the session or are simply interested in engaging with colleagues from different generations, this is an opportunity to exchange ideas, expand your network, and help shape a more connected and inclusive industry.
Sponsored by: AdvaMed Advance®, an industry-wide initiative dedicated to unlocking the potential of all talent and strengthening medtech through leading inclusion and belonging practices.read more · Original Link ↗
☆
Mon Oct 19 · 4:30 PM - 5:30 PM
SMTA Meet Up
● Networking
Networking
📍 Exhibit Level, Medtech Campus, AdvaMed HQ
Join us to meet, mingle, and connect with state and regional medtech communities from across the country. All are welcome. · Original Link ↗
Join this focused networking meet-up bringing together members of the Indian medtech delegation, including startups, innovators and leading manufacturers - with attendees looking to better understand the Indian market and build meaningful business connections in India.Join this focused networking meet-up bringing together members of the Indian medtech delegation, including startups, innovators and leading manufacturers - with attendees looking to better understand the Indian market and build meaningful business connections in India.
This intimate, small-group gathering is designed to spark conversation and create connections. Meet potential partners, exchange perspectives on the market, explore pathways for market entry and collaboration, and connect with a broader community of leaders actively engaged in India’s growing medtech ecosystem.read more · Original Link ↗
Connect with fellow AdvaMed Accel members and other small-company executives over breakfast and learn leadership skills and industry insights from a leading medtech CEO.Connect with fellow AdvaMed Accel members and other small-company executives over breakfast and learn leadership skills and industry insights from a leading medtech CEO. This year we are excited to welcome as our guest speaker Alan Lotvin, CEO of Sequel Medtech, who has 30+ years of healthcare experience from CVS Health® and Caremark®, and as a trained cardiologist.
Program: AdvaMed in Action, Investor Forumread more · Original Link ↗
JC ScottAdvaMed (Moderator)
Alan LotvinSequel Med Tech
Built for you by(617)-PATRICK, Champion AI speaker
A series of company presentations hosted by Bank of America. Agenda:
8:30 am - 9:00 am | SetPoint Medical
9:00 am - 9:30 am | Cleerly, Inc. 9:30 am - 10:00 am | Koya Medical, Inc.A series of company presentations hosted by Bank of America.
Agenda:
8:30 am - 9:00 am | SetPoint Medical
9:00 am - 9:30 am | Cleerly, Inc.
9:30 am - 10:00 am | Koya Medical, Inc.
10:00 am - 10:30 am | RapidAI
10:30 am - 11:00 am | Elucent
11:00 am - 11:30 am | Ventric Health
#BankofAmerica
Program: Investor Forumread more · Original Link ↗
The NextGen Innovation Challenge is a flagship, one-day engineering competition focused on personalized surgery.The NextGen Innovation Challenge is a flagship, one-day engineering competition focused on personalized surgery. Using a real hip femoroacetabular impingement (FAI) case, participants move from preoperative CT imaging and patient-specific planning to the design of AI-enabled technologies that improve intraoperative decision-making. The experience emphasizes precision medicine, computer vision, and clinical workflow rather than robotics alone. Aiming to answer the question, how might we better integrate patient-specific preoperative planning into intraoperative surgical decision-making for hip FAI?
9:00 - 9:15 AM | Check-in
9:15 AM | Clinical case
10:00 AM | Prototyping Begins
12:00 PM | Break for Lunch
12:45 PM | Mentoring
3:30 PM | Presentations & Judging
4:30 PM | Awardsread more · Original Link ↗
Presenting startups:
- Noah Labs - First voice-based algorithm that non-invasively detects heart failure decompensation up to 29 days before hospitalization.Presenting startups:
- Noah Labs - First voice-based algorithm that non-invasively detects heart failure decompensation up to 29 days before hospitalization.
- UltraSight - UltraSight is an AI-powered medical imaging company advancing access to high-quality cardiac ultrasound through the UltraSight Echosystem, a comprehensive platform that combines structured training, real-time AI guidance, and advanced analytics to enable any provider to safely and efficiently perform focused echocardiography (FoCUS) exams regardless of experience level.
- Vektor Medical - vMap is a non-invasive cardiac arrhythmia analysis technology, designed with AI, that rapidly identifies likely arrhythmia sources directly from a standard 12-lead ECG to support faster, safer, and more effective ablation strategies.
Program: Investor Forumread more · Original Link ↗
Butterfly Medical is a medical device company developing a novel, minimally invasive implant for the treatment of benign prostatic hyperplasia (BPH), designed to provide durable symptom relief while preserving prostate tissue and sexual function.Butterfly Medical is a medical device company developing a novel, minimally invasive implant for the treatment of benign prostatic hyperplasia (BPH), designed to provide durable symptom relief while preserving prostate tissue and sexual function. The Butterfly device is CE Marked under MDR and is investigational in the U.S.
Company Sector: Urology
Program: Investor Forumread more · Original Link ↗
Patrick MacCarthyButterfly Medical
☆
Tue Oct 20 · 9:25 AM - 9:35 AM
Company Presentation: BrilliantStrings Therapeutics
Tendon and ligament injuries represent one of the largest unmet needs in musculoskeletal medicine.Tendon and ligament injuries represent one of the largest unmet needs in musculoskeletal medicine. BrilliantStrings Therapeutics is commercializing a minimally-invasive, injectable, platform technology that restores functional collagen architecture to load-bearing soft tissue injuries - a class of wounds that has resisted regenerative medicine for decades due to the failure of existing biologics to recapitulate the structural properties of native tendon.
Company Sector: Orthopaedic
Program: Investor Forumread more · Original Link ↗
Jeffrey RubertiBrilliantStrings Therapeutics
Built for you by(617)-PATRICK, Champion AI speaker
How Family Offices Are Filling the MedTech Funding Gap
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 157C
The MedTech funding landscape is undergoing a structural reset. Traditional venture capital is increasingly concentrated in fewer, later-stage bets and shorter return horizons - leaving early-stage, capital-intensive, and clinically complex MedTech innovations struggling to secure funding.The MedTech funding landscape is undergoing a structural reset. Traditional venture capital is increasingly concentrated in fewer, later-stage bets and shorter return horizons - leaving early-stage, capital-intensive, and clinically complex MedTech innovations struggling to secure funding. In this environment, family offices are playing a growing role as a source of capital, though they often remain somewhat mysterious.
This panel will explore how family offices are filling the MedTech funding gap with patient, long-term capital and flexible investment structures. Panelists will explore both the similarities and the differences between family offices and institutional VCs in how they evaluate risk, time horizons, and founder partnerships - and why those differences matter for founders navigating today’s market.
The discussion will also demystify how family offices really operate: how they source deals, how they underwrite regulatory and clinical risk, how they make investment decisions, and why their investment styles can vary so widely. Importantly, the panel will address the most common misconceptions founders have about family offices - from speed and check size to governance and follow-on capital.
Designed for MedTech founders, operators, and investors, this session offers a practical look at an important source of capital in today’s market - and how to engage family offices as long-term partners in building successful MedTech companies.
Also tagged: Emerging Companies
Program: Investor Forumread more · Original Link ↗
Jing LinKOFA Healthcare (Moderator)
Jarret FassPierpoint Capital
Lakshana HuddarSparta Group LLC
Rhiya PauLaerdal Million Lives
☆
Tue Oct 20 · 9:30 AM - 9:45 AM
Remarks from Governor Tim Walz, State of Minnesota
Join Minnesota Governor Tim Walz on the CEOs Unplugged stage for special remarks at The MedTech Conference. A former teacher, National Guard veteran, and six-term U.S. congressman, Walz serves as Minnesota’s 41st governor.Join Minnesota Governor Tim Walz on the CEOs Unplugged stage for special remarks at The MedTech Conference. A former teacher, National Guard veteran, and six-term U.S. congressman, Walz serves as Minnesota’s 41st governor. Minnesota is a leading hub for medtech innovation, ranking second nationally in medical device manufacturing and first in pacemaker-related patents per capita.read more · Original Link ↗
☆
Tue Oct 20 · 9:30 AM - 10:30 AM
The Future of AI Regulation: Concepts and Frameworks to Support Innovation and Adoption
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 160ABC
As AI-enabled medical devices evolve from static algorithms to more sophisticated, adaptive systems, regulators worldwide are assessing ways to enable innovation and promote AI-adoption while ensuring safety and effectiveness.As AI-enabled medical devices evolve from static algorithms to more sophisticated, adaptive systems, regulators worldwide are assessing ways to enable innovation and promote AI-adoption while ensuring safety and effectiveness.
This panel brings together senior regulatory leaders from three of the world's most influential health authorities to discuss the future of AI regulation. Panelists will explore emerging approaches to regulatory agility, including regulatory sandboxes, Predetermined Change Control Plans (PCCPs), and the evolving balance between premarket review and lifecycle oversight.
The discussion will provide attendees with unique insights into how the FDA and MHRA are considering regulatory frameworks that support innovation while maintaining public trust. Participants will gain a deeper understanding of where global regulatory approaches are converging, where differences remain, and what these developments mean for medical device manufacturers developing next-generation AI technologies.
#AdvaMedinAction
Also tagged: Regulatory, Quality and Good Manufacturing Practices
Program: AdvaMed in Actionread more · Original Link ↗
Geeta PamidimukkalaAdvaMed (Moderator)
Rick AbramsonU.S. Food and Drug Administration (FDA)
Jessica PaulsenU.K. Medicines and Healthcare Products Regulatory Agency (MHRA)
☆
Tue Oct 20 · 9:30 AM - 10:30 AM
China from the General Manager Lens
● International
Panel Session
📍 Meeting Level 1, Room 159
This session brings together general managers from leading medtech companies for on-the-ground perspectives on what it takes to compete and win in China today.This session brings together general managers from leading medtech companies for on-the-ground perspectives on what it takes to compete and win in China today. Panelists will share how MNCs are adapting their strategies amid a rapidly evolving reimbursement and innovation landscape, and where the greatest opportunities for future growth lie.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Jonathan ZhuKorn Ferry (Moderator)
June ChangBoston Scientific Corporation
Alex GuMedtronic
Jason LiuIntuFosun
☆
Tue Oct 20 · 9:30 AM - 10:30 AM
Mass Tort Trends and Third-Party Litigation Financing: Emerging Risks for MedTech Companies
● Legal and Health Care Compliance Best Practices
Panel Session
📍 Meeting Level 1, Room 161
This panel will examine the evolving landscape of mass tort litigation and the growing influence of third-party litigation financing (TPLF) on claims involving medical technology companies.This panel will examine the evolving landscape of mass tort litigation and the growing influence of third-party litigation financing (TPLF) on claims involving medical technology companies. Panelists will discuss emerging mass tort trends, including the increasing scale and sophistication of coordinated plaintiff campaigns, the role of advertising and aggregation in driving claim volume, and the implications for product liability risk and reputational exposure. The session will also explore how TPLF is reshaping litigation dynamics by providing capital to plaintiffs and law firms, potentially prolonging cases, increasing settlement pressure, and raising concerns about transparency, control, and conflicts of interest. Attendees will gain practical insights into how these developments are affecting defense strategies, insurance markets, and corporate risk management, as well as the policy and legislative efforts underway to address the impact of TPLF and ensure fairness and balance in the civil justice system.read more · Original Link ↗
Phil GoldbergShook Hardy & Bacon L.L.P. (Moderator)
David CoonerBecton Dickinson (BD)
Christiana JacxsensB. Braun Medical Inc.
Jack KalavritinosJK Strategies
Nathan MorrisJohnson & Johnson
☆
Tue Oct 20 · 9:30 AM - 10:30 AM
From Fee-for-Service to Medicare Advantage: Scaling Contractor-Priced Codes After MAC Success
● Market Access, Payment and Health Care Delivery
Panel Session
📍 Meeting Level 1, Room 157AB
Securing Medicare Fee-for-Service (FFS) pricing through Medicare Administrative Contractors (MACs) is often a critical early milestone for innovative medical technologies - but it is no longer sufficient for scale.Securing Medicare Fee-for-Service (FFS) pricing through Medicare Administrative Contractors (MACs) is often a critical early milestone for innovative medical technologies - but it is no longer sufficient for scale. With Medicare Advantage (MA) enrollment now exceeding 50% of Medicare beneficiaries and plans exercising increasing autonomy over coverage, utilization management, and payment policy, medtech companies face a second - and often more complex - market access challenge: translating FFS success into sustainable Medicare Advantage adoption.
This session builds directly on the 2025 MedTech Conference discussion of engaging MACs for contractor-priced codes and examines what comes next. Panelists will explore how MA plans interpret FFS pricing signals, when FFS coverage does (and does not) influence MA decisions, and how value narratives must evolve from contractor pricing to plan-specific economics. The discussion will address plan variation, delegated risk models, supplemental benefits, utilization management tools, and emerging CMS policy signals shaping MA behavior under the new administration.
Drawing on real-world case studies, payer perspectives, and physician insights, this session will provide practical guidance on sequencing evidence, structuring MA engagement strategies, and avoiding common pitfalls that stall adoption after early FFS wins. Attendees will leave with a clear roadmap for bridging the gap between MAC-based reimbursement and scalable Medicare Advantage market access.read more · Original Link ↗
J.R. MurrayPan American Risk Management, LLC (Moderator)
Shana DurantAetna, a CVS Health Company
Bonnie HandkeCVRx, Inc.
☆
Tue Oct 20 · 9:30 AM - 10:10 AM
Advancing MedTech Patient Engagement: Real-World Wins and Strategies
● Patient Engagement
Panel Session
📍 Exhibit Level, Medtech Campus, Patient Pavilion
As patient-centric approaches become increasingly vital in healthcare innovation, understanding how to effectively partner with patients is a crucial capability.As patient-centric approaches become increasingly vital in healthcare innovation, understanding how to effectively partner with patients is a crucial capability. While other industries, such as Pharma, have been able to implement more structured patient-centric approaches, MedTech has been slower in clearly defining consistent strategies and demonstrating the value that they deliver.
In this panel discussion, MedTech experts in regulatory, marketing, and clinical fields will share actionable guidance and success stories demonstrating how patient insights have shaped decisions across the product life cycle. Panelists will also explore practical methods, highlight best practices, and discuss the impact of patient engagement on product development, clinical research and market adoption.
This timely conversation will uncover how cross-functional collaboration and direct partnership with patients leads to more meaningful patient experiences and business impact.
This session will provide valuable takeaways for MedTech professionals that seek to drive patient engagement forward - provided by experts in the field.read more · Original Link ↗
Cohesys developed BoneTape, a resorbable surgical fixation platform designed to replace rigid plates and screws with flexible implants that anchor directly to bone using ultrasound.Cohesys developed BoneTape, a resorbable surgical fixation platform designed to replace rigid plates and screws with flexible implants that anchor directly to bone using ultrasound. The platform is built to make fixation faster, less invasive, and more versatile, while opening the door to capabilities traditional hardware cannot offer, including localized drug delivery. Cohesys is entering the market through craniomaxillofacial surgery, with a broader platform opportunity spanning orthopedic trauma, extremities, reconstructive surgery, bone graft fixation, and drug-eluting implants.
Company Sector: Orthopedics, Surgical Devices, Drug Delivery
Program: Investor Forumread more · Original Link ↗
Founded in Richmond, Virginia, Liquet Medical is developing breakthrough medical technology to improve the treatment of pulmonary embolism, one of the leading causes of cardiovascular death.Founded in Richmond, Virginia, Liquet Medical is developing breakthrough medical technology to improve the treatment of pulmonary embolism, one of the leading causes of cardiovascular death. Its FDA-cleared Versus™ Catheter introduces real-time physiologic feedback into treatment, enabling a more personalized approach to patient care while simplifying procedures for physicians.
Company Sector: Cardiology
Program: Investor Forumread more · Original Link ↗
John SchindlerLiquet Medical Inc
☆
Tue Oct 20 · 9:45 AM - 10:00 AM
Corporate Reverse Pitch Presentation: Dexcom
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Presenting startups:
- Approxima - Percutaneous right ventricular reshaping system to treat patients with tricuspid valve regurgitation. - Tau Medical - Transcatheter Tricuspid Repair Spacer: A minimally invasive, flow-guided system to treat tricuspid regurgitation while preserving the heart's native anatomy.Presenting startups:
- Approxima - Percutaneous right ventricular reshaping system to treat patients with tricuspid valve regurgitation.
- Tau Medical - Transcatheter Tricuspid Repair Spacer: A minimally invasive, flow-guided system to treat tricuspid regurgitation while preserving the heart's native anatomy.
- Spheric Bio - Personalized AFib stroke prevention via soft, custom implants formed directly inside the heart.
- Symphera GMBH - Automated in-body instrument switching that keeps surgeries flowing smoothly and removes workflow friction in MIS.
Program: Investor Forumread more · Original Link ↗
Sonal PatelJohnson & Johnson (Moderator)
Tyson JangTau Medical
Michal JaworekApproxima
Connor VerheyenSpheric Bio
Nico WeigandSymphera GMBH
☆
Tue Oct 20 · 9:50 AM - 10:05 AM
Solutions Showcase: Regulatory: The Hidden Growth Lever
Your commercial team has growth targets to hit. Your regulatory team knows what it will take to get products into new markets. How often are they building the plan together?Your commercial team has growth targets to hit. Your regulatory team knows what it will take to get products into new markets. How often are they building the plan together? Across MedTech portfolios, getting to market weeks earlier can mean millions in revenue coming in sooner. Yet companies still fund regulatory like a back-office function. Join Jay Patel and Bruce McKean of Rimsys for a practical look at growth planning. They’ll share how a global top 10 manufacturer is delivering growth with Rimsys, what other companies can learn from its approach, and three steps you can take next quarter.read more · Original Link ↗
Every year, 3 million implants fail in the human body - slowing healing, causing pain and infection, and forcing a cascade of corrective surgeries and reoperations.Every year, 3 million implants fail in the human body - slowing healing, causing pain and infection, and forcing a cascade of corrective surgeries and reoperations. Nowhere is this failure more acute than in combat trauma: open fractures and blast injuries carry contamination burdens far exceeding civilian norms, and implant-associated infection remains a leading cause of reoperation, prolonged disability, and limb loss in deployed and post-deployment care - inside forward surgical systems with little tolerance for repeat procedures.
BioMetal Health delivers a patented bioresorbable metal platform: metal engineered to heal as it dissolves in the body, naturally becoming YOU. Applied as a coating on today's implant hardware or realized as the entire structural implant as the technology matures, the BioMetal alloy makes bone regeneration, anti-inflammatory action, and antimicrobial protection INHERENT properties of the metal itself - releasing ions as it resorbs over 6 to 18 months, matching biology's own healing timeline.
From civilian orthopedic and cardiovascular procedures to the operating conditions of forward military medicine, BioMetal is built to end the cascade - reducing reoperations now, and eliminating hardware-removal procedures altogether as the platform matures. With a signed LOI and advanced regulatory, operational, and client traction, BioMetal Health targets commercial revenue in 1H 2027.
Company Sector: Cardiology, Orthopaedic, Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Jerry YenBioMetal Health
Built for you by(617)-PATRICK, Champion AI speaker
Corporate Reverse Pitch Presentation: B. Braun Medical
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Megi Health is an AI-native cardiovascular platform - a Software as a Medical Device - built specifically for women, starting with hypertension in pregnancy, the leading cause of maternal mortality and a strong predictor of lifelong cardiovascular disease.Megi Health is an AI-native cardiovascular platform - a Software as a Medical Device - built specifically for women, starting with hypertension in pregnancy, the leading cause of maternal mortality and a strong predictor of lifelong cardiovascular disease. Most complications develop in the gaps between clinical visits, and a third of US counties are now maternity care deserts.
Megi combines an AI companion that works in a woman's own language, smartphone-camera, wearables and blood pressure capture, and continuous risk scoring that alerts her clinician before a crisis. To reach underserved populations, Megi deploys through a certified community-doula workforce. Its predictive models are trained on 2M+ clinician-annotated data points across 20,000+ patients - a proprietary dataset validated with King's College London and published in JMIR.
Megi is CE-marked in Europe (MDR Class I) and operates in the US as clinical decision support, with an FDA pathway in progress. The payer-funded model is already reimbursable under existing CPT codes (99453, 99454, 99457, 99458) and delivers ~3× payer ROI at the population level. Megi has 1,000+ certified doulas across 40 states, a Blue Cross Blue Shield Texas payer pilot, and partnerships with the March of Dimes and the American Heart Association.
Company Sector: Cardiology, Digital Health, Women's Health
Program: Investor Forumread more · Original Link ↗
Nina SestoMegi Health
☆
Tue Oct 20 · 10:10 AM - 10:25 AM
Solutions Showcase: From Multiphysics Modeling to Digital Twins, Now Assisted by AI: Accelerating Medical Device Innovation with COMSOL Multiphysics®
Developing modern medical technology demands design solutions that accurately predict real-world behavior and enable rapid iteration and collaboration across multidisciplinary teams.Developing modern medical technology demands design solutions that accurately predict real-world behavior and enable rapid iteration and collaboration across multidisciplinary teams. The COMSOL Multiphysics® software provides a unified modeling environment that enables engineers and scientists to simulate complex interactions involving multiple physics phenomena.
This presentation will highlight the COMSOL® software's capabilities for simulating implantable devices, drug delivery, diagnostic instruments, and many more medical technologies. Through use cases, attendees will see how multiphysics simulation helps reduce prototyping costs, improve device performance, and accelerate regulatory-ready design decisions.
The session will also explore how GPU-enabled computing and AI-assisted workflows are helping engineers solve increasingly sophisticated models more efficiently. Finally, we will demonstrate how models can be transformed into apps and digital twins, enabling simulation-driven decision-making across teams - even for users without simulation expertise.read more · Original Link ↗
AQUAPASS is a highly effective non-invasive therapy for fluid overload creating the new standard of care in the multi-billion dollar market of Heart Failure and Kidney disease.
Company Sector: Cardiology, Dialysis
Program: Investor Forum · Original Link ↗
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Presenting startups:
- HICKY - Leadless phrenic nerve stimulator to treat central sleep apnea in heart failure patients.Presenting startups:
- HICKY - Leadless phrenic nerve stimulator to treat central sleep apnea in heart failure patients.
- NEVENT - The airbag of vascular catheter placement; a patented device that prevents the patient harm and healthcare system costs of retained guidewires.
- Medyria AG - PyCath is based on a unique blood flow velocity sensor, enabling the precise diagnosis of angina pectoris.
Program: Investor Forumread more · Original Link ↗
Kilele’s wearable biosensor platform enables precision medicine by bringing real-time molecular insights into everyday care. Applications include chronic disease management, therapeutic drug monitoring, and continuous hormone monitoring.Kilele’s wearable biosensor platform enables precision medicine by bringing real-time molecular insights into everyday care. Applications include chronic disease management, therapeutic drug monitoring, and continuous hormone monitoring. Our focus is chronic cardiometabolic disease beginning with a phenylalanine sensor for phenylketonuria (PKU) and GLP-1 associated sarcopenia management, to be followed by heart failure, diabetes, chronic kidney disease, and functional medicine. We begin human testing in PKU 2Q26. Sensor form factor and UI/UX mimic proven continuous glucose monitoring devices. We’ve raised $3.9M in non-dilutive to achieve first-in-world 10 days’ aptamer sensor life in an animal, and we have locked down the aptamer biosensing field with a bevy of first-to-file patents. Kilele wrapped up a $2M preferred equity Seed I 4Q25 to fund an initial human pilot study. Our preferred equity Seed II will open later in 2026 based on the human data generated in our upcoming pilot.
Company Sector: Cardiology, Diabetic Care, Digital Health, Patient Monitoring, Women’s Health
Program: Investor Forumread more · Original Link ↗
Andrew Cothrel MSKilele Health Inc.
Built for you by(617)-PATRICK, Champion AI speaker
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Alex SauterStryker
☆
Tue Oct 20 · 10:30 AM - 10:45 AM
Solutions Showcase: Why Medical Manufacturers are Switching to Vision Inspection
As medical device manufacturers face increasing demands for quality, efficiency, and regulatory compliance, many are transitioning from traditional manual inspection methods to machine vision technologies.As medical device manufacturers face increasing demands for quality, efficiency, and regulatory compliance, many are transitioning from traditional manual inspection methods to machine vision technologies. This shift is helping organizations improve product quality, reduce inspection variability, accelerate production, and streamline compliance with industry standards and regulations. We will highlight why machine vision is becoming an essential component of modern medical device production and help you to understand how fully and semi-automated systems are enabling manufacturers to enhance quality control, and increase throughput. Discover practical considerations for transitioning from manual to automated inspection processes, and learn how automated inspection systems improve quality, efficiency, and compliance.read more · Original Link ↗
Reveal Life Science is a Canadian clinical-stage MedTech company developing AI-enabled Raman spectroscopy platforms for real-time cancer detection across surgical and diagnostic workflows.Reveal Life Science is a Canadian clinical-stage MedTech company developing AI-enabled Raman spectroscopy platforms for real-time cancer detection across surgical and diagnostic workflows. The company’s lead platform, Sentry™, is designed to support intraoperative tumor tissue detection in neurosurgery, with expansion potential across other surgical oncology indications.
Reveal is also developing Clarion™ for biopsy adequacy and tissue triage, Sage™ for biofluid-based diagnostics, and Atlas™ as the AI/data infrastructure supporting molecular intelligence across applications. The platform has been clinically validated across 700+ patients and is transitioning from clinical validation to regulatory execution and commercialization readiness.
Company Sector: Diagnostic Imaging, Digital Health, Endoscopy, Imaging, In Vitro Diagnostics, Neurology, Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Christian SauvageauREVEAL SURGICAL INC / EXCLARO INC
☆
Tue Oct 20 · 10:45 AM - 11:45 AM
Working with Academia and Health Systems: A Playbook for Strategics and Startups
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 157C
Academic institutions and health systems are critical engines of medical innovation, generating clinical insight, early-stage technologies, and translational research.Academic institutions and health systems are critical engines of medical innovation, generating clinical insight, early-stage technologies, and translational research. Yet for both startups and established medtech companies, engaging with these institutions effectively can feel opaque and misaligned with industry timelines and incentives.
In today’s evolving federal funding and policy landscape, industry leaders are reassessing how to diversify innovation pipelines and strengthen partnerships beyond reliance on government-supported research pathways. Strategic engagement with academic institutions and health systems can provide earlier access to clinical insight, translational infrastructure, and high-impact technologies in ways that are both resilient and scalable.
Drawing on real-world experience from J&J MedTech, Mayo Clinic, and other ecosystem leaders, this session provides a practical playbook for how industry and startups can work with academic institutions and health systems across the innovation lifecycle. Panelists will compare traditional engagement models such as licensing, sponsored research, joint ventures, co-development, and clinical trials; and discuss when these approaches work best, where they break down, and common pitfalls that delay progress.
Beyond traditional structures, the session will also highlight emerging and innovative engagement models that are gaining traction across the medtech ecosystem. These include access to clinical data, structured clinical observation programs, clinician-led unmet-need discovery and validation, partnerships with accelerators and translational programs, and relationship-based approaches that build trust and visibility earlier in the development process.
Attendees will leave with actionable frameworks, informed by industry execution, to determine how, when, and why to engage academia as a strategic growth partner in today’s global medtech landscape.
Also tagged: Emerging Companiesread more · Original Link ↗
Katie Reuther PhD, MBAUniversity of Pennsylvania (Moderator)
Lisa CarmelMayo Clinic
Chris CoburnMass General Hospital
Roger KittermanMass General Brigham Ventures
JaBaris Swain MD MPH MBAJohnson & Johnson MedTech
☆
Tue Oct 20 · 10:45 AM - 10:55 AM
Company Presentation: Advanced Tomography Systems, Inc.
Advanced Tomography Systems is dedicated to developing and commercializing innovative imaging solutions that redefine diagnostic capabilities, elevate patient care, and streamline healthcare processes. The company specializes in cutting-edge ultra-fast computed tomography, advanced AI-driven imaging technologies, and optimized workflow solutions.Advanced Tomography Systems is dedicated to developing and commercializing innovative imaging solutions that redefine diagnostic capabilities, elevate patient care, and streamline healthcare processes. The company specializes in cutting-edge ultra-fast computed tomography, advanced AI-driven imaging technologies, and optimized workflow solutions.
We are developing the world's first truly portable, ultra-fast, and static computed tomography (CT) scanner (Static CT). By eliminating the traditional rotating gantry and replacing it with a 360-degree array of electronically controlled X-ray sources, ATS has developed a disruptive imaging platform that is less than 20% the size and weight of conventional CT scanners. Weighing under 1,000 pounds, the system captures 60 to 80 tomographic images per second, up to 20 times faster than traditional systems. This ultrafast imaging capability enables visualization of true anatomical motion, including the beating heart, rather than relying solely on gated or reconstructed snapshots. Its compact footprint and minimal requirements for additional cooling, plumbing, or electrical infrastructure can lower deployment costs, simplify installation, and expand access to advanced imaging in sites unable to accommodate conventional CT systems.
Company Sector: Diagnostic Imaging, Imaging
Program: Investor Forumread more · Original Link ↗
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
David DeMartinoZimmer Biomet
Tarun MahajanZimmer Biomet
☆
Tue Oct 20 · 10:45 AM - 11:45 AM
Promise and Perils of AI for Older Adults
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 159
By 2050, Americans ages 65 and older will be the nation’s largest demographic group. They will experience longer lifespans, rising chronic disease burdens, fragmented support networks, and escalating medical costs.By 2050, Americans ages 65 and older will be the nation’s largest demographic group. They will experience longer lifespans, rising chronic disease burdens, fragmented support networks, and escalating medical costs. The key question is not whether AI should be adopted to address these concerns, but how to protect the public interest while ensuring the responsible and fair implementation of AI.
Policy frameworks that connect AI’s potential in early detection, remote monitoring, and decision support with sustainable, person-centered care for older adults throughout aging are urgently needed. However, as the use of AI-based technologies grows in patient care, older adults consistently prioritize face-to-face clinical encounters over technical novelty and many lack access to and understanding of how to use technology. Creating clear regulatory frameworks at the FDA and coverage and reimbursement standards at CMS that recognize older patient preferences can help ensure the responsible and effective integration of AI to improve their health.
Beyond making health care more effective and efficient, there is promise in AI-based technologies to provide additional benefits: reducing caregiver workload to enable high-quality care, equipping primary care physicians with critical information for timely treatment, increasing health literacy, and helping patients age with dignity and respect at home. Achieving these goals, however, depends on building strong public trust in technology and a clear understanding of its benefits and risks.
Speakers will review regulatory, coverage, and reimbursement policy gaps and opportunities to support the successful use of AI technologies for older adults.
Also tagged: Patient Engagementread more · Original Link ↗
Sue Peschin MHSAlliance for Aging Research (Moderator)
Jennifer GoldsackAmerican Medical Association (AMA)
Nathan Brown JDAkin Gump Strauss Hauer & Feld LLP
Carla Cartwright JDJohnson & Johnson
☆
Tue Oct 20 · 10:45 AM - 11:45 AM
Regulator Perspectives: Advancing Global Harmonization to Accelerate Access to Medtech
● International
Panel Session
📍 Meeting Level 1, Room 157AB
Global harmonization of regulatory requirements is essential to ensure patients around the world have access to safe, high-quality therapies in an efficient and timely manner.Global harmonization of regulatory requirements is essential to ensure patients around the world have access to safe, high-quality therapies in an efficient and timely manner. Globally convergent regulation brings us closer to one transparent, predictable, and trusted standard, no matter the jurisdiction - thereby expediting patient access to safe and effective medical technologies.
In this session, regulators will provide updates on how each jurisdiction is working toward global harmonization, how they are partnering with other regulators in furtherance of these goals, and updates from the International Medical Device Regulators Forum meeting and other efforts working towards global convergence.
#AdvaMedinAction
Also tagged: Regulatory, Quality and Good Manufacturing Practices
Program: LatAmread more · Original Link ↗
Melissa TorresAdvaMed (Moderator)
Raymond ChuaHealth Sciences Authority
Kenichi IshibashiPharmaceuticals and Medical Devices Agency (PMDA)
Kenneth Cavanaugh PhD Jr.U.S. Food and Drug Administration
Vivian Cardoso Morais de OliveiraANVISA - Brazilian Health Regulatory Agency
Sally PrawdzikHealth Canada
Freya RowlandU.K. Medicines and Healthcare Products Regulatory Agency (MHRA)
☆
Tue Oct 20 · 10:45 AM - 11:45 AM
CMS Town Hall
● Market Access, Payment and Health Care Delivery
Panel Session
📍 Meeting Level 1, Room 160ABC
Join CMS leaders for a dynamic conversation on the coverage, reimbursement, and payment policy issues shaping the future of the medtech industry.Join CMS leaders for a dynamic conversation on the coverage, reimbursement, and payment policy issues shaping the future of the medtech industry. Gain insights into key developments and emerging priorities, hear directly from key voices, and discover what these changes could mean for medtech companies.
Program: AdvaMed in Actionread more · Original Link ↗
Kirsten Tullia JD, MPHAdvaMed (Moderator)
Jeneen IwugoCenters for Medicare & Medicaid Services (CMS)
Dora Hughes MD, MPHCenters for Medicare & Medicaid Services (CMS)
Ryan Howe PhDCenters for Medicare & Medicaid Services (CMS)
☆
Tue Oct 20 · 10:45 AM - 11:45 AM
The Ghost in the Machine - Exploring the Business Impact and Strategic Approaches Addressing Cybersecurity and Technology Risks in MedTech
● Regulatory, Quality and Good Manufacturing Practices
Panel Session
📍 Meeting Level 1, Room 162AB
Esteemed panelists from industry, regulators and academia with decades of experience wrestling some of the most difficult technology risks in MedTech will share meaningful insights that can shape your product portfolio strategies and turn technology risk into advantage. · Original Link ↗
Chris Reed MA,CISSP,HCISPP,GCIAMedtronic (Moderator)
Scott ColburnU.S. Food and Drug Administration (FDA)
Kevin FuNortheastern University / Archimedes Center for Healthcare and Medical Device Cybersecurity
As healthcare systems increasingly prioritize outcomes over volume, medtech and diagnostics companies must adapt to a rapidly evolving reimbursement and market access landscape.As healthcare systems increasingly prioritize outcomes over volume, medtech and diagnostics companies must adapt to a rapidly evolving reimbursement and market access landscape. This panel will explore the shift from traditional fee-for-service models toward value-based pricing and examine the implications for manufacturers seeking to demonstrate clinical, economic, and patient-centered value.
The discussion will also examine the growing role of in vitro diagnostics (IVDs) as data partners within the healthcare ecosystem, particularly in collaboration with pharmaceutical companies to enable personalized care and evidence-based decision-making. Panelists will further explore the rise of artificial intelligence as a diagnostic partner, discussing how more than 1,000 AI-enabled medical devices have already entered the market and what the next wave of innovation may mean for providers, patients, regulators, and payers. Attendees will gain insights into the opportunities and challenges shaping the future of reimbursement, market access, and data-driven healthcare.read more · Original Link ↗
Seth Goldenberg PhDVeeva MedTech (Moderator)
Sharon BrackenSiemens Healthineers
Sandy OttensmannIllumina
Carla Goulart PeronPhilips
☆
Tue Oct 20 · 10:50 AM - 11:05 AM
Patient Story: Philips
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
Closer to Care: Through a Child’s Eyes
When seven-year-old Mason needed an MRI, his family needed more than advanced technology. They needed answers, reassurance and access to the right care, close to home.Closer to Care: Through a Child’s Eyes
When seven-year-old Mason needed an MRI, his family needed more than advanced technology. They needed answers, reassurance and access to the right care, close to home. Mason and his family join us to share their experience at Nicklaus Children’s Health System and how compassionate care, thoughtful innovation and strong partnerships came together to turn an uncertain moment into one of comfort and confidence. Their story is a powerful reminder that healthcare innovation matters most when it makes a meaningful difference in the lives of patients and their families.read more · Original Link ↗
Kristine MullenPhilips (Moderator)
Tom Faller
☆
Tue Oct 20 · 10:50 AM - 11:05 AM
Solutions Showcase: HCLTech AI Force.MedTech - AI Native Intelligence Platform for Regulated Product Lifecycles
MedTech companies spend nearly 6 - 8% of revenue on R&D and Quality Assurance and Regulatory Affairs (QARA) and yet face high costs of quality and compliance persistently with no margin for error given the direct impact on patient outcomes.MedTech companies spend nearly 6 - 8% of revenue on R&D and Quality Assurance and Regulatory Affairs (QARA) and yet face high costs of quality and compliance persistently with no margin for error given the direct impact on patient outcomes.
Regulatory and quality activities often take as much or even more, effort than the engineering work itself. In sustenance projects, compliance costs can far exceed the cost of the actual fix, leading to longer product lifecycles and slower innovation.
HCLTech has been a trusted partner to MedTech organizations, supporting R&D and QARA with deep industry expertise. Today, as clients seek AI-powered delivery models, the highly regulated nature of MedTech demands solutions designed specifically for the industry, not generic AI or IT tools.
In this session, Partha Marella , EVP and Head of Lifesciences will talk about HCLTech AI Force.MedTech - AI native intelligence platform for regulated product lifecycles and how the solution addresses the following challenges:
- Eliminate incremental quality costs by blending human and artificial intelligence
- Enable hyper-collaboration through self-healing, agent-driven feedback loops
- Automate regulatory documentation (including DHF management) via domain-rich knowledge bases and small language models
- Capture and activate knowledge across documents and systems using trace graphs
- Ensure repeatability and reproducibility of all artifacts
- Embed applicable regulatory and quality standards nativelyread more · Original Link ↗
PexyEazy® is a minimally invasive device for treating hemorrhoids, one of the world's most common conditions. The procedure takes less than 15 minutes under light sedation, reducing costs while increasing clinic efficiency.PexyEazy® is a minimally invasive device for treating hemorrhoids, one of the world's most common conditions. The procedure takes less than 15 minutes under light sedation, reducing costs while increasing clinic efficiency. Clinical studies show outcomes comparable to the gold standard but with just one day of sick leave instead of 3 - 4 weeks. Its intuitive mechanical design requires no special equipment or electricity, enabling global scalability. With a hemorrhoid treatment market projected to exceed $1.3 billion by 2030, we are raising $2 million in Q3 - Q4 2026 to support US and EU market launch in 2027.
Company Sector: Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Johan UngerstedtDeveloperation AB
☆
Tue Oct 20 · 10:55 AM - 11:35 AM
MedTech Innovator Showcase: ASPS Track - Plastic Surgery Tech
Presenting startups:
- GenAssist Inc. - A muscle-regenerating implantable biomaterial. - GenesisTissue - Regenerative Breast Tissue (RBT) is a personalized 3D bioprinted scaffold for adipose tissue regeneration.Presenting startups:
- GenAssist Inc. - A muscle-regenerating implantable biomaterial.
- GenesisTissue - Regenerative Breast Tissue (RBT) is a personalized 3D bioprinted scaffold for adipose tissue regeneration. It provides shape and structure for fat grafting and is designed to fully degrade leaving the patient with a naturally reconstructed breast.
- ImageAssist - ImageAssist is a ground-breaking AI driven clinical photography platform that helps providers capture, manage, and use medical photos.
- Tissuelock - TissueTape is an internal tissue plane sealant designed for any head-to-toe surgery to bring together tissue planes and minimize tissue "dead space" and associated complications. Our technology replaces progressive tension sutures and eliminates painful drains.
- Feminai - Feminai enables breast cancer screening from home, by providing an early detection tool for the most common cancer in women.
Program: Investor Forumread more · Original Link ↗
Bill PerryAmerican Society of Plastic Surgeons (Moderator)
Joe BeggsGenAssist, Inc.
Michael GolinkoImageAssist
Karny IlanFeminai
Katherine WeimerGenesisTissue
Matt WoodTissuelock
Built for you by(617)-PATRICK, Champion AI speaker
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Nanotherm Therapeutics is developing the next generation of precision cancer ablation with its proprietary Nanotherm Therapy System (NTTS).Nanotherm Therapeutics is developing the next generation of precision cancer ablation with its proprietary Nanotherm Therapy System (NTTS). Unlike conventional ablation technologies, NTTS uses a unique two-step approach: magnetic nanoparticles are first delivered into the tumor and then activated non-invasively by an external magnetic field, enabling predictable, millimeter-precise tumor destruction while minimizing damage to surrounding healthy tissue. Headquartered in Wilmington, Delaware we produce all components in the U.S. and at another facility in Berlin, Germany.
The company’s current focus is early-stage lung cancer, where NTTS addresses one of the greatest challenges in current ablation - respiratory motion - without requiring complex real-time tumor tracking. The platform has demonstrated compelling preclinical results and builds on a clinically validated technology with more than 200 patient treatments across previous cancer indications. Global lung cancer development is led by renowned interventional pulmonologist Dr. Erik Folch, with multinational clinical studies now underway.
Nanotherm Therapeutics is redefining tumor ablation by delivering precision where conventional technologies reach their limits.
Company Sector: Surgical Device, Instruments and Accessories
Program: Investor Forumread more · Original Link ↗
Georg Jordan PhDNanotherm Therapeutics Inc
☆
Tue Oct 20 · 11:10 AM - 11:25 AM
Solutions Showcase: The Battery Nobody Knows About: Engineering Power That Meets Medtech's Next Decade
Connected medical devices are getting smaller, smarter and more numerous, and the load on every cell is rising with them: more sensing, more on-device intelligence, higher and longer peak currents, longer expected wear.Connected medical devices are getting smaller, smarter and more numerous, and the load on every cell is rising with them: more sensing, more on-device intelligence, higher and longer peak currents, longer expected wear. The component least designed for that future is usually the one chosen last and cheapest, the battery. This session traces how Duracell engineered its way past that ceiling: a chemistry breakthrough, Power Boost, that took over a decade and more than 160,000 screened compounds to prove out, now built into medical-grade cells with the discharge stability, pulse power and shelf-life connected devices will need at population scale. It closes with what stands behind the cell: dedicated medical-device manufacturing, rigorous device-tuned validation, and the geographic supply resilience of a global manufacturer. Built for OEM engineering, quality and supply chain leaders planning their next decade of devices, not just their next design cycle.read more · Original Link ↗
BLASTID™ is a Boston-based diagnostics company developing a faster way to diagnose bloodstream infections and provide actionable information to support earlier treatment decisions.BLASTID™ is a Boston-based diagnostics company developing a faster way to diagnose bloodstream infections and provide actionable information to support earlier treatment decisions. Today, bloodstream infection diagnosis typically depends on blood culture, which can take days to provide pathogen identification and antimicrobial susceptibility results.
BLASTID’s SPLENDID™ platform is designed to bypass this culture bottleneck by isolating viable pathogens directly from whole blood. From a single blood draw, SPLENDID enables rapid rare cell and pathogen detection, species-level identification in under one hour, and phenotypic antimicrobial susceptibility testing (AST) within 1-3 hours, providing clinicians with critical diagnostic information during the early treatment window.
The platform combines proprietary microfluidics, advanced optical imaging, and AI/ML-based analysis to detect and characterize rare cells directly from blood. BLASTID is supported by the ARPA-H DARTS program in collaboration with Harvard Medical School.
Blood, Imaging, In Vitro Diagnostics, Infectious Disease
Program: Investor Forumread more · Original Link ↗
Paulo Garcia PhDBLASTID
☆
Tue Oct 20 · 11:15 AM - 11:30 AM
Corporate Reverse Pitch Presentation: Resmed
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Grant OlsenResmed
☆
Tue Oct 20 · 11:15 AM - 11:30 AM
Patient Story: BD
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
From Patient Experience to Practical Solutions: Building Tools That Expand Access to MedTech
Access to needed medical technologies does not end with innovation.From Patient Experience to Practical Solutions: Building Tools That Expand Access to MedTech
Access to needed medical technologies does not end with innovation. For many patients and caregivers, it also requires navigating insurance requirements, documentation, denials, appeals, and follow-up - often without a clear roadmap.
In this fireside conversation, Peter Menziuso, EVP & President, BD Interventional, will interview patient advocate Ali Ingersoll about how lived experience can help identify access barriers and shape practical, product-neutral resources for patients and caregivers. The discussion will highlight the CareKey™ Patient Advocacy Toolkit, developed with input from patient advocates, healthcare professionals, and patient advocacy organizations to support health insurance navigation and self-advocacy.
Attendees will hear a real-world example of how MedTech companies, patient advocates, clinicians, and advocacy organizations can work together to move from patient stories to actionable tools, helping bridge the gap between innovation and access, and advancing more patient-centered care beyond traditional boundaries.read more · Original Link ↗
Biometrica is a remote patient monitoring (RPM) platform that transforms fragmented, episodic healthcare into continuous, data-driven care.Biometrica is a remote patient monitoring (RPM) platform that transforms fragmented, episodic healthcare into continuous, data-driven care. We bridge the 99% of patient life that happens outside the clinic by collecting real-time health data, interpreting it instantly, and delivering actionable clinical insights directly into providers' workflows.
Company Sector: Digital Health, Patient Monitoring
Program: Investor Forumread more · Original Link ↗
Anthony DannBiometrica Health
Built for you by(617)-PATRICK, Champion AI speaker
MedTech is entering a new era of portfolio transformation, with companies using M&A, divestitures, spin-offs, and strategic investments to sharpen focus, accelerate growth, and create shareholder value.MedTech is entering a new era of portfolio transformation, with companies using M&A, divestitures, spin-offs, and strategic investments to sharpen focus, accelerate growth, and create shareholder value. This panel will explore how leaders make critical portfolio decisions, including where to invest, what to divest, and when transformative actions can unlock value. The discussion will examine the realities of executing major change, from separation and integration challenges to talent retention and building successful independent organizations. Panelists will also discuss how M&A priorities evolve through periods of transformation, the role of portfolio optimization in creating more focused businesses, and where the next wave of consolidation and growth opportunities may emerge across MedTech.
Program: Investor Forumread more · Original Link ↗
Pete CataldoTruist (Moderator)
Peter ArduiniGE HealthCare
Rachel EllingsonSolventum
Ivan TornosZimmer Biomet
☆
Tue Oct 20 · 11:30 AM - 11:45 AM
Corporate Reverse Pitch Presentation: Haemonetics
● Corporate Reverse Pitch
Corporate Reverse Pitch
📍 Meeting Level 2, Room 260
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Rajeev VarmaHaemonetics
☆
Tue Oct 20 · 11:30 AM - 11:45 AM
Solutions Showcase: MedTech Is Scaling Fast. Is Your Operating Model Keeping Up?
This session will share how a large MedTech company tackled the challenge of asset visibility at scale, implementing a Clinical Device Management (CDM) solution to modernize tracking, servicing, and governance of clinical and non-clinical assets across thousands of US locations.This session will share how a large MedTech company tackled the challenge of asset visibility at scale, implementing a Clinical Device Management (CDM) solution to modernize tracking, servicing, and governance of clinical and non-clinical assets across thousands of US locations.
Key Takeaways:
- Implementation approach: A practical, phased rollout from foundational data through asset workflows and mobile execution
- Data insights: How a single CDM platform consolidated asset data, improved location visibility, and accelerated adoption through targeted notifications and escalation workflows
- Outcomes: Smarter capital allocation and improved asset planning in support of patient careread more · Original Link ↗
1.1M Americans suffer from Parkinson’s Disease (PD), a debilitating neurodegenerative disease that presents a host of motor symptoms impacting balance, gait, movement, posture, and stability.1.1M Americans suffer from Parkinson’s Disease (PD), a debilitating neurodegenerative disease that presents a host of motor symptoms impacting balance, gait, movement, posture, and stability. PD patients typically begin treatment with medications, which can wane in effectiveness over time and can have intense side effects such as dyskinesia (writhing movements). Surgical interventions, such as Deep Brain Stimulation (DBS) can be effective, and are often reserved for severe PD due to the surgery’s invasiveness and risk.
500,000 Americans with moderate PD fall into a treatment gap - medications lose efficacy and can cause side effects, while DBS is invasive and typically reserved for advanced disease.
The Solution
Highland has innovated ESStim™, a novel noninvasive brain stimulation platform to help patients address PD. ESStim™ combines independently controlled transcranial ultrasound and electrical stimulation. This combination has a synergistic effect, resulting in enhanced neuromodulation. ESStim™ has been evaluated in 4 randomized, double-blind, sham-controlled trials of 130 total PD patients. ESStim™ patients have demonstrated 20-35% improvement in PD symptoms when compared to baseline according to Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III), with particular improvements in balance, gait, posture, and speed of movement. ESStim™ treatment consists of 20-minute daily sessions for 10 days over two weeks in clinic, with no need for imaging, targeting, or sedation.
Company Sector: Neurology
Program: Investor Forumread more · Original Link ↗
Alex HerzlingerHighland Instruments
☆
Tue Oct 20 · 11:40 AM - 12:00 PM
Funding the Frontline of Diagnostics and Devices: Meet the MTI Vantage Hub in Partnership with BARDA
Join Paul Grand of MedTech Innovator (MTI) and Manbir Singh of the Biomedical Advanced Research and Development Authority (BARDA) for a fireside chat exploring the new MTI Vantage Hub as part of the BARDA Accelerator Network and its role in...Join Paul Grand of MedTech Innovator (MTI) and Manbir Singh of the Biomedical Advanced Research and Development Authority (BARDA) for a fireside chat exploring the new MTI Vantage Hub as part of the BARDA Accelerator Network and its role in advancing and funding the next generation of diagnostics and medical devices. They’ll discuss how Vantage combines non-dilutive funding, accelerator support, and technical and commercialization expertise to help innovators develop, evaluate, validate, and bring forward technologies that strengthen U.S. health security. Hear what BARDA is looking for, how companies and industry stakeholders can engage with the ecosystem, and where the biggest opportunities lie for innovators building the next generation of diagnostic and medical device technologies.
Program: Investor Forumread more · Original Link ↗
Paul GrandMedTech Innovator (Moderator)
Manbir SinghBARDA (Moderator)
☆
Tue Oct 20 · 11:40 AM - 11:55 AM
Patient Story: Abbott
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
Advancing Cancer Screening: When Early Detection Becomes Personal
Allison Barry, director of portfolio communications within Abbott’s cancer diagnostics business, helped bring the Cancerguard® multi-cancer early detection test to life.Advancing Cancer Screening: When Early Detection Becomes Personal
Allison Barry, director of portfolio communications within Abbott’s cancer diagnostics business, helped bring the Cancerguard® multi-cancer early detection test to life. But when she decided to take the test herself, she never expected the results would change her own future. Despite feeling generally well, Allison received a positive result that ultimately led to the diagnosis of stage 1 ovarian cancer.
This panel will explore how Allison’s experience underscores the potential impact of early cancer detection, particularly for cancers that often go unnoticed until later stages. Panelists will discuss the promise of multi-cancer early detection technologies, the importance of identifying cancer before symptoms appear and how advances in testing may help provide new opportunities for earlier diagnosis and intervention.read more · Original Link ↗
Sana Health is a commercial-stage medical device company. Our device is the world's first FDA-cleared audiovisual neuromodulation (AVN) therapy for chronic neuropathic pain (De Novo clearance, January 2026, first in class).Sana Health is a commercial-stage medical device company. Our device is the world's first FDA-cleared audiovisual neuromodulation (AVN) therapy for chronic neuropathic pain (De Novo clearance, January 2026, first in class). It delivers 16-minute self-administered sessions of rhythmic light and sound. In the pivotal RCT (published BMC Neurology, March 2026): NNT 2.89, 67% responder rate, 78% reduction in gabapentinoid use vs 8% on sham, with the active arm reducing opioid use while the sham arm increased it, and zero related serious adverse events. Backed by 14 issued US patents (71 granted worldwide) and $5M+ in DoD/NIH non-dilutive funding.
Company Sector: Digital Health, Neurology, Patient Monitoring, Women's Health
Program: Investor Forumread more · Original Link ↗
These 15-minute presentations feature global business and corporate development execs presenting their companies’ strategic priorities.
Program: Investor Forum · Original Link ↗
Komeil NasrollahiSiemens Healthineers
Built for you by(617)-PATRICK, Champion AI speaker
Open to All-Access passholders only
Tuesday’s featured keynote session will bring together leaders for a fireside chat on the economic landscape and the opportunities ahead for investment, growth, and innovation in medtech.Open to All-Access passholders only
Tuesday’s featured keynote session will bring together leaders for a fireside chat on the economic landscape and the opportunities ahead for investment, growth, and innovation in medtech. The conversation will explore global business trends, capital markets, and the forces shaping the future of the medtech industry and health care.read more · Original Link ↗
MedTech leaders are being asked to create growth in an environment where the traditional value-creation playbook is evolving.MedTech leaders are being asked to create growth in an environment where the traditional value-creation playbook is evolving. Companies are making sharper choices about where to focus, how to balance organic and inorganic growth, and how to fund the next wave of innovation. At the same time, they are rethinking how the organization itself needs to evolve, including how to structure businesses, where to build shared capabilities, how to operate across geographies, and how to redesign operating models.
This discussion will bring together both leading CEOs and healthcare investors to examine current white spaces, how to unlock and fund new sources of value, and how different innovation paradigms will shape the next phase of MedTech growth.
Program: Investor Forumread more · Original Link ↗
Vikram AggarwalBoston Consulting Group (BCG) (Moderator)
Presenting startups:
- Eupnoos - Eupnoos detects early cardio-pulmonary changes of heart failure and drug induced lung injury at home using non-invasive acoustic breath biomarkers.Presenting startups:
- Eupnoos - Eupnoos detects early cardio-pulmonary changes of heart failure and drug induced lung injury at home using non-invasive acoustic breath biomarkers.
- Lucentia - Software that turns routine non-contrast CT scans into virtual CCTA, enabling early and accessible heart disease detection.
- OMINI - Fingerprick multiplex blood test for heart failure measuring 4 biomarkers to guide treatment in community and homecare.
- Prima Medical, Inc - A real-time, closed loop ablation guidance platform to improve efficiency and procedure outcomes in the PFA era.
Program: Investor Forumread more · Original Link ↗
Anne CoxAmerican Heart Association Ventures (Moderator)
Ryan BokanPrima Medical, Inc
Sahar JalalLucentia
Joanne KanaanOMINI
Deepak KotakEupnoos
☆
Tue Oct 20 · 1:45 PM - 4:30 PM
Presenting Companies
● Presenting Companies
Presenting Companies
Room not listed on conference website
CEOs Unplugged, Patient Stories, Reverse Pitches, Company Presentations, Solutions Showcase, MedTech Innovator Showcase · Original Link ↗
☆
Tue Oct 20 · 1:45 PM - 2:00 PM
Solutions Showcase: From Factory to Field: Powering MedTech Execution with Process Intelligence
Discover how Process Intelligence helps manufacturing, supply chain, commercial operations, field service, and revenue teams eliminate execution constraints, improve operational performance, and enable Enterprise AI with the execution context needed to deliver measurable business outcomes. · Original Link ↗
Shaurya AggarwalCELONIS
Built for you by(617)-PATRICK, Champion AI speaker
A Conversation with MedTechVets: Bridging Military Service to Patient Care with Purpose
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 160ABC
Veterans bring proven leadership, adaptability, and a mission-driven mindset that make them valuable contributors across the MedTech industry.Veterans bring proven leadership, adaptability, and a mission-driven mindset that make them valuable contributors across the MedTech industry. This session will explore how MedTechVets connects military talent with MedTech organizations through education, mentorship, networking, and strategic hiring partnerships, helping veterans continue serving through careers that improve patient care.
Attendees may learn about the MedTechVets mission, hear success stories from veteran leaders, and discover practical ways to engage through recruitment efforts, employee resource groups, and community partnerships. Join the conversation to learn how your organization can help build a stronger MedTech workforce by creating meaningful opportunities for veteran talent.
Also tagged: Patient Engagementread more · Original Link ↗
Thomas CherryCook Medical, Inc.
Derek HerreraMedTechVets, Bright Uro
Mike PanosInsulet
☆
Tue Oct 20 · 2:00 PM - 3:00 PM
Where Investment Dollars are Moving in MedTech (And Why)
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 162AB
After several years of capital tightening and valuation resets, MedTech investment has become more selective, disciplined, and thesis-driven. Capital is still flowing - but with sharper scrutiny around regulatory risk, clinical validation, capital efficiency, and global scalability.After several years of capital tightening and valuation resets, MedTech investment has become more selective, disciplined, and thesis-driven. Capital is still flowing - but with sharper scrutiny around regulatory risk, clinical validation, capital efficiency, and global scalability.
This executive-level panel brings together venture investors, corporate venture leaders, private equity partners, and strategic acquirers to examine where sophisticated capital is deploying in 2026 - and why. Are investors favoring AI-enabled diagnostics, robotics, connected care, and data-driven platforms? Which segments are being overlooked despite strong fundamentals? How are evolving regulatory expectations and longer commercialization timelines shaping deal structures and valuations?
Panelists will discuss how they underwrite risk, what milestones truly “de-risk” a company, and how exit expectations have shifted in a slower IPO environment. The session will also explore how corporate strategics are approaching minority investments, partnerships, and platform acquisitions in a changing market.
Rather than predicting the next hype cycle, this discussion will focus on durable investment theses and the signals experienced investors are watching to identify long-term value in MedTech.
Program: Investor Forumread more · Original Link ↗
Roberta DressenMedical Alley Association (Moderator)
Charlie AttlanBoston Scientific Corporation
Mike BlueHistosonics
J.P. PeltierPiper Sandler & Co.
☆
Tue Oct 20 · 2:00 PM - 3:00 PM
Next-Generation Diagnostics: Tapping into the Global Need for Diagnostics for an Aging Population
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 159
As global populations age, healthcare systems are under increasing pressure to diagnose chronic and neurodegenerative diseases earlier, more accurately, and at scale.As global populations age, healthcare systems are under increasing pressure to diagnose chronic and neurodegenerative diseases earlier, more accurately, and at scale. Next-generation diagnostics - including blood-based biomarkers, advanced imaging alternatives, and AI-enabled assays - are reshaping how diseases are detected, staged, and monitored across care settings.
Using blood-based Alzheimer’s disease diagnostics as a real-world case study, this session explores how next-generation diagnostics move beyond discovery science into routine clinical practice. Panelists will discuss how emerging assays are being integrated alongside, and in some cases replacing, PET imaging and CSF testing; how clinical utility is being defined; and how regulatory pathways, clinical guidelines, and reimbursement frameworks are evolving to support adoption.
Attendees will gain a forward-looking view of how next-generation diagnostics can enable earlier intervention, better patient stratification, and more efficient care delivery - and what it takes to translate innovation into sustainable, real-world impact.
Also tagged: In Vitro Diagnostic Tests and Technologiesread more · Original Link ↗
David KowalskiIQVIA MedTech (Moderator)
Alireza AtriBanner Health
Jeremiah HinsonDanaher Diagnostics
Ian KremerLEAD Coalition
☆
Tue Oct 20 · 2:00 PM - 3:00 PM
DHT Signal: An AdvaMed Digital Health Tech Town Hall
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 157AB
Join board members from AdvaMed’s Digital Health Tech board for an interactive townhall discussion on the most pressing policy and advocacy issues shaping the future of digital health and AI.Join board members from AdvaMed’s Digital Health Tech board for an interactive townhall discussion on the most pressing policy and advocacy issues shaping the future of digital health and AI. This session will offer a look at our strategic priorities and ongoing efforts to champion the value of digital and AI solutions in Washington, D.C. and beyond, including key legislative and regulatory challenges and opportunities facing our members. We invite you to engage directly with the board members, ask your most pressing questions, and discover how your involvement can amplify our collective voice and drive meaningful progress for the entire digital health ecosystem.
Program: AdvaMed in Actionread more · Original Link ↗
Kirsten Tullia JD, MPHAdvaMed (Moderator)
Robert CohenStryker Corporation
Julia StrandbergPhilips
☆
Tue Oct 20 · 2:00 PM - 3:00 PM
Unlocking LATAM Innovation: Reliance Pathways for Faster, Predictable MedTech Access
● International
Panel Session
📍 Meeting Level 1, Room 161
Latin America is rapidly advancing medical device regulatory convergence, drawing on IMDRF workstreams and reliance based pathways to reduce duplication, strengthen post market oversight, and accelerate responsible access.Latin America is rapidly advancing medical device regulatory convergence, drawing on IMDRF workstreams and reliance based pathways to reduce duplication, strengthen post market oversight, and accelerate responsible access. This executive level panel will translate policy momentum into practical execution for global MedTech leaders. Senior regulators and industry policy experts will map where convergence is materializing - reliance mechanisms, e labeling, SaMD, UDI, and post market surveillance - and what remains to be solved to ensure predictable, scalable approvals across major LATAM markets.
Attendees will learn how IMDRF guidance is being referenced or adapted, what documentation and quality evidence consistently travel across borders, and how to structure dossiers and GMP strategies to benefit from reliance. Through concrete case examples, panelists will show how firms have shortened time to market while maintaining safety and effectiveness, and how authorities are coordinating regionally to build capacity.
Participants will leave with a concise, country by country mini roadmap covering: priority IMDRF workstreams to monitor, practical reliance tactics (including sequencing and risk classification nuances), and common pitfalls that derail convergence benefits. A one page checklist and resource links will be provided to help translate insights into submission planning, regulatory operations, and leadership decision making in 2026.
Also tagged: Regulatory, Quality and Good Manufacturing Practices
Program: LatAmread more · Original Link ↗
Sandra Ligia GonzálezIACRC - Inter‑American Coalition for Regulatory Convergence - Medical Technology Sector (Moderator)
Marcos BalaguerGeneral Directorate of Medicines, Food, and Health Products (DIGEMAPS)
Roberto Orbe ColónMexican Secretariat of Economy
Bruno Bezerra Director - Brazilian Innovative Health Industry Alliance / Chair - AdvaMed Brazil Working Group, J&J MedTech Brasil
Carola MedinaMinistry of Foreign Trade - Costa Rica (COMEX)
Vivian Cardoso Morais de OliveiraANVISA - Brazilian Health Regulatory Agency
☆
Tue Oct 20 · 2:00 PM - 3:00 PM
FDA’s De Novo Program: Exploring Opportunities for Increased Engagement
● Regulatory, Quality and Good Manufacturing Practices
Panel Session
📍 Meeting Level 1, Room 157C
The De Novo Program is the U.S. regulatory pathway for innovative medical technologies that present low to moderate risk to patients.The De Novo Program is the U.S. regulatory pathway for innovative medical technologies that present low to moderate risk to patients. Established in 1997, the Program has evolved considerably in recent years, with increasing manufacturer use to bring novel devices to market and continued FDA authorization of novel products. Because the innovative nature of products eligible for De Novo do not have an established regulatory precedent, effective engagement with the FDA and a sound regulatory strategy play an important role in supporting reviews and successful marketing authorization.
This panel will explore challenges and best practices for De Novo submissions under the current MDUFA V framework. Panelists will also discuss opportunities under consideration for the next user fee cycle (MDUFA VI), including potential improvements to the De Novo Program. This session will help attendees anticipate potential future changes, including a discussion on proposed process improvements to engagement with the FDA before and during the Agency’s review of a De Novo request. The panel will culminate in an interactive question-and-answer session, allowing participants to engage directly with the panelists.
#AdvaMedinAction
Program: AdvaMed in Actionread more · Original Link ↗
Joshua SilversteinStryker (Moderator)
Joshua Nipper MEU.S. Food and Drug Administration (FDA)
Geeta PamidimukkalaAdvaMed
☆
Tue Oct 20 · 2:05 PM - 2:20 PM
Solutions Showcase: From Data to Decisions: AI-Powered Intelligence Across the MedTech Lifecycle
MedTech organizations are generating more product, quality, and service data than ever, but much of it remains fragmented across systems, teams, and lifecycle stages.MedTech organizations are generating more product, quality, and service data than ever, but much of it remains fragmented across systems, teams, and lifecycle stages. As regulatory pressure increases and innovation cycles accelerate, leaders are seeking ways to turn this data into actionable intelligence.
This session explores how AI can be applied across engineering, manufacturing, quality, and service processes through a unified, intelligent product lifecycle. Rather than treating AI as a standalone capability, we will demonstrate how it enhances decision-making by surfacing insights in context across design, validation, regulatory submission, and post-market service.
Attendees will see how contextual, narrative-driven intelligence helps teams understand not only what is happening across the lifecycle, but why it matters. This enables faster, more confident decisions while improving compliance, traceability, operational efficiency, and decision velocity.read more · Original Link ↗
Presenting startups:
- Chambertech - A one-step hybrid ablation platform for persistent AF that treats both the inside and outside of the heart in a single minimally invasive procedure.Presenting startups:
- Chambertech - A one-step hybrid ablation platform for persistent AF that treats both the inside and outside of the heart in a single minimally invasive procedure.
- Cerevia Neurosciences Inc - Cerevia Neurosciences is developing the Ladybug Sanctuary, a non-invasive, fMRI-guided closed-loop neuromodulation platform designed to deliver AI-enabled personalized therapy to restore cognitive function in dementia patients.
- Envera Medical - A neuro balloon catheter that improves ease-of-use and procedural safety during neurovascular embolization procedures.
- Flux Robotics - Flux uses magnets and robotics to make guidewire navigation predictable, cutting preclinical crossing failure from 25% to under 5% in a market linked to 1M amputations and $8B in US costs each year.
Program: Investor Forumread more · Original Link ↗
Anne CoxAmerican Heart Association Ventures (Moderator)
Richard ChambersChambertech
Ida GoodCerevia Neurosciences Inc
Christoff HeunisFlux Robotics
Eric MintzEnvera Medical
☆
Tue Oct 20 · 2:25 PM - 2:40 PM
Patient Story: Dexcom
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
You Can't Treat What You Can't See: The power of glucose insights and why access is so important
René Syler, former CBS News anchor, author, and founder of The Sweet Reversal, understands firsthand how powerful glucose insights can be.You Can't Treat What You Can't See: The power of glucose insights and why access is so important
René Syler, former CBS News anchor, author, and founder of The Sweet Reversal, understands firsthand how powerful glucose insights can be. Through glucose biosensing technology, she has learned how the choices she makes every day, from what she eats to how she exercises and manages stress, can influence her health. Equipped with new insights, René lowered her A1C from 12.8 at diagnosis to 5.4 without medication, transforming her personal success into a larger mission to help others navigate prediabetes, Type 2 diabetes, and insulin resistance.
Join René and Dexcom SVP of Regulatory & Government Affairs Neeta Sharma for a conversation about her journey and the role biosensing technology can play in helping more people better understand their health, particularly the 115 million Americans living with prediabetes and the 25 million Americans living with Type 2 diabetes.read more · Original Link ↗
Neeta SharmaDexcom (Moderator)
René Syler
☆
Tue Oct 20 · 2:25 PM - 2:40 PM
Solutions Showcase: Commercializing Novel Diagnostics: Translating Clinical Performance into Economic Value
Novel diagnostics often face commercialization challenges unique from those associated with drugs, devices, or procedures. Here we discuss the crucial elements, roadblocks, and takeaways to consider when developing an economic story.Novel diagnostics often face commercialization challenges unique from those associated with drugs, devices, or procedures. Here we discuss the crucial elements, roadblocks, and takeaways to consider when developing an economic story. We present this guidance as a “roadmap” consisting of six essential phases of economic evidence development for diagnostics: 1) Defining the value hypothesis, 2) Mapping the care pathway, 3) Building the early model, 4) Engaging payers & refining assumptions, 5) Conducting post-market observational research, and 6) Updating and communicating value.read more · Original Link ↗
John SchneiderAvalon Health Economics
Built for you by(617)-PATRICK, Champion AI speaker
Medtech companies are evolving far beyond traditional device manufacturing. Today's leaders are building integrated ecosystems that combine hardware, software, data, and services to deliver continuous value across the care journey.Medtech companies are evolving far beyond traditional device manufacturing. Today's leaders are building integrated ecosystems that combine hardware, software, data, and services to deliver continuous value across the care journey. In this candid CEO conversation, industry leaders will discuss how they are transforming their organizations into healthcare platforms-redefining business models, forging new partnerships, and creating technology-enabled solutions that extend well beyond the device itself. From remote monitoring and AI-enabled insights to digital services and value-based care alignment, this session will explore how medtech companies are positioning themselves for the next decade of healthcare delivery.
Also tagged: Digital Health Technologiesread more · Original Link ↗
Ariann StonePremier, Inc. (Moderator)
Tom Polen Jr.BD
Deepak NathSmith+Nephew
Michael PardenB. Braun of America
☆
Tue Oct 20 · 2:45 PM - 3:00 PM
Solutions Showcase: Biological Twins: Engineering the Human Cell to Digital Twins of Organs for Virtual Clinical Trials and Spatial Surgery
This presentation explores how biological twins turn patient data, physics-based modeling, and AI into predictive digital replicas of human organs.This presentation explores how biological twins turn patient data, physics-based modeling, and AI into predictive digital replicas of human organs. Attendees will learn how these models can simulate responses to drugs, devices, and surgery before treatment, support faster and safer virtual clinical trials, and guide precision procedures through real-time imaging and robotics. Examples in cardiac electrophysiology and nasal drug delivery will illustrate the approach, along with the validation and regulatory requirements for clinical adoption.read more · Original Link ↗
Srinivasan JayaramanCognizant
☆
Tue Oct 20 · 2:50 PM - 3:05 PM
Patient Story: Vantive
● Patient Engagement
Patient Story
📍 Exhibit Level, Medtech Campus, Patient Pavilion
Finding Freedom at Home: A Conversation on Life with Peritoneal Dialysis
Living with kidney failure can bring significant challenges, but it can also create opportunities for independence, resilience, and growth.Finding Freedom at Home: A Conversation on Life with Peritoneal Dialysis
Living with kidney failure can bring significant challenges, but it can also create opportunities for independence, resilience, and growth. In this inspiring conversation, Melanie Pina shares her experience with peritoneal dialysis and how home-based therapy has helped her take an active role in managing her care. Attendees will hear firsthand about the realities of living with dialysis, the value of a strong support system, and the impact innovative solutions can have in helping people live fuller, more flexible lives.read more · Original Link ↗
In medtech, supply chain resilience is a patient outcome, not just a cost line. But most networks still run on siloed data and forecasts that react to disruption rather than anticipate it.In medtech, supply chain resilience is a patient outcome, not just a cost line. But most networks still run on siloed data and forecasts that react to disruption rather than anticipate it.
Genpact's life sciences and supply chain leaders share what's actually working as medtech companies move from fragmented planning to intelligent orchestration with agentic AI: early risk sensing, autonomous next-best-action, and humans plus compliance controls in the loop. Leave with the three highest-value starting use cases, the data foundations agents need to scale, and the guardrails to set first.read more · Original Link ↗
Jason AltmanGenpact
Alok JhaGenpact
☆
Tue Oct 20 · 3:15 PM - 4:15 PM
Big Deals. Bold Bets. The Future of Diagnostics.
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 161
A new era of diagnostics dealmaking is underway. Since 2025, a series of major acquisitions, investments, and strategic combinations have highlighted the growing importance of diagnostics and precision medicine in healthcare.A new era of diagnostics dealmaking is underway. Since 2025, a series of major acquisitions, investments, and strategic combinations have highlighted the growing importance of diagnostics and precision medicine in healthcare. But which deals will truly reshape the industry, and what do they mean for innovators, investors, providers, and patients? Join a panel of seasoned diagnostics market observers as we unpack the biggest transactions, debate the strategic rationale behind them, and explore where capital is likely to flow next. Whether you're an operator, investor, or diagnostic executive, this session offers a front-row view into the trends redefining the future of diagnostics.
Also tagged: In Vitro Diagnostic Tests and Technologiesread more · Original Link ↗
Donna Hochberg PhDHealth Advances (Moderator)
Scott GarrettWater Street Healthcare Partners, LLC
Max MasucciRoth Capital Partners
Brian WeinsteinWilliam Blair
☆
Tue Oct 20 · 3:15 PM - 4:15 PM
Protecting EBIT in a Volatile World: Risk Responsive Execution and Agentic Planning in MedTech Supply Chains
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 157C
MedTech supply chains are entering a new phase of evolution.MedTech supply chains are entering a new phase of evolution. Following the industry’s shift toward networked ecosystems and greater cross company collaboration, leaders now face a more persistent challenge: how to execute through continuous volatility driven by geopolitical tension, trade policy shifts, regionalization, cost inflation, and regulatory constraints. Tariffs and supply disruption are no longer episodic events; they represent a structural operating reality with material EBIT exposure across portfolios and product lines.
In response, leading MedTech organizations are moving beyond transparency and traditional analytics toward risk responsive execution. This evolution is enabled by stronger data foundations, AI driven insights, and agentic, governed planning and execution solutions - where systems continuously sense risk, evaluate scenarios, and recommend or activate pre approved actions within clearly defined regulatory, quality, and governance guardrails. Rather than pursuing full autonomy, these capabilities augment human decision making, improve planning speed and consistency, and support faster, better coordinated responses to disruption.
This interactive session will explore how MedTech companies are progressing from insight to action across complex, legacy driven supply networks, while maintaining compliance, patient safety, and product availability. Through practical examples and audience driven discussion, attendees will gain a clearer understanding of how leading organizations are evolving operating models, planning processes, and supply chain capabilities to protect margin through optimized inventory and resource deployment, improve OTIF performance, and enable faster, more confident decisions - without compromising quality, compliance, or patient access.
Also tagged: Supply Chainread more · Original Link ↗
Ehap SabriEY (Moderator)
Mike Arena MBAFUJIFILM Sonosite, Inc.
Punit MenonMedtronic
Andrea Morgan-VandomeBlue Yonder
☆
Tue Oct 20 · 3:15 PM - 4:15 PM
From Innovation to Implementation: Integrating AI with CPT, and Payer Perspectives
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 157AB
The healthcare landscape is undergoing a profound transformation as clinical artificial intelligence (AI) and other digital innovations accelerate the pace of change.The healthcare landscape is undergoing a profound transformation as clinical artificial intelligence (AI) and other digital innovations accelerate the pace of change. However, the pathways for coding and reimbursement have struggled to adapt to the rapid change, creating friction for innovators, providers, and patients alike. As new technologies emerge, the gap between innovation and integration widens - making it increasingly difficult to ensure that groundbreaking solutions are effectively brought to market and seamlessly adopted in clinical practice.
A focal point of the panel discussion will be the evolution of the CPT Editorial Panel’s work on Appendix S, the taxonomy that provides guidance for classifying various artificial intelligence/augmented intelligence (AI) applications for medical services and procedures. This has become increasingly relevant as AI and digital health solutions reshape the healthcare ecosystem. We’ll examine how Appendix S and the broader CPT process are adapting to reflect the unique value propositions and clinical outcomes offered by these technologies - often extending beyond the scope of conventional healthcare interventions.
Critically, we will explore how these developments impact payer decision-making, determine coverage, and support appropriate reimbursement. We’ll also discuss how the CPT process, is distinct from the FDA regulatory pathway, and why understanding this is critical for successful commercialization.
Our expert panel - including representatives from the CPT Panel, Digital Medicine Coding Committee (DMCC), and the Chair of the AMA Specialty Society/RVS Update (RUC) - will explore how coding, coverage and payment challenges, and the regulatory environment affect market access. Attendees will come away with actionable insights to navigate challenges in an era defined by rapid technological evolution.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Amy Palatiello MPHMedtronic (Moderator)
Zach HochstetlerAmerican Medical Association
Richard Frank MD, PhDFrank Healthcare Advisors, LLC
Zeke SilvaAMA RVS Update Committee (RUC)
☆
Tue Oct 20 · 3:15 PM - 4:15 PM
Equipping Legal and Compliance Programs for the Digital Future of MedTech: Navigating the Evolving Privacy, AI, and Cybersecurity Landscape
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 159
AI, privacy, and cybersecurity are critical and interconnected components of enterprise value and patient safety.AI, privacy, and cybersecurity are critical and interconnected components of enterprise value and patient safety. This session will bring together industry leaders to highlight how medtech companies are restructuring legal and compliance teams to eliminate silos and better partner with IT leadership to proactively address emerging challenges in the privacy, AI, and cybersecurity space. This internal partnership is also better equipping companies to address the proliferation and patchwork of US state and federal laws, including FDA expectations, as well as laws around the world. Panelists will share lessons learned and best practices
Also tagged: Legal and Health Care Compliance Best Practicesread more · Original Link ↗
Mary Devlin CapizziFaegre Drinker Biddle & Reath LLP (Moderator)
Matthew McDonellZimmer Biomet
Ericka SnyderBoston Scientific
James VinocurBaxter Healthcare
☆
Tue Oct 20 · 3:15 PM - 4:15 PM
Connected Implants: The Next Frontier in Patient Care and Empowerment
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 162AB
Implantable digital health platforms are redefining how clinicians monitor disease, personalize care, and engage and empower patients.Implantable digital health platforms are redefining how clinicians monitor disease, personalize care, and engage and empower patients. This session brings together leaders advancing connected implants across heart failure management, brain - computer interfaces, and orthopedic aftercare to illustrate what is possible today and what is next. We will explore the technological innovations, clinical evidence, patient experience, and ecosystem behind these cutting-edge solutions. Attendees will learn how sensor-enabled implants deliver continuous insights, enable earlier interventions, and engage and empower patients to have more confidence and control of their own care. The panel will compare development and regulatory pathways, integration of these digital platforms with traditional care, reimbursement considerations, and real-world deployment lessons.
Also tagged: Patient Engagementread more · Original Link ↗
Jennifer RentasZimmer Biomet (Moderator)
Omid ForouzanSynchron
Jeff GrossCanary Medical
Angad SinghEdwards Lifesciences
☆
Tue Oct 20 · 3:15 PM - 4:15 PM
Advancing Global Regulatory Convergence: Enabling Innovation and Patient Access
● International
Panel Session
📍 Meeting Level 1, Room 160ABC
Do you market your medical devices and/or in-vitro diagnostics in more than one jurisdiction? The global medical device regulatory landscape continues to evolve, bringing new opportunities as well as increasing complexity for manufacturers and regulators.Do you market your medical devices and/or in-vitro diagnostics in more than one jurisdiction? The global medical device regulatory landscape continues to evolve, bringing new opportunities as well as increasing complexity for manufacturers and regulators. In this environment, regulatory reliance and convergence remain critical to fostering innovation and ensuring timely patient access to medical devices and in-vitro diagnostics. This session will provide the latest updates on global efforts, emerging developments, implementation challenges, and opportunities to advance more efficient, aligned regulatory approaches across jurisdictions. Join industry and regulatory leaders for a forward-looking discussion on the progress being made and the work that remains to achieve greater global regulatory alignment.
Also tagged: Regulatory, Quality and Good Manufacturing Practicesread more · Original Link ↗
Diane Wurzburger RACGE HealthCare (Moderator)
Nicole Taylor Smith JDPhilips
Kenneth Cavanaugh PhD Jr.U.S. Food and Drug Administration
Fatemeh RazjouyanMedtronic
Bradford SpringRoche Diagnostics
Melissa TorresAdvaMed
☆
Tue Oct 20 · 3:20 PM - 3:50 PM
The ASC Reckoning: How Medtech Leaders are Rebuilding to Win
The shift of surgical volume to ambulatory surgery centers is separating medtech companies building for where care is headed from those still optimized for where it has been.The shift of surgical volume to ambulatory surgery centers is separating medtech companies building for where care is headed from those still optimized for where it has been. Hospital-bound procedures are becoming outpatient at a pace medtech commercial models weren't designed to absorb. The buyer is different. The economics are different. The decision-maker, workflow, contract structure and margin calculus are all different. For medtech CEOs, this demands far more than a sales force adjustment or a channel tweak. Winning the ambulatory era requires a fundamental rethink of portfolio strategy, capital allocation, product architecture, organizational structure and incentives. In this session, leaders share where they are placing bets, lessons learned and how they are building organizations capable of leading the ambulatory era.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Bhargav ManthaZS (Moderator)
Lisa EarnhardtAbbott
Kevin LoboStryker
Winborne MacphailSCA Health
☆
Tue Oct 20 · 3:25 PM - 3:40 PM
Solutions Showcase: From Design to Patient: How Connected Quality Accelerates MedTech Innovation and Performance
Medical device companies face growing pressure to accelerate innovation while navigating increasingly complex regulatory requirements. Yet many organizations still manage quality, design, suppliers, manufacturing, and post-market activities across disconnected systems and manual processes.Medical device companies face growing pressure to accelerate innovation while navigating increasingly complex regulatory requirements. Yet many organizations still manage quality, design, suppliers, manufacturing, and post-market activities across disconnected systems and manual processes.
Join us to learn how a leading MedTech manufacturer transformed quality into a connected business capability, improving visibility across the product lifecycle, reducing investigation and release times, strengthening supplier collaboration, and increasing inspection readiness. Discover practical strategies for building a connected quality environment that drives operational excellence, accelerates innovation, and ultimately improves patient outcomes.read more · Original Link ↗
Nikki WillettComplianceQuest
Built for you by(617)-PATRICK, Champion AI speaker
MedTech Innovator $350,000 Grand Finals Competition
● Special Program
Special Program
📍 Exhibit Level, Medtech Campus, Keynote Theater
Be part of the most exciting medtech competition of the year! From a pool of 1,800 applicants, four finalists will compete for a $350,000 prize in the Grand Finals of the 2026 MedTech Innovator Accelerator.Be part of the most exciting medtech competition of the year! From a pool of 1,800 applicants, four finalists will compete for a $350,000 prize in the Grand Finals of the 2026 MedTech Innovator Accelerator. Hear leading strategic judges ask the hard questions, cast your vote, and join us in crowning this year’s winner.
Early Stage Grand Prize Award Finalists:
- Karny Ilan, Feminai
- Eddie McDaid, Galenband
- Adam Yaacov, Urologic Health
- Tushar Sharma, Vivifi Medical
Judges:
- Tarun Mahajan, Zimmer Biomet
- Mirren Mandalia, LivaNova
- Sonal Patel, Johnson & Johnson
- Arthur Stephen, BD Surgery
This program is open to all registration types.
Program: Investor Forumread more · Original Link ↗
Paul GrandMedTech Innovator (Moderator)
Karny IlanFeminai
Tarun MahajanZimmer Biomet
Mirren MandaliaLivaNova
Eddie McDaidGalenband
Sonal PatelJohnson & Johnson
Tushar SharmaVIVIFI MEDICAL INC
Arthur StephenBD - Surgery
Adam YaacovUrologic
☆
Tue Oct 20 · 3:45 PM - 4:00 PM
Solutions Showcase: The Breakthrough Hiding in Plain Sight
Some of healthcare's greatest opportunities are hiding within its most common procedures.Some of healthcare's greatest opportunities are hiding within its most common procedures. This session explores how the BD Peripheral Line Draw Solution, featuring Nexiva™ with NearPort™ IV Access and PIVO™ Pro Needle-free Blood Collection Device, reimagines vascular access and blood collection as a connected care journey rather than a series of separate tasks. Discover how innovation focused on the ordinary can create meaningful impact for patients, clinicians, and health systems.read more · Original Link ↗
For MedTech CEOs, the next competitive advantage is not the best device, platform, or algorithm. It is the ability to make a complex partner ecosystem feel seamless to the customer.For MedTech CEOs, the next competitive advantage is not the best device, platform, or algorithm. It is the ability to make a complex partner ecosystem feel seamless to the customer. Leading organizations are building integrated, partner-enabled models that bring together providers, payers, platforms, distributors, data ecosystems, and care teams around a shared customer journey. The harder challenge is making many partners, functions, and decisions operate as one enterprise.
AI, especially agentic AI, is central to this shift, connecting workflows across clinical, regulatory, manufacturing, and commercial domains and enabling greater visibility and coordination across the value chain. Delivering on that promise requires equal attention to the human side. Accenture's recent Talent Reinventors report - based on research across more than 1,300 C-suite executives, 4,500 employees across 20 industries - identifies six characteristics that separate leaders from the rest: strategic clarity, intelligent teaming, talent mobility, co-learning, breakthrough leadership, and personalized employee experiences. Organizations that embed these traits deliver measurably stronger revenue and profit growth than peers.
As work moves from job titles to skill portfolios, MedTech leaders face a growing talent gap. The capabilities that matter most now combine technical fluency, clinical and regulatory expertise, digital execution, and ecosystem orchestration alongside the ability to work effectively with intelligent systems. As automation expands, the premium on judgment, coordination, and cross-functional alignment continues to rise.
This CEO Unplugged conversation will explore how leaders can build partner-led operating models, use AI to strengthen decision-making, and develop skills-based talent models that enable the enterprise to act as one.
Also tagged: Digital Health Technologiesread more · Original Link ↗
Connect with Accel members and the MedTech Innovator 2026 cohort.Connect with Accel members and the MedTech Innovator 2026 cohort. Celebrate the winner of the Virginia Shimer Rybski Memorial Award - one outstanding Innovation Pavilion exhibitor will be selected by a panel of leading investors and partners for this award, which honors the legacy of Virginia Shimer Rybski, a scientist, entrepreneur, and visionary medtech leader.read more · Original Link ↗
Don’t miss a unique opportunity to hear directly from senior leadership at the FDA’s Center for Devices and Radiological Health (CDRH) during Wednesday morning’s CDRH Town Hall.Don’t miss a unique opportunity to hear directly from senior leadership at the FDA’s Center for Devices and Radiological Health (CDRH) during Wednesday morning’s CDRH Town Hall. This session offers an inside look at the center’s current strategic direction and key priorities.
Keynote and Breakfast open to all attendees
Program: AdvaMed in Actionread more · Original Link ↗
Zach Rothstein JDAdvaMed (Moderator)
Rick AbramsonU.S. Food and Drug Administration (FDA)
Angela KruegerU.S. Food and Drug Administration (FDA)
Michelle Tarver MD, PhDFood & Drug Administration (FDA)
Owen Faris PhDU.S. Food and Drug Administration (FDA)
Edward Margerrison PhDU.S. Food and Drug Administration (FDA)
As MedTech regulatory and market demands intensify, traditional linear development paths can no longer keep pace with the urgent need for rapid innovation.As MedTech regulatory and market demands intensify, traditional linear development paths can no longer keep pace with the urgent need for rapid innovation. To innovate faster and maintain a competitive edge, leading device developers must shift evidence generation to the very beginning of the product lifecycle. Rather than waiting for late-stage clinical trials or physical prototyping loops to uncover performance limits, engineering and R&D teams are now leveraging virtual patient populations and high-fidelity computational modeling. We will discuss how integrating virtual testing at the concept stage enables innovators to:
Impact the early design cycle
- Drive innovation and move faster
- Build a predictable regulatory pathread more · Original Link ↗
J. Cris Salinas, MDDassault Systèmes (Moderator)
Sheri DoddTactile Medical
Namal NawanaDePuy Synthes
Ivan TornosZimmer Biomet
☆
Wed Oct 21 · 9:45 AM - 10:45 AM
Future-Proofing MedTech Supply Chains in an Era of Constraints
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 162AB
Critical-input scarcity is no longer an episodic supply disruption - it is an existential structural challenge. What can senior MedTech leaders do now to address supply chain uncertainty in the future?Critical-input scarcity is no longer an episodic supply disruption - it is an existential structural challenge. What can senior MedTech leaders do now to address supply chain uncertainty in the future?
Explore the ways a practical scenario-planning approach can help teams make three key decisions: Building no-regret foundations (visibility, playbooks, governance); Placing directional bets (network posture, partnerships, platform choices); and Preserving optionality (warm alternates and pre-validated substitutions).
From prioritizing the most consequential exposures and reshaping supplier and manufacturing ecosystems, to embedding resilience into planning and capital decisions - hear candid lessons learned on what’s worked, what didn’t, and where leadership attention matters most.
Also tagged: Supply Chainread more · Original Link ↗
Rohini PrasadDeloitte (Moderator)
Nick CorcoranTransMedics
Mike Arena MBAFUJIFILM Sonosite, Inc.
Jessica MolesSteris
Joan SmithCardinal Health
☆
Wed Oct 21 · 9:45 AM - 10:30 AM
Leveraging Industry-Academic Partnerships: What Works, What Doesn’t
Academic-industry partnerships can accelerate innovation, strengthen product development, and create long-term value when built on the right foundation.Academic-industry partnerships can accelerate innovation, strengthen product development, and create long-term value when built on the right foundation. This session brings together leaders from medtech companies and academic institutions to explore successful collaboration models, lessons learned, and best practices for developing partnerships that advance innovation and deliver meaningful outcomes for both organizations.
Also tagged: Emerging Companiesread more · Original Link ↗
Youseph YazdiJohns Hopkins School of Medicine (Moderator)
Ibraheem BadejoJohnson & Johnson MedTech
Kolaleh EskandanianMedStar Health
Howard LevinCoridea
Joe SmithBD
Michael WolfsonNational Institutes of Health (NIH)
☆
Wed Oct 21 · 9:45 AM - 10:45 AM
Next-Generation M&A: AI-Driven Diligence and the Rise of Elite Deal Teams
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 159
In MedTech M&A, scale and complexity have increased dramatically - yet value creation has not kept pace. Too many transactions erode value rather than generate it, often because diligence processes are slow, fragmented, and focused on the wrong questions.In MedTech M&A, scale and complexity have increased dramatically - yet value creation has not kept pace. Too many transactions erode value rather than generate it, often because diligence processes are slow, fragmented, and focused on the wrong questions. The result: deals that look compelling at signing but struggle during integration and fail to meet long-term growth expectations.
This panel explores how leading acquirers are redesigning their approach. True value creation begins at NDA signing, with a disciplined, cross-functional deal team that can rapidly evaluate technical design, clinical outcomes, quality systems, manufacturing, supply chain resilience, and pro forma financial impact. In organizations with tens of thousands of employees, success increasingly depends on small, empowered teams that can synthesize complex data quickly and make aligned decisions.
We will also examine how advanced AI tools are transforming diligence - enabling faster analysis, deeper insights, and more rigorous pre-LOI evaluation. Despite these capabilities, many strategics still rely heavily on informal feedback loops, such as customer or KOL sentiment, which may validate a clinical concept but overlook operational, regulatory, and scalability risks.
Bringing together business development leaders who have executed both successful and underperforming transactions, this discussion will provide practical frameworks for building high-performance deal teams, modernizing diligence, and improving post-close integration outcomes. Attendees will gain actionable strategies to turn M&A from a risk factor into a repeatable engine of growth.
Also tagged: Digital Health Technologies
Program: Investor Forumread more · Original Link ↗
Mrigasha PatelQuadriga Partners LLC (Moderator)
Gary ChenCurewell Capital
Matt DumontBoston Scientific
Bryan GrulkeVolcano Capital
Alex SauterStryker
☆
Wed Oct 21 · 9:45 AM - 10:45 AM
From KOLs to VACs: The New Rules for MedTech Commercialization Success
● Business Strategies and Finance
Panel Session
📍 Meeting Level 1, Room 157C
The rules of MedTech adoption have changed. A decade ago, a respected surgeon’s endorsement could accelerate adoption. Today, Value Analysis Committees (VACs) are institutional gatekeepers, demanding localized evidence, financial rationale, and cross‑functional consensus. This shift is structural, not temporary.The rules of MedTech adoption have changed. A decade ago, a respected surgeon’s endorsement could accelerate adoption. Today, Value Analysis Committees (VACs) are institutional gatekeepers, demanding localized evidence, financial rationale, and cross‑functional consensus. This shift is structural, not temporary.
This panel unites commercial leaders, health‑economics experts, and VAC insiders to define what successful value articulation looks like in 2026. We’ll explore four imperatives: embedding clinical champions in broader stakeholder networks, converting evidence into institution‑specific business cases, sustaining momentum through long approval cycles, and scaling adoption beyond early champions.
Through a detailed case study of how premium products can navigate a VAC and secure approval and long‑term adoption. The key: engaging finance, operations, procurement, and clinical teams simultaneously to craft a cross‑departmental value story.
Attendees will leave with clear frameworks for structuring VAC submissions, equipping champions with tailored evidence, navigating committee bottlenecks, and turning pilot wins into multi‑site adoption. For commercialization leaders, investors, and strategists, this session offers pragmatic insights into how real differentiation happens, and where most companies still falter.
Also tagged: Market Access, Payment and Health Care Deliveryread more · Original Link ↗
Charles Mathews MPPClearView Health (Moderator)
Yan HaoBeth Israel Lahey Health
Martin Gold MBAWave Neuroscience
Mena MesihaPRIMA CARE
☆
Wed Oct 21 · 9:45 AM - 10:45 AM
Licensing as a Growth Engine: How Startups, Strategics, and Investors Structure Deals for Novel Devices
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 161
As software-driven and data-rich medical devices blur the lines between product and platform, licensing strategy has become a core lever for commercialization and go-to-market success.As software-driven and data-rich medical devices blur the lines between product and platform, licensing strategy has become a core lever for commercialization and go-to-market success. This panel brings together a strategy and licensing executive from an emerging/small company, an executive from a larger medtech organization, a venture capital investor, and a partner from a life sciences and licensing practice to discuss key strategy considerations and licensing structure for novel medical devices.
The discussion will explore how parties define and negotiate intellectual property rights, and how those definitions influence value, control, and risk allocation. Panelists will compare approaches to escrow arrangements, regulatory maintenance, update rights, and commercial support in software-enabled devices, highlighting differences from traditional medical device. They will also examine platform-versus-product thinking: when to license a narrowly scoped indication versus a broader technology stack, and how rights such as right of first refusal, territory, and field-of-use affect long-term partnership potential as well as valuation and exit opportunities.
Using real-world examples from recent licensing and collaboration deals, the speakers will share practical lessons on how to structure agreements that are financeable, scalable, and durable - while preserving the flexibility to pivot strategy as technologies, markets, and regulatory expectations evolve. Attendees will leave with a cross-functional view of licensing that connects term-sheet language to commercialization pathways and patient impact.
Also tagged: Emerging Companies
Program: Investor Forumread more · Original Link ↗
Jennifer LavantureMedRhythms, Inc. (Moderator)
Sarah Cooleybeck JDFoley Hoag, LLP
Yuri Maricich MD, MBAAngelini Ventures
Eric SchantzMedtronic
Built for you by(617)-PATRICK, Champion AI speaker
Converging Paths: How MedTech and Pharma Can Accelerate Agentic AI Innovation Through Mutual Learning
● Digital Health Technologies
Panel Session
📍 Meeting Level 1, Room 162AB
The MedTech and Pharma industries share a great deal of common DNA but often operate in silos. Historically, the narrative has been that MedTech should simply look to Pharma's larger R&D budgets for inspiration.The MedTech and Pharma industries share a great deal of common DNA but often operate in silos. Historically, the narrative has been that MedTech should simply look to Pharma's larger R&D budgets for inspiration. However, with the rapid rise of Agentic AI, the opportunity for innovation is now a two-way street, where each side can learn from the other.
While Pharma leads in massive foundational AI investments and large-scale data processing, MedTech brings significant expertise in agile frameworks and the Software Development Life Cycle (SDLC). A major focal point for both industries is the increasing emphasis on collecting data as an asset, relying on high-quality structured data for AI to work on top of.
This panel will explore the powerful cross-pollination of ideas between these two sectors. We will discuss how MedTech can adapt Pharma’s advanced Agentic AI models throughout the product development life cycle. Conversely, we will uncover what Pharma can learn from MedTech’s rapid approach to integrating AI into connected care ecosystems.
Moving beyond theory, the session will highlight high-overlap areas, particularly within clinical trials, where devices and sensors are increasingly used alongside drug delivery to collect critical information. The panel will also dive into emerging shared frontiers, such as PDURS (Prescription Drug Use-Related Software).
This session is designed for R&D leaders, regulatory and quality executives, and innovation leads in both MedTech and Pharma who are looking to break down industry silos and accelerate product development without compromising safety or compliance.read more · Original Link ↗
Bernhard KappeOrthogonal (Moderator)
Cecilia AlmeidaU.S. Food and Drug Administration (FDA)
Annie SahaOracle
DeLin ShenMedtronic
Hui ZhangEli Lilly and Company
☆
Wed Oct 21 · 11:00 AM - 12:00 PM
Equity in Pulse Oximetry: Closing Gaps Through Science, Design, and Standards
● Health Access
Panel Session
📍 Meeting Level 1, Room 161
Pulse oximetry is used ubiquitously in health care to non-invasively monitor oxygen saturation. Concerns have been raised about its accuracy in individuals with darker skin pigmentation.Pulse oximetry is used ubiquitously in health care to non-invasively monitor oxygen saturation. Concerns have been raised about its accuracy in individuals with darker skin pigmentation. The COVID-19 pandemic brought these issues to greater prominence, showing that pulse oximeters can overestimate arterial blood oxygen levels, potentially leading to delays in critical treatment in patients with darker skin.
Addressing the challenge of improving equity in pulse oximetry requires a multi-faceted approach from engaging diverse communities to increase broad representation in clinical trials, ensuring technology is designed to perform equitably for a global population, educating the clinical field on improvements in technology and its effect on practice, to working with international standards organizations to ensure more transparent and equitable standards and regulations.
This session will highlight a detailed approach to improving technology for more equitable care.read more · Original Link ↗
Jennifer DoyleMedtronic (Moderator)
Rohit LoombaFeinberg School of Medicine, Northwestern University/Ann and Robert H. Lurie Children’s Hospital
Jonathan TanPerelman School of Medicine, University of Pennsylvania/Children’s Hospital of Philadelphia
Paste one into your AI after the list, or create your own.
Pick my 3 best sessions. Skip the invite-only ones.
ROLE: Expert conference advisor for MedTech 2026 attendees
CONTEXT: I'm pasting over 250 sessions for the MedTech 2026. I am a medtech executive or investor. I want AI and digital health sessions, business strategy and market access insights, and time with investors and industry leaders.
GOAL: Pick the top 3 sessions for me.
INVITE-ONLY: Some sessions are labelled (Invite-Only) - sponsored roundtables closed to general attendees. Still recommend one if it genuinely fits me, but begin that session's explanation with the words 'Invite-only' so I can see it at a glance and decide whether it is worth asking the sponsor for a seat. If I would rather not see them at all, I will say 'skip the invite-only sessions'.
OUTPUT FORMAT: List in chronological order. Label each with its relevance rank (e.g. the third one listed might be Rank #1 of over 250). Include day, time, and session title. Write 2-3 sentences on why each fits my goals.
VERIFICATION: Before answering, confirm how many sessions you received. You should have at least 250. If you received significantly fewer, tell me immediately - my paste was probably truncated.
Which sessions are right for you?
Describe yourself and what you want from MedTech 2026. The more specific you are, the better this works.
You can also say how many you want or when you're free - “give me 10”, “give me 20”, “only Friday afternoon”. You get 3 unless you ask for more. If you can't get into the sponsors' invite-only roundtables, say “skip the invite-only ones” and they won't be suggested.
There is a daily limit on the phone version
so it can stay free for everyone at the event.
However, you can run it as many times as you want using your own AI account at home:
go to the bottom of the page
download the session list, then tap Click for sample prompts
paste the list, then a prompt, into Claude, ChatGPT, or Gemini.
Powered by Claude. Your text is sent to Anthropic to generate the ranking, and is logged on this site so the feature can be improved. Please don't type anything confidential.
